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1 Introduction 
1.1 Taxonomy and epidemiology of filoviruses 
 
Marburg virus (MARV) belongs together with the Ebolaviruses (EBOV) and the 
recently described Lloviuvirus (LLOV) to the family of Filoviridae in the order of 
Mononegavirales (Bukreyev et al., 2014; Kuhn et al., 2010; Negredo et al., 2011). 
Viruses from the order of Mononegavirales including Paramyxoviruses, 
Rhabdoviruses and Bornaviruses share a non-segmented negative sense RNA 
genome. The name Filoviridae derives from the filamentous (lat. filum = thread) 
appearance of the virions (Geisbert & Jahrling, 1995; Murphy et al., 1978). The 
complete taxonomy of the Filoviridae is shown in table 1. Filoviruses induce 
severe diseases in humans, associated with high fatality rates (Bausch et al., 
2006; Siegert et al., 1967; Towner et al., 2006). The severity of the filoviral 
disease and the lack of effective treatments and vaccines leads to the 
classification of filoviruses as BSL-4 agents.   
The Marburg virus is named after the city Marburg (Hesse, Germany), which 
happened to be the first place of a known filoviral disease and virus isolation 
(Siegert et al., 1967). The initial Marburg virus outbreak occurred in parallel in 
Marburg, Frankfurt and Belgrade in 1967. Laboratory workers and zookeepers 
were infected by direct contact with specimens from infected African green 
monkeys (Fig. 1-2). Thirty-two persons fell ill, seven individuals developed a 
 
Table 1: Taxonomy of filoviruses, (ICTV 2015) 
 
: Taxonomy of filoviruses, (ICTV 2014) 
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severe hemorrhagic fever which led to death (Slenczka & Klenk, 2007).  
In 1976, the currently much better known and studied member of the Filoviridae, 
the Ebola virus, was discovered in Africa (Bowen et al., 1977). In following years, 
both viruses caused sporadic outbreaks associated with high lethality rates. Until 
1998 it was believed that EBOV had higher lethality rates than MARV. However, 
the 1998 MARV outbreaks in the Democratic Republic of Congo and the 2004 
outbreak in Angola demonstrated the severity of the MARV disease, with lethality 
rates above 80% (Bausch et al., 2006; Towner et al., 2006). However, the 
reliability of the case fatality rates is questionable due to significant 
underreporting. Filoviral outbreaks were considered as self-containing due to the 
severity of the disease and the predominant occurrence in rural regions of central 
Africa, affecting either small villages or single tourists (Albariño et al., 2013a; 
Amman et al., 2014; Bausch et al., 2006; CDC, 2009; Siegert et al., 1967; Towner 
et al., 2006). An overview of the MARV-induced outbreaks and single cases is 
shown in figure 1. However, the 2013-2016 EBOV outbreak clearly showed the 
potential of filoviruses to cause long lasting large-scale outbreaks associated with 
high lethality rates. 28,616 people became infected of which 11,310 died, 
resulting in an overall lethality rate of 40% (Acharya, 2014; Carroll et al., 2015; 
WHO, 2016b). Despite the biological threat to mankind, this outbreak massively 
 
Figure 1: History of Marburg virus cases and outbreaks  
Height of the column indicates the total case numbers (survivors of MARV infections are shown in 
black, lethal MARV cases are shown in grey). * indicates an accidental laboratory exposure. 
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affected the local and regional economy, and highlights the importance of filovirus 
research (Bartsch et al., 2015).  
Previous zoonotic MARV infections were regularly traced back to the entry of 
humans into bat caves (Brauburger et al., 2012). In 2007, MARV was isolated 
from Egyptian fruit bats (Rousettus aegyptiacus) which belong to the family of 
Pteropodidae, and soon after, fruit bats were confirmed as natural MARV 
 
Figure 2: Geographic distribution of Marburg fever outbreaks and habitats of fruit bats from the 
Pteropodidae family  
MARV outbreaks caused by contact to tissues of imported and infected monkeys shown in yellow. 
Countries with reported MARV outbreaks, shown in red. The green line indicates the presence of bats 
from the Pteropodidae family reported as known reservoirs for MARV. Graphic modified from WHO 
2009. 
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reservoir (Pourrut et al., 2009; Swanepoel et al., 2007; Towner et al., 2009; 
Towner et al., 2007). The distribution of fruit bats from the Pteropodidae family, 
including Rousettus aegyptiacus, and human MARV outbreaks overlaps (Fig. 2). 
 
1.2 Clinical appearance 
 
Transmission of MARV to humans occurs either via direct contact to infected 
animals, such as bats or primates, or may occur by consumption of contaminated 
bush meat (Beeching et al., 2014; Martini & Siegert, 1971). Human to human 
transmission of MARV is a result of contact to bodily fluids (such as blood, feces, 
urine, vomit or sweat) of an infected person.  
The onset of symptoms occurs after an incubation period of 2 to 21 days, 
depending on several factors, such as the infectious dose and transmission route 
(Martini & Siegert, 1971; WHO, 2012). In addition, individual factors, for instance, 
the genetic background or an existing immune suppression might play a role in 
the disease outcome (Martini & Siegert, 1971; Rosenke et al., 2016; WHO, 2012).
  
The initial phase of the disease is characterized by unspecific symptoms, e.g., 
high fever, headaches, muscle pain, nausea and gastrointestinal symptoms, such 
as diarrhea and vomiting. Especially in the initial phase MARV disease is hard to 
distinguish from other diseases such as the flu, dengue fever, malaria, yellow 
fever and Lassa fever (Drosten et al., 2002; WHO, 2014). The first MARV disease 
symptom that allows distinction from the flu is a frequently observed 
maculopapular rash (Martini & Siegert, 1971; Mehedi et al., 2011). During disease 
progression the medical condition quickly worsens, many patients display 
abnormal vascular permeability, edema, dyspnea and some develop 
hemorrhagic symptoms such as petechiae, mucosal bleedings and bloody 
diarrhea, neurological symptoms can appear, such as confusion, aggression or 
disorientation (Mehedi et al., 2011). Death occurs by shock due to multi-organ 
failure, on average between day eight and nine after the onset of symptoms 
(WHO, 2012).  
 
The large 2013-2016 Ebola outbreak helped to increase the understanding of 
filoviral disease in humans significantly. Now it is well accepted that survival 
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frequently leads to the post-Ebolavirus disease-syndrome accompanied by 
chronic muscle aches, joint pain, temporary memory loss, exhaustion and 
impairment of sight and/or hearing (Hunt & Knott, 2016; Mattia et al., 2016; 
Nanyonga et al., 2016). Viral RNA or infectious virus can persist up to nine 
months in the semen or the ocular fluid of infected individuals (Deen et al., 2015; 
Varkey et al., 2015). Sexual transmission of MARV has been observed first during 
the initial Marburg virus outbreak and multiple sexual transmissions of EBOV 
confirmed that transmission of filoviruses can occur by sexual contact, even when 
patients were in convalescence (Christie et al., 2015; Martini & Schmidt, 1968; 
Mate et al., 2015). Persistence of infectious virus and sexual transmission has to 
be considered as a possible source of disease flare-ups after an outbreak.  
 
1.3 Vaccines and antivirals 
 
Currently, neither licensed vaccines nor therapeutics against filoviral diseases 
are available. Numerous different approaches have been made to create an 
efficient vaccine. Approaches with inactivated virus produced contrary results and 
full protection was not observed in non-human primates (NHPs) (Ignatyev et al., 
1996). Due to the ease of use and production, viral glycoprotein (GP) containing 
virus-like particles (VLPs) were used for vaccination and showed promising 
results in both rodents and NHPs (Swenson et al., 2008; Swenson et al., 2005). 
However, the most promising approaches are vaccine platforms based on 
reverse genetic systems of low pathogenic viruses like the vesicular stomatitis 
virus (VSV) or adenoviruses (Wang et al., 2006). A VSV based vaccine which 
lacks the VSV glycoprotein and contains the MARV-GP instead (VSVΔG/MARV-
GP) has been 100% protective in NHPs and was successful as post exposure 
treatment in NHPs (Daddario-DiCaprio et al., 2006; Geisbert et al., 2009). During 
the 2013 EBOV outbreak, a VSVΔG/EBOV-GP has been shown as efficient in 
preventing infection in humans (Henao-Restrepo et al., 2016). However, neither 
VSVΔG/MARV-GP nor VSVΔG/EBOV-GP are licensed to date.  
 
Generally, supportive treatment takes place upon the course of disease such as 
replenishing blood, fluids and administration of antibiotics, which reduces overall 
lethality (Baseler et al., 2016; WHO, 2016a). Despite the lack of licensed 
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antivirals, effective treatment options have been demonstrated in NHPs, such as 
siRNA based therapeutics and small molecules (Heald et al., 2015; Thi et al., 
2014; Ursic-Bedoya et al., 2014).  
 
1.4 The importance of animal models in filoviral research  
 
1.4.1 Animal models for filovirus research 
 
Due to the high lethality of the Marburg virus disease and the potential to cause 
prolonged large-scale outbreaks, it is necessary to develop antivirals and 
vaccines. In order to test the efficacy of treatment and prophylaxis options, 
relevant animal models are essential (Acharya, 2014; Carroll et al., 2015). 
Experimental infection of NHPs with human MARV isolates results in lethal 
disease displaying all hallmarks of a human infection (Banadyga et al., 2016; 
Nakayama & Saijo, 2013; Sanchez et al., 2006). Disadvantages of NHPs as 
animal model are ethical issues, high costs and maintenance, the restricted 
availability of laboratories with the expertise and capacities to work with NHPs 
under BSL-4 conditions (Banadyga et al., 2016; Bente et al., 2009). Small animal 
models (mice, hamsters, guinea pigs) allow to overcome some of these issues 
and could provide general insights into the potentials of treatments and vaccines 
(Banadyga et al., 2016; Nakayama & Saijo, 2013). However, experimental 
infection of rodents with human wildtype filovirus isolates does not induce a lethal 
disease (Cross et al., 2015; Ebihara et al., 2006; Lofts et al., 2007; Lofts et al., 
2011; Marzi et al., 2016; Mateo et al., 2011; Qiu et al., 2014; Volchkov et al., 
2000a; Warfield et al., 2007; Warfield et al., 2009). Filoviruses requires several 
passages in rodents for the selection of virus inducing a lethal disease (Cross et 
al., 2015; Lofts et al., 2007; Lofts et al., 2011; Marzi et al., 2016; Qiu et al., 2014; 
Warfield et al., 2009). 
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1.4.2 Adaptation of MARV to rodents 
 
Passaging of MARV in rodents, so called adaptation of MARV to rodents, is 
accompanied by mutations in the viral genome (Lofts et al., 2007; Lofts et al., 
2011; Mateo et al., 2011; Qiu et al., 2014; Volchkov et al., 2000a; Warfield et al., 
2007; Warfield et al., 2009). A previously published study by Lofts and colleagues 
was devoted to adaption of MARV Musoke, an isolate from a human case (Kenia, 
1980), to guinea pigs (Lofts et al., 2007). Eight passages of MARV in guinea pigs 
resulted in selection of a virus variant which induces a lethal disease in guinea 
pigs (Lofts et al., 2007). Much more passages, 23 to 28, were necessary for 
adaptation of MARV to mice (Lofts et al., 2007; Lofts et al., 2011; Qiu et al., 2014; 
Warfield et al., 2009). Mouse-adapted MARV (MA-MARV) had up to 19 amino 
acid substitutions, while the guinea pig-adapted MARV contained only four 
mutations (Lofts et al., 2007; Lofts et al., 2011; Qiu et al., 2014; Warfield et al., 
2009). Thus, the increase of MARV pathogenicity in guinea pigs occurred earlier 
during passaging and was accompanied by lower number of mutations in viral 
genome in comparison with adaptation of MARV to mice (Fig. 5) (Lofts et al., 
2007; Lofts et al., 2011; Qiu et al., 2014; Warfield et al., 2009). Adaptation of 
EBOV to guinea pigs took less passages, as well as, less adaptive mutations 
were observed than in mice-adapted EBOV (Banadyga et al., 2016). Remarkably, 
it has been shown by using the reverse genetics approach that not all mutations 
detected in rodent-lethal EBOV are necessary for the increased pathogenicity 
(Ebihara et al., 2006; Mateo et al., 2011). For example, 10 non-silent mutations 
were detected in 5 genes of MA-EBOV, but only two mutations (one mutation in 
VP24 and one in NP) introduced into recombinant EBOV were sufficient to induce 
lethal disease in mice (Ebihara et al., 2006). Whether this is the case for rodent-
lethal MARV (RL-MARV) is unknown because there are no studies on molecular 
determinants of RL-MARV using a reverse genetics approach.  
 
How rodent-lethal MARV mutations influence the function of viral proteins in a 
new host remains mostly unknown, so far only the impact of mutations in VP40 
of MA-MARV on the VP40 interferon antagonistic function in mouse cells has 
been analyzed (Feagins & Basler, 2014; 2015; Valmas & Basler, 2011).  
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1.5 Morphology and genome organization  
 
Electron microscopic (EM) analysis of Marburg virus particles revealed that the 
virions can have filamentous, six-shaped, crooked- or donut-like shapes (Bharat 
et al., 2011; Geisbert & Jahrling, 1995; Siegert et al., 1967; Welsch et al., 2010). 
Interestingly, a link between particle shape and infectivity has been suggested, 
for instance, donut-shaped particles are considered as non-infectious (Welsch et 
al., 2010). Virions are variable in length and can reach up to 1400 nm (Bharat et 
al., 2011). The diameter of virions is 80 nm (Bharat et al., 2011; Geisbert & 
Jahrling, 1995). The core of the particle consists of the viral RNA encapsidated 
by the nucleocapsid proteins NP, VP30, VP35, VP24 and L (Fig. 3) (Becker et al., 
1998; Feldmann et al., 1993; Martini & Siegert, 1971). The nucleocapsid complex 
is covered by a host derived lipid bilayer containing the matrix protein VP40 on 
the inner side of the envelope and the homotrimeric glycoprotein GP inserted into 
the envelope (Fig. 3) (Bamberg et al., 2005; Bharat et al., 2011; Feldmann et al., 
1991; Noda et al., 2002).  
The non-segmented RNA genome is 19.1 kb long and of negative orientation. It 
encodes seven proteins NP, VP35, VP40, GP, VP35, VP24 and L (Fig. 4) 
(Feldmann et al., 1992; Kiley et al., 1988; Mühlberger et al., 1992). Due to its 
orientation, the genome itself is not infectious and the nucleocapsid proteins are 
mandatory to run viral replication and transcription.   
 
Figure 3: Marburg Virus particle morphology and composition  
Representative electron microscopic picture of a MARV particle (left), kindly provided by Dr. Larissa 
Kolesnikova. Schematic picture of a MARV particle and its protein composition (right), kindly provided 
by Dr. Gordian Schudt. 
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The genome is flanked by non-transcribed regions (3’ leader and 5’ trailer) that 
contain signals for replication initiation as well as for packaging by the 
nucleoprotein NP (Mühlberger, 2007). The open reading frames (ORF) are 
separated by non-transcribed intergenic regions, which overlap between the 
VP30 and VP24 genes, and are known to contain highly conserved signals for 
the transcription–initiation and –termination (Feldmann et al., 1992; Mühlberger 
et al., 1996; Sanchez et al., 1993; Weik et al., 2005). Transcription-re-initiation is 
prone to failure at every gene border, resulting in a constant decline of 
transcription of the following gene (Shabman et al., 2013; Shabman et al., 2014). 
Therefore, the quantity of viral mRNAs forms a gradient, with NP as the most 
abundant and L as the least transcribed gene (Shabman et al., 2013; Shabman 
et al., 2014).  
  
 
Figure 4: Genome organization of the Marburg virus  
The non-segmented negative strand virus genome starts with the 3‘ leader followed by the sequences 
coding for the viral proteins NP, VP35, VP40, GP, VP30, VP24 and the L protein (gray boxes) and 
ends with the 5’ trailer sequence. Between the protein encoding sequences are non-transcribed 
intergenic sequences (white boxes) containing an overlap between VP30 and VP24. 
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1.6 Functions of Marburg virus proteins and mutations 
detected in rodent-lethal Marburg virus 
 
1.6.1 Nucleoprotein (NP) 
 
This chapter will briefly introduce the MARV proteins. The aim is to give an insight 
into the main functions of the viral proteins for the viral life cycle and to provide 
informations about the presence, of mutations that were detected in RL-MARV. 
In addition, information about studies devoted to the impact of RL-MARV 
mutations on the viral protein function in a new species will be shown. 
The nucleoprotein (NP) encapsidates the genomic and antigenomic viral RNAs 
and serves as the structural basis of the nucleocapsid complex necessary for 
transcription and replication (Mühlberger et al., 1998). During virus infection or 
single ectopic expression, NP accumulates in perinuclear inclusion bodies. Viral 
inclusion bodies represent the site of viral transcription and replication (Becker et 
al., 1998; Hoenen et al., 2012). NP directly interacts with VP30, VP35 and shows 
weak interactions with VP40 (Becker et al., 1998; Bharat et al., 2011; Dolnik et 
al., 2008; Dolnik et al., 2010; Liu et al., 2011; Spiegelberg et al., 2011).  
 
In total only three mutations, T14S, Y210H and Y536H have been observed in 
NP from four RL-MARV strains (Cross et al., 2015; Lofts et al., 2007; Lofts et al., 
2011; Warfield et al., 2009) (Fig. 5). Interestingly the mutation T14S was 
observed twice in a guinea pig- and a mouse-lethal Marburg Ravn virus (Cross 
et al., 2015; Warfield et al., 2009). The effect of these mutations in NP on the 
virulence of the rodent-lethal viruses has not been investigated to date.  
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1.6.2 Viral protein 35 (VP35) 
 
The viral protein 35 (VP35) acts as a polymerase cofactor and is mandatory for 
efficient viral replication and transcription (Mühlberger et al., 1998; Mühlberger et 
al., 1999). VP35 binds to L and leads to a re-localization of L into NP-derived 
inclusions (Becker et al., 1998). Besides these functions VP35 blocks the 
interferon (IFN) production, by prevention of the activation of retinoic acid 
inducible gene I (RIG-I) through binding to dsRNA (Bale et al., 2012; Ramanan 
et al., 2012).  
 
In total nine amino acid substitutions were observed in VP35 from four different 
strains of RL-MARV (Lofts et al., 2007; Marzi et al., 2016; Qiu et al., 2014; 
Warfield et al., 2009) (Fig. 5). All mutations were located in the N-terminal region 
of VP35 (Lofts et al., 2007; Qiu et al., 2014; Warfield et al., 2009). No studies 
were performed to analyze the importance of these mutations in VP35 for the 
virulence of MARV in rodents. An effect of these mutations on the IFN 
antagonistic function of VP35 has not been analyzed, perhaps, because the IFN 
inhibitory domain is located in the C-terminal domain of VP35 (Albariño et al., 
2015; Ramanan et al., 2012).  
 
1.6.3 Viral protein 40 (VP40) 
 
The viral protein 40 (VP40) is encoded by the third MARV gene, contains 303 
amino acids, and fulfils many functions in the viral life cycle: assembly, budding, 
IFN antagonist, regulator of transcription and replication. VP40 consists of an N-
terminal domain important for homo-oligomerization and an containing an 
interferon antagonistic function, and a C-terminal domain vital for membrane 
binding (Oda et al., 2015). VP40 is synthesized as cytosolic protein and 
associates rapidly after synthesis with membranes (Kolesnikova et al., 2004a). 
VP40 is the driving force of particle assembly and budding, single ectopic 
expression of VP40 results in production and release of filamentous virus-like 
particles (VLPs), resembling virions (Kolesnikova et al., 2004b; Noda et al., 2002; 
Swenson et al., 2004). Co-expression of VP40 and nucleocapsid proteins results 
in redistribution of nucleocapsid proteins from the perinuclear region to the 
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plasma membrane and incorporation of nucleocapsid-like complexes into VLPs 
(Dolnik et al., 2008; Kolesnikova et al., 2007b; Mittler et al., 2007; Wenigenrath 
et al., 2010). Remarkably, not only nucleocapsid proteins, but also GP can be 
redistributed by VP40 to the site of budding, for example, in polarized cells 
apically located GP is redistributed to the basolaterally located VP40-enriched 
membrane clusters (Kolesnikova et al., 2007b). Due to an unknown mechanism 
co-expression of VP40 and GP enhances the release of VP40-induced VLPs 
(Han & Harty, 2005; Kolesnikova et al., 2004b; Swenson et al., 2004).  
 
In MARV infected cells, VP40 is detectable in multivesicular bodies and to a 
lesser extent in inclusion bodies and in the nuclei (Kolesnikova et al., 2004b). A 
role of VP40 in regulation of transcription and replication has been observed, but 
is poorly understood (Hoenen et al., 2010). VP40 has a regulatory role on 
minigenome replication and transcription and substantially suppresses the 
reporter gene activity upon co-expression in the minigenome system (Hoenen et 
al., 2010; Koehler et al., 2016; Koehler et al., 2015).  
 
MARV VP40 is a potent IFN antagonist. It inhibits the activation of the Jak-STAT 
pathway by inhibiting the phosphorylation of Janus kinase 1 (Jak1) (Valmas et 
al., 2010). Regulation of the different VP40 functions remains poorly understood, 
it might be mediated through specific structural states of VP40 such as 
monomers, dimers and higher oligomers (Dolnik et al., 2008; Lenard, 1996; Oda 
et al., 2015).  
 
Almost all so far developed RL-MARVs contain mutations in VP40 (Fig. 5). Up to 
ten mutations (Y7H, Y19H, Y27S, L34P, V57A, Q112L, T165A, D184N, N189S, 
T190A) in VP40 have been detected in mouse-lethal MARV Ravn, and from one 
to three mutations have been observed in VP40 of guinea pig-lethal MARV (Cross 
et al., 2015; Lofts et al., 2007; Lofts et al., 2011). Analysis of MA-MARV mutations 
in VP40 was devoted to the interferon antagonistic function of VP40 in a new host 
(Fig. 5) (Feagins & Basler, 2015; Valmas & Basler, 2011). It has been shown that 
the mutations V57A, T165A and G79S are important while, D184N, Y7H, Y19H, 
Y27S, L34P, Q112L, N189S and T190A are not important for the inhibition of the 
interferon signaling in mouse cells (Feagins & Basler, 2015; Valmas & Basler, 
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2011). 
The D184N mutation is of special interest due to its repeated occurrences in 
VP40 of rodent-lethal MARV strains (Lofts et al., 2007; Lofts et al., 2011; Marzi 
et al., 2016; Warfield et al., 2009). The D184N mutation in VP40 appeared at 
early passages in two MA-MARV strains suggesting its necessity for adaption of 
MARV to rodents (Lofts et al., 2011). In addition, the D184N mutation is present 
in the reference sequence of MARV Ci67, obtained after several passages in 
hamsters (Lofts et al., 2011). However, the impact of the D184N mutation in VP40 
for the MARV pathogenicity in rodents remains unclear.  
 
1.6.4 Glycoprotein (GP) 
 
The single surface glycoprotein GP, is the only MARV protein which is 
synthesized at the endoplasmatic reticulum (Feldmann et al., 1991). Following 
synthesis, GP is post-translationally modified by glycosylation, phosphorylation 
and acylation (Becker et al., 1996; Feldmann et al., 1991; Funke et al., 1995; 
Sänger et al., 2002). GP is cleaved in the trans Golgi network into GP1 and GP2 
by either furin or furin-like proteases (Volchkov et al., 2000b). The subunits 
remain linked via two disulfide bonds (Volchkov et al., 2000b). Trimers of filoviral 
GP are present in the viral envelope, necessary for virus attachment and cell 
entry through binding to the endosomal/lysosomal receptor Niemann-Pick C1 
(NPC1) (Carette et al., 2011).  
 
Only four amino acid mutations, F445P, N422D, N283H and G435A have been 
observed in GP of mouse-lethal MARV (Cross et al., 2015; Lofts et al., 2011; Qiu 
et al., 2014) (Fig. 5). Whether these mutations in GP improve MARV entry into 
mouse cells remains to be analyzed.  
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1.6.5 Viral protein 30 (VP30) 
 
The viral protein 30 (VP30) is a component of the nucleocapsid complex and 
recruited by NP into perinuclear inclusion bodies (Becker et al., 1998). The role 
of VP30 in the viral life cycle is not fully understood. MARV VP30 is not essential 
for replication and transcription in a minigenome based reporter assay, however 
presence of VP30 is crucial to rescue recombinant MARV (Enterlein et al., 2006; 
Mühlberger et al., 1998). VP30 has a regulatory role on viral transcription, since 
siRNA mediated knockdown of VP30 reduced the transcription of all other viral 
mRNAs (Fowler et al., 2005).  
 
Only one mutation, N103D, has been found in VP30 of a mouse-lethal MARV 
(Qiu et al., 2014) (Fig. 5). The importance of this mutation for the increased MARV 
pathogenicity in rodents is unknown.  
 
1.6.6 Viral protein 24 (VP24) 
 
The viral protein 24 (VP24) is the smallest MARV protein. Within the virion, VP24 
is in close proximity to the nucleocapsid, supporting the growing evidence that it 
might act as a condensation factor of the nucleocapsid complex (Bharat et al., 
2011; Watt et al., 2014). A role of VP24 as nucleocapsid maturation factor or its 
importance for viral assembly has been presumed as well (Bamberg et al., 2005). 
It has been shown that a Flag-tagged MARV VP24 does not suppress viral 
replication and transcription (Bamberg et al., 2005). The specific role of VP24 
remains enigmatic.  
 
Three amino acid changes in VP24 were found in mouse-lethal MARV, V157M, 
V66I and L216S (Fig. 5) (Cross et al., 2015; Qiu et al., 2014). The relevance of 
these mutations for the higher MARV virulence in rodents remains unknown.  
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1.6.7 Polymerase L protein (L) 
 
The polymerase L protein (L) is the largest of the seven MARV proteins. It 
consists of 2331 amino acids and has an apparent molecular weight of 267 kDa 
(migrates at ~220 kDa in SDS-PAGE) (Mühlberger et al., 1992). L together with 
VP35 forms the RNA-dependent RNA polymerase (RdRp) complex essential for 
viral transcription and replication of the viral genome (Becker et al., 1998; 
Mühlberger et al., 1998). The MARV L protein has six conserved regions (CR I - 
VI) which show a high degree of sequence homologies with L proteins of other 
non-segmented negative strand (NNS) RNA viruses (Mühlberger et al., 1992; 
Poch et al., 1990). The CR I - IV of MARV L are presumed to be part of the 
predicted RNA-dependent RNA polymerase domain (Liang et al., 2015; Poch et 
al., 1990). CR III contains the highly conserved GDN motif which is present in all 
L proteins of NNS RNA viruses (Liang et al., 2015; Poch et al., 1990). Mutations 
in or in close proximity to the GDN motif severely abolish the polymerase function, 
supporting the idea that CR III represents the active site of the L protein (Magoffin 
et al., 2007; Malur et al., 2002; Noton et al., 2012; Schnell & Conzelmann, 1995; 
Sleat & Banerjee, 1993; Smallwood et al., 2002). CR IV most likely encodes the 
mRNA capping domain necessary for production of mRNAs. CR VI is suggested 
to encode a methyltransferase domain important for regulation of viral 
transcription (Poch et al., 1990). While CR I - IV are highly conserved among L 
proteins of NNS, CR V and CR VI are more variable and considered as regions 
that interact with host cell cofactors (Dortmans et al., 2011; Poch et al., 1990; 
Sidhu et al., 1993).  
 
Adaptive mutations in the L protein of MARV upon passaging in rodents were 
observed only once, in a guinea pig-adapted MARV. All three detected mutations 
were located in the active site of the L protein (Fig. 5) (Lofts et al., 2007). The 
functional relevance of these guinea pig-adaptive mutations in L is unknown. 
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Figure 5: Scheme representing amino acid substitutions in rodent-lethal MARVs 
Amino acid substitutions are indicated by the one letter amino acid code and the position of the substitution 
within each gene is marked by arrows. Red colored substitutions indicate mutations which have been 
demonstrated to have an impact on the species-specific protein function. MA (Mouse-adapted), GPA (Guinea 
pig-adapted), HA (Hamster-adapted), Ravn (Marburg virus Ravn isolate), Mus (Marburg virus Musoke 
isolate), Ang (Marburg virus Angola isolate). Figure modified from (Banadyga et al., 2016). 
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1.7 The viral replication cycle 
 
In a simplistic view virus replication can be divided into three phases. First, virions 
attach to the host cell and enter via macropinocytosis (Mulherkar et al., 2011; 
Nanbo et al., 2010). Second, transcription and replication of the viral genome 
takes place. Third, newly produced viruses assemble and bud from the infected 
cell.  
Research on the attachment and entry mechanisms of MARV are limited 
compared to EBOV. However, due to high structural similarities of the filoviral 
glycoproteins, it is assumed that cell entry is achieved in a similar manner 
(Hashiguchi et al., 2015; Koellhoffer et al., 2012).  
Figure 6: The viral replication cycle  
Attachment and binding of MARV virions to the host cells can be facilitated through several surface 
molecules such as DC-SIGN or TIM-1 (1). MARV particles enter the cell predominantly via 
macropinocytosis (2). By interaction of GP with NPC1 the viral envelope fuses with the endosomal 
membrane, leading to entry of the nucleocapsid into the cytoplasm (3). Steps 4-6 are processes that are 
carried out in inclusion bodies, they are shown in the transparent red box. Once the nucleocapsid 
entered the cell, primary transcription is initiated and production of viral mRNAs starts (4). The viral 
mRNAs are translated into the corresponding proteins (5). Production of the viral proteins supports 
secondary transcription and finally leads to replication of the viral genome via the intermediate 
antigenome (6). Maturation of the nucleocapsids takes place in the inclusion bodies (red), the mature 
nucleocapsids are transported to the plasma membrane via polymerization of actin (7). In close proximity 
to the membrane the mature nucleocapsid comes in close contact to VP40 (yellow) and GP (black 
speckles) leading to assembly of the viral particles (8). The virus particle is released into the supernatant 
via filopodia (9). 
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Filoviral attachment and entry is provided by interactions with one or multiple 
cellular receptors e.g. T-cell immunoglobuline and mucin domain 1 (TIM-1), Ax1, 
Mer and several C-type lectins including DC-SIGN and LSECtin (Fig. 6, step 1) 
(Becker et al., 1995; Brindley et al., 2011; Gramberg et al., 2005; Kondratowicz 
et al., 2011; Marzi et al., 2004; Shimojima et al., 2006). However, cells lacking 
these molecules are still susceptible to filoviral infection, suggesting the presence 
of additional mechanisms for viral attachment and entry (Kondratowicz et al., 
2011; Matsuno et al., 2010). Existence of such mechanisms would explain the 
wide cell tropism of filoviruses (Kondratowicz et al., 2011; Sinn et al., 2003). The 
major entry route of filoviruses into target cells is considered to be 
macropinocytosis, the macropinosome fuses subsequently with endosomes (Fig. 
6, step 2) (Aleksandrowicz et al., 2011; Bhattacharyya et al., 2011; Mulherkar et 
al., 2011; Nanbo et al., 2010; Saeed et al., 2010). GP1 is proteolytically activated 
by endosomal host proteases (Chandran et al., 2005; Misasi et al., 2012). 
Activation of GP1 allows binding to the filovirus specific endosomal receptor 
Niemann-Pick 1 (NPC1), while GP2 mediates fusion between the viral and the 
endosomal membrane (Fig. 6, step 3) (Carette et al., 2011; Markosyan et al., 
2016). Enzymes that proteolytically activate GP1 are unknown for MARV, but it 
has been shown that EBOV GP is activated by Cathepsin B and L (Gnirss et al., 
2012). Upon fusion of the viral envelope and the endosomal membrane the viral 
nucleocapsid is released into the cytoplasm (Koellhoffer et al., 2012; Markosyan 
et al., 2016).  
Primary transcription and production of viral mRNAs starts soon after the entry of 
the nucleocapsid into the cytoplasm and is detectable 2-4 h post EBOV infection 
(p.i.) (Fig. 6, step 4) (Hoenen et al., 2012; Nanbo et al., 2013). Transcription is 
carried out by the polymerase complex consisting of NP, VP35 and L (Mühlberger 
et al., 1998). MARV VP30 seems to have a supportive role (Mühlberger et al., 
1998). Initiation of transcription occurs at the 3’-leader region of the genome 
exclusively (Mühlberger et al., 1999). The transcribed mRNAs follow a gradient 
as previously explained, see chapter 1.4 (Shabman et al., 2013; Shabman et al., 
2014).  
Translation of viral mRNAs is facilitated by the host translational machinery (Fig. 
6, step 5). Except GP, all viral mRNAs are translated by free ribosomes in close 
proximity to the perinuclear region. Translation of the NP mRNA, which is the 
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most abundant, results in formation of perinuclear inclusion bodies (Kolesnikova 
et al., 2000). GP is synthesized on ER associated ribosomes, it is processed and 
transported to the cell surface via the secretory pathway (Volchkov et al., 2000b). 
 
Replication of viral genomes occurs in perinuclear inclusion bodies and can be 
detected 12-16 h p.i. by reverse transcription quantitative PCR (RT-qPCR) and 
in-situ hybridization (Fig. 6, step 6) (Hoenen et al., 2012; Nanbo et al., 2013). 
During replication, the 5’-3’ antigenome is synthesized, which then serves as 
template for the synthesis of negative sensed viral 3’-5’ genomes (Fig. 6, step 6). 
Both, the 3’- and the 5’- end contain short complementary sequences of 13 
nucleotides, which most likely provide binding sites for the polymerase complex 
(Enterlein et al., 2009; Whelan et al., 2004). The viral antigenome and viral 
genome are encapsidated by the nucleoprotein, preventing viral RNA from 
degradation by cellular RNases (Mühlberger et al., 1998; Mühlberger et al., 
1999).  
 
Mature nucleocapsids assemble and accumulate in inclusion bodies, their 
transport to the plasma membrane depends on polymerization of actin (Fig. 6, 
step 7) (Schudt et al., 2013). Envelopment of nucleocapsids with VP40- and GP-
enriched membrane and fission of viral particle from plasma membrane leads to 
the formation of infectious virions. Budding of infectious virions occurs at the tip 
of filopodia and to a lesser extent at the flat surfaces of the plasma membrane 
(Fig. 6, step 8-9) (Bharat et al., 2011; Kolesnikova et al., 2007a; Kolesnikova et 
al., 2007b; Welsch et al., 2010). Filopodia are known as dynamic, actin enriched, 
filamentous cellular protrusions, which are hijacked by filoviruses, and most likely 
provide efficient transfer of virus particles to neighboring cells (Faix & Rottner, 
2006; Kolesnikova et al., 2007a). 
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1.8 BSL-2 models as a tool to study the function of viral 
proteins in a new host 
 
Reverse genetics are commonly used for BSL-3/4 viruses to develop powerful 
BSL-2 compatible tools able to simulate multiple steps of the viral life cycle 
(Schmidt & Mühlberger, 2016; Wenigenrath et al., 2010). These model systems 
are useful for the analysis of functional changes in viral proteins induced by 
mutations, e.g., adaptive mutations occurring in rodent-lethal filoviruses. 
Reverse genetics are defined by the directed introduction of nucleotide changes 
 
Figure 7: MARV reverse genetic systems  
(A) Minigenome system, (B) infectious virus-like particle system and the (C) Rescue system for 
recombinant viruses. In the minigenome system viral replication and transcription process is simulated 
by transfection of plasmids encoding NP, VP35, VP30, L and the minigenome (A). In the iVLP system 
additional transfection of VP24-, GP- and VP40-encoding plasmids leads to production of infectious 
virus-like particles (B). All systems require transfection of the T7 polymerase (T7-pol) facilitating efficient 
expression of the negative orientated RNA minigenome or the full-length RNA genome. Viral RNA 
minigenomes or the full-length genomes are encapsidated by the expressed nucleocapsid proteins. 
Transcription of the minigenome leads to reporter gene expression in the minigenome and iVLP system 
(A, B). iVLPs can be used for infection of indicator cells (B). Plasmids in brackets are not crucial for 
efficient replication and transcription but enhance the reporter gene activity. Figure modified from 
(Schmidt & Mühlberger, 2016). 
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within a specific gene, for example, into viral genes, and the subsequent 
characterization of the resulting phenotype. Application of plasmids encoding 
mutated proteins and relevant assays in cell lines of different species might help 
to understand whether mutations can provide rodent-lethal MARV with species-
specific advantages.  
 
1.8.1 Minigenome system 
 
The first minigenome system was developed in the early 90s for the vesicular 
stomatitis virus (Pattnaik et al., 1992; Pattnaik & Wertz, 1990; 1991). The 
minigenome systems for filoviruses were developed in 1998 (Mühlberger et al., 
1998; Mühlberger et al., 1999). The MARV minigenome contains the 3’- and 5’- 
sequences of the viral genome which contain the cis-acting signals for initiation 
of replication, transcription and encapsidation under the control of the T7 
promoter, as well as the sequence encoding a reporter gene (Mühlberger et al., 
1998). Transfection of cells with the minigenome encoding plasmid, plasmids 
encoding the T7 polymerase (T7-pol) and the viral proteins NP, VP30, VP35 and 
L allows synthesis of the T7-pol-derived minigenomic RNA (Mühlberger et al., 
1998; Schmidt & Mühlberger, 2016). The negative-sensed RNA minigenome is 
then encapsidated by NP. The resulting mininucleocapsid is transcribed by the 
ectopically expressed viral polymerase complex to generate the reporter mRNA, 
which is subsequently translated to the reporter protein (Fig. 7A). While the 
original MARV minigenome contained a chloramphenicol acetyltransferase as 
reporter, the minigenome used in this study encoded the Renilla luciferase. Thus, 
measurement of the luciferase reporter gene activity allowed to determine and 
compare the transcription and replication activity in cells derived from different 
species, as well as for wild type and mutated nucleocapsid complex proteins.  
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1.8.2 Infectious virus like particle (iVLP) assay  
 
The expression of all plasmids required for the minigenome assay together with 
the expression of plasmids encoding VP40, GP and VP24 results in production 
of infectious virus-like particles (iVLP) (Wenigenrath et al., 2010). The iVLP assay 
allows to study the assembly, budding and infectivity of iVLP (Fig 7B). Application 
of this assay can clarify e.g., which step of virus assembly is influenced by 
adaptive mutations in viral proteins.  
 
1.8.3 Rescue system of recombinant MARV 
 
Rescue systems of NNS viruses are available since the mid-90s and have greatly 
improved the understanding of the viral life cycle and functions of viral proteins 
(Schnell et al., 1994). Rescue of recombinant full-length viruses is based on a 
DNA plasmid that encodes the full length viral genome under the control of the 
T7-pol (Albariño et al., 2013b; Enterlein et al., 2006; Krähling et al., 2010). 
Presence of the T7-pol allows the generation of the full-length genome template 
which is then replicated and packaged into infectious virus particles by the 
ectopically expressed viral nucleocapsid proteins (Schmidt & Mühlberger, 2016). 
Recombinant MARVs have been used in several studies to determine the effect 
of mutations in the viral genome on virus production (Albariño et al., 2015; Dolnik 
et al., 2014; Mittler et al., 2013). Addition or deletion of genes in a new ORF or 
tagging of viral proteins have been successfully performed (Fig. 7C) (Enterlein et 
al., 2006; Halfmann et al., 2008; Schmidt et al., 2011; Schudt et al., 2013).   
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1.9 Aim of the study 
The virulence of MARV is species-specific. While being highly pathogenic in 
humans and non-human primates, MARV is non-virulent for rodents. An increase 
in pathogenicity of MARV in rodents can be induced by multiple passages of the 
virus in rodents. Those rodent-lethal MARVs harbor several mutations in the viral 
genome (Fig. 5). A guinea pig-lethal MARV established by Lofts et al. in 2007 
harbors four amino acid changes, a D184N mutation in VP40 and three 
mutations, S741C, D758A and A759D, in the L protein (Fig.5). How these 
mutations influence the function of viral proteins in the guinea pig cells remains 
obscure.  
 
VP40 is a multifunctional protein that fulfills many important functions in the viral 
life cycle (Fig. 8) (Kolesnikova et al., 2012). This work aims to determine the effect 
of the D184N mutation in VP40 on the different functions of VP40, such as virus 
assembly, budding, inhibition on replication and transcription and the VP40-
mediated interferon antagonism in guinea pig and human cells (Dolnik et al., 
2008; Hoenen et al., 2010; Kolesnikova et al., 2004a; Kolesnikova et al., 2004b; 
Valmas et al., 2010). This will be clarified using different methods to investigate 
 
Figure 8: Schematic presentation of the aims of the study  
Mutations present in viral proteins of the guinea pig-lethal MARV (Lofts et al. 2007) are indicated by 
arrows above the schematic viral genome. The boxes show the single functions of the viral proteins 
VP40 (yellow) and L (green) and the approaches that will be used to determine the impact of these 
mutations on the protein functions in human and guinea pig cells. 
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the influence of the D184N mutation on the multiple functions of VP40 in human 
and guinea pig cells (Fig. 8).  
  
The viral polymerase L is essential for transcription and replication (Fig. 8) 
(Becker et al., 1998; Mühlberger et al., 1998; Mühlberger et al., 1999). There are 
no antibodies that detect the MARV polymerase L, therefore, to allow efficient 
detection of the L protein by Western blotting and immunofluorescence a 
functional L protein containing a mCherry-tag will be created. Furthermore, we 
plan to insert all possible combinations of the guinea-pig lethal mutations into the 
fluorescently tagged L protein to characterize the effect of these mutations on 
replication and transcription activity (Fig. 8). This will be addressed by analysis of 
the wildtype L protein or the L mutants in minigenome reporter assays in human 
and guinea pig cells (Fig. 8). Additionally, a possible additive effect of the single 
D184N mutation in VP40 and relevant L mutations on replication and transcription 
will be analyzed using the minigenome assay. It is expected that these studies 
will elucidate the role of the mutations present in the guinea pig-lethal MARV for 
the species-specific improvement of the viral protein functions and increase of 
viral fitness. This study could lead to a better understanding of factors that 
modulate MARV virulence.  
 
The aim of this study was to analyze the species-specific effects of these guinea 
pig-adaptive mutations on the function of VP40 and L (Fig. 8). 
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2 Methods 
 
2.1 Molecular biological and biochemical methods 
 
2.1.1 Polymerase chain reaction (PCR), amplification of specific 
DNA sequences 
 
The polymerase chain reaction (PCR) is a method used to amplify specific DNA 
sequences in vitro. Short complementary DNA sequences (15-25 bp), so called 
primers, provide the sequence specificity of the reaction. The primer pair binds to 
the target sequence and is recognized by DNA dependent DNA polymerases, 
leading to synthesis and amplification of the desired fragment. Depending on the 
aim and strategy of the cloning project, the 5’- end can be modified to introduce 
additional restriction enzyme cutting sites or small tags (e.g. myc-tag). DNA 
polymerases contain a 5’-3’ polymerase activity as well as a proofreading activity 
carried out by the 3-5’ exonuclease activity able to correct mismatches of the 
newly synthesized DNA strand. Polymerases can differ in their replication and 
error rate. The commonly used Pwo polymerase has a low error rate (McInerney 
et al., 2014). PCR products were purified via agarose gel electrophoresis and 
subsequent gel extraction with the E.Z.N.A Gel Extraction Kit. A reaction for a 
PCR was set up as following according to the manufacturer’s manual: 
Reagent Amount 
DNA sample 25-100 ng 
dNTPs each 10 mM 
Forward primer 12.5 µM 
Reverse primer 12.5 µM 
10x buffer, Peqlab 5 µL 
Pwo Polymerase (1 U/ µL), Peqlab 0.125 µL 
dH20  Ad 50 µL 
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2.1.2 Separation and visualization of DNA via gel 
electrophoresis 
 
DNA has a negative charge provided by the phosphate groups. DNA fragments 
of different size are separated, depending on the agarose concentration of the 
agarose gels, by their physicochemical properties. The concentration of agarose 
in the gels varies depending on the size of the desired fragments but is usually 
between 0.5 and 2 %. The agarose was solved by heating in 1x TAE buffer and 
poured into an agarose gel chamber. 10-30 µL of sample were mixed with 6x Gel 
Loading Dye (NEB). As a marker for the fragment size 5 µL of the O’GeneRuler 
1 kb Plus DNA Ladder (Thermo Scientific) were used. The gel electrophoresis 
ran at 100 V at maximum current for ~1 h with 1x TAE-buffer, pH 8.0 (chapter 
7.5). DNA was stained with an aqueous ethidium bromide solution (1 µg/mL) for 
at least 15min. The ethidium bromide stained DNA was visualized with the 
GelDoc 2000 system (BioRad). 
 
2.1.3 DNA digestions via restriction enzymes 
 
Restriction enzymes can hydrolytically cleave double stranded DNA (dsDNA) via 
specific, often palindromic, nucleotide motifs. Restriction enzymes are used to 
generate DNA fragments for insertion into a plasmid. Alternatively, restriction 
enzymes can be used as a diagnostic tool, digestion of a plasmid at specific sites 
will result in a distinct band pattern upon agarose gel electrophoresis. Different 
DNA molecules, which differ in the number or position of restriction sites generate 
different DNA band patterns upon agarose gel electrophoresis. The used enzyme 
 Temperature Time Cycles 
Denaturation 94°C 2 min 1 
Denaturation 94°C 15 sec 
30-40 Annealing 50-65°C 30 sec 
Elongation 72°C 1 min/kb 
Elongation 72°C 2 min 1 
Storage 4°C ∞ 1 
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buffers and reaction conditions may vary between enzymes. 1-20 µg of DNA were 
used for one reaction. The reactions were performed according to the NEB 
manufacturers guide or for double digestions according to the DoubleDigest 
finder tool available at the NEB homepage (www.neb.com/tools-and-
resources/interactive-tools/double-digest-finder). The purification of the digested 
DNA fragment was performed with the E.Z.N.A DNA Probe Purification Kit or by 
separation of the fragment of interest on an agarose gel and consecutive sample 
purification with the E.Z.N.A. Gel Extraction Kit. 
 
Set up for a diagnostic digestion:  100-500 ng of DNA  
1 µL 10x buffer according to the 
manufacturers guide  
(1 µL of 10% BSA, optional)  
1-5 U restriction enzyme  
ad 10 µL dH2O  
 
Set up for digestion of DNA for cloning:  5-20 µg of DNA  
10 µL 10x buffer according to the 
manufacturers guide  
(10 µL of 10% BSA, optional)  
10-20 U restriction enzyme  
ad 100 µL dH2O 
 
2.1.4 DNA purification 
 
DNA fragments resulting from PCR amplification or restriction digests were 
purified using the E.Z.N.A. DNA Probe Purification Kit according to the 
manufacturer’s protocol. The purification of specific fragments from agarose gels 
was done using the E.Z.N.A Gel Extraction Kit. The fragment of interest was 
removed from the agarose gel using a scalpel and a UV-light table (λ=302 nm). 
Purified DNA was stored at -20°C.  
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2.1.5 Dephosphorylation of DNA 
 
In commonly used cloning strategies fragments of interest are inserted into 
linearized plasmids. Dephosphorylation via e.g. alkaline phosphatases are 
routinely used to restrict the religation of the linearized plasmid reducing the 
background of the ligation reaction. 1-20 µg of DNA (chapter 2.1.3) were used in 
a volume of 87 µL dH2O for one reaction. The calf intestine phosphatase (CIP) 
and the dephosphorylation buffer (CIP buffer) were purchased from Roche. The 
dephosphorylation was performed according to the manufacturer’s instructions. 
Reagent Volume [µL] 
Linearized vector (1-20 µg)  87 
10x CIP buffer, Roche 10 
CIP (1 U/ µL), Roche 3 
 
The reaction was incubated for 75 min at 37°C. The dephosphorylated DNA was 
purified via the E.Z.N.A DNA Probe Purification kit.  
 
2.1.6 Ligation of DNA fragments into linearized vector 
 
DNA ligases catalyze binding of phosphodiester bonds between a free 5’- 
phosphate from a DNA strand and a free 3’-OH of another adjacent DNA strand. 
This allows to clone DNA fragments into a linearized dephosphorylated vector. 
The ligation reaction was performed using the T4 DNA ligase (NEB) for at least 
1 h at RT according to the manufacturer’s protocol. The reaction mix was then 
transformed into competent bacteria (chapter 2.1.7). Due to their size (>19 kb) 
full-length plasmids were ligated overnight at 16°C.  
 
 
 
 
 
Reagent Volume [µL] 
Fragment of interest 100-200 ng 
Vector DNA 25-50 ng 
Ligation buffer 10x, NEB 2 
T4 DNA Ligase, NEB 0.5 
dH20 Ad 20 
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2.1.7 Transformation and selection of plasmids in bacteria 
 
Upon transformation plasmid DNA is transferred into competent bacteria. 
Competent bacteria were prepared by treating E.coli (XL1 blue) according to the 
Z-Competent™ E.coli Transformation Kit (ZymoResearch). The transformation 
was carried out by thawing 100 µL of competent bacteria on ice and addition of 
DNA (e.g. 10 µL ligation reaction, 100 ng of plasmid DNA). The mixture of 
competent bacteria and DNA was incubated on ice for 20 min. After the 
transformation 100 µL of the bacteria were added to the LB plates (chapter 7.7.1) 
and incubated for >16 h at 37°C. LB plates contained 100 µg/mL of ampicillin, 
allowing efficient and selective growth of successfully transformed bacteria. PCR 
products from the QuikChange™ Multi Site Directed Mutagenesis Kit (Agilent) 
were transformed according to the protocol provided by the manufacturer.  
 
2.1.8 DNA preparation from bacteria (mini-/ maxi-prep) 
 
Plasmids were isolated from bacteria either from small scale 5 mL (mini prep) or 
large scale cultures 150 mL (maxi prep). The LB media (chapter 7.7.1) containing 
100 µg/mL of ampicillin, for specific selection of the plasmid, was inoculated with 
a single bacterial colony. The inoculated media was incubated overnight (>16 h) 
at 37°C. Isolation of the plasmid DNA was performed using the manufacturer’s 
protocol of either the E.Z.N.A Plasmid DNA Mini Kit I for mini preps or the E.Z.N.A 
FastFilter Plasmid DNA Maxi Kit for maxi preps. The isolated plasmid DNA was 
eluted in 50 µL (mini preps) or 1.5 mL (maxi preps) of elution buffer. The quality 
and concentration of the DNA was controlled using a photometer (NanoDrop Lite, 
Thermo Scientific). The sequence integrity was controlled via sequencing.  
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2.1.9 DNA quantification via the NanoDrop 
 
DNA can be quantified directly in aqueous solutions due to the direct relation of 
the optical density and the DNA concentration at a wavelength of 260 nm (OD 
260). The calculation for the concentration of double stranded DNA is based on 
the following equation:  
 
OD 260 x dilution x 50 = DNA concentration [µg/ µL]  
 
The quotient of the OD 260 to the OD 280 indicates the purity of the DNA. 
Quotients from 1.7 to 2.0 are considered as pure DNA preparations. Values <1.6 
indicate contaminations by proteins or RNA. All samples were measured with the 
NanoDrop Lite, Thermo Scientific.  
 
2.1.10 Site directed mutagenesis 
 
The QuikChange™ Multi Site Directed Mutagenesis Kit (Agilent) was used to 
insert single mutations, deletions or insertions into plasmids of interest. 
Mutagenic primers were designed with the online tool: QuikChange Primer 
Design, the mutagenesis of the plasmids was accomplished using the 
manufacturer’s protocol.  
 
2.1.11 One step quantitative real-time PCR (RT-qPCR) 
 
RT-qPCR is a very sensitive tool to detect and quantify a specific target sequence 
within a RNA pool. RT-qPCR can detect changes in the expression of target 
genes or determine the number of viral genome copies in a sample. RT-qPCR 
was performed according to the manufacturer’s protocol of either the QuantiTect® 
Probe RT-PCR Kit to determine the number of viral genomes or the QuantiTect® 
SYBR® Green RT-PCR Kit to detect minigenomes present in the supernatants of 
virus-infected cells or iVLP preparations. Viral genomes were detected by primers 
and probes specifically designed to detect a unique region of the MARV 
polymerase L gene. Minigenomes were detected by primers directed against 
unique regions in the minigenome. The viral genome copies were calculated via 
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a standard curve and the minigenome copies based on their CT value. One 
reaction for the QuantiTect® Probe RT-PCR Kit consisted of:  
 
Reagent Conc. Stock Volume [µL] 
5x QuantiTect™ RT-PCR buffer, Qiagen 5x 6 
QuantiTect™ RT Mix, Qiagen  1.2 
dNTPs 10 mM 1.2 
MARV rev 10 µM 0.6 
MARV Probe  10 µM 0.6 
DEPC H2O  7.28 
Template  10 
 
 Temperature Time Cycles 
Reverse transcription 50°C 30min 1 
Denaturation 95°C 15min 1 
Denaturation 94°C 20sec 
46 Annealing 58°C 45sec 
Elongation 72°C 15sec 
 
One reaction for the QuantiTect® SYBR® Green RT-PCR Kit was composed of: 
Reagent Conc. Stock Volume [µL] 
2x QuantiTect® SYBR Green RT 
PCR Master Mix, Qiagen 
2x 25 
Forward primer 0.5 µM 2.5 
Reverse primer 0.5 µM 2.5 
QuantiTect® RT Mix, Qiagen  0.5 
dH20   14.5 
Template  5 
  
Methods 
32 
 
 Temperature Time Cycles 
Reverse transcription 50°C 30 min 1 
Denaturation 95°C 15 min 1 
Denaturation 94°C 15 sec 
45 Annealing 55°C 30 sec 
Elongation 72°C 30 sec 
 
2.1.12 DNA sequencing 
 
Sanger sequence analyses were carried out by Seqlab laboratories. Samples 
were prepared as follows: 700-1500 ng of plasmid DNA and 30 pmol of the 
according primer were filled up to 15 µL with dH2O. Plasmids containing the full 
genomic sequence of MARV were linearized by restriction digest with the enzyme 
NaeI and PvuI and subsequently purified via the E.Z.N.A. DNA Probe Purification 
Kit and sequenced.  
 
2.1.13 Sodium dodecyl sulfate-polyacrylamide gel-
electrophoresis (SDS- PAGE) 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
commonly used method for separation of proteins based on their electrophoretic 
mobility. SDS serves as anionic detergent which denatures proteins and puts a 
negative charge on them. When an electric current is applied the proteins move 
towards the anode into an SDS containing polyacrylamide gel where the proteins 
will be separated predominantly by sheer size. The Tris-glycine or Tris-acetate-
gel consists of a 5% polyacrylamide stacking gel followed by a separation gel with 
a higher concentrations of polyacrylamide. 4x loading buffer was added to the 
samples and the samples were denatured for 10 min at 100°C. The samples and 
a marker protein mixture, PageRuler™ Prestained Protein Ladder Plus, 
containing proteins with a specific molecular weight, were loaded on a 12% gel 
and separated in a SDS chamber filled with SDS running buffer at 25 mA at 
maximum voltage for 45-60 min for detection of VP40. After separation the SDS 
gel was either used for silver staining or Western blot analysis. The chemicals 
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used for preparation of four Tris- glycine SDS gels shown in the Table below.   
For SDS-PAGE of samples aiming to detect the mCherry-tagged L, commercially 
available 7% Tris-acetate gels were purchased from BioRad, and the separation 
ran 1-2 h at constant 150 V. 
Chemical Stacking gel  
5% 
Separation gel 
12% 
dH20 6.8 mL 6.6 mL 
30% polyacrylamide solution 
(Rotiphorese® 30) 
1.7 mL 8 mL 
SDS PAGE Stacking gel buffer 1.25 mL --- 
SDS PAGE Separation gel buffer --- 5.3 mL 
APS 10% in dH20 0.1 mL 0.2 mL 
TEMED 0.01 mL 0.01 mL 
 
2.1.14 Silver Staining 
 
Silver staining is a fast and sensitive method for detection of proteins within a 
SDS gel. Silver staining of SDS gels was used to compare the protein 
composition of virus stocks between wildtype and mutant viruses. The silver 
staining was carried out according to the manufacturer’s instructions from the 
Pierce® silver stain kit. The gel was scanned and the band intensities where 
measured with the Image Lab software.  
2.1.15 Western Blot 
 
Western blotting allows the specific detection of proteins transferred from an SDS 
gel to a polyvinyldifluoride (PVDF) membrane using antibodies. Different variants 
of Western blotting techniques exist such as semi-dry and wet blotting. Semi-dry 
blotting works fast and is well suited for the detection of proteins with a low 
molecular weight. Semi-dry blotting was used for the blots shown in chapter 3.1-
3.7. Detection of large proteins is complicated using the semi-dry blotting 
approach, therefore for efficient detection of the mCherry-tagged polymerase 
(size of ~250 kDa) a wet blot protocol was used.  
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2.1.15.1 Semi-dry blotting 
 
Initially, the PVDF membrane was activated by incubation of the membrane in 
100% methanol and then transferred into 1x transfer buffer. Per SDS gel a total 
of 8 Whatman papers (6.3 x 9.1 cm) where wetted in 1x transfer buffer. The 
components were arranged onto the anode of a blotting chamber in the following 
order. 4 pieces of Whatman paper followed by the PVDF membrane and the SDS 
gel covered by 4 additional pieces of Whatman paper. Bubbles were removed by 
rolling of a glass pipette over the SDS gel layers. The blotting chamber was 
closed and the transfer from the SDS gel onto the PVDF membrane takes place 
at 20 V with a maximal current for 25 min.  
 
2.1.15.2 Wet blotting 
 
The PVDF membrane was activated by incubation in 100% methanol and then 
washed with 1x transfer buffer. A total of 8 Whatman papers (6.3 x 9.1 cm) where 
wetted in 1x transfer buffer. The components were arranged facing the anode of 
a blotting chamber in the following order. First a sponge followed by 4 pieces of 
Whatman paper then the PVDF membrane and then the SDS gel covered by 4 
additional pieces of Whatman paper and another sponge. A glass pipette was 
rolled over the SDS gel layers to remove bubbles. The blotting chamber, 
containing an ice pack, was closed and the transfer from the SDS gel onto the 
PVDF membrane was performed at 40 mA at 4°C over night. 
 
2.1.15.3 Staining of PVDF membranes 
 
Detection of the proteins by Western blotting relies on the ability of primary 
antibodies to bind specific proteins on the PVDF membrane, which in turn can be 
detected by secondary antibodies. The secondary antibody is commonly 
conjugated with fluorophores or horseradish peroxidase (HRP). HRP cleaves its 
substrate resulting in the emission of light. The emitted light is detected via the 
BioRad ChemiDoc system and stands in direct relation to the amount of protein 
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present on the PVDF membrane. Unspecific signals were blocked by incubation 
of the membrane in 10 % milk powder in PBSdef for 1 h at RT. The primary 
antibody was incubated on the membrane for 1h at RT. Unspecific bound 
antibodies were removed by three consecutive 5 min washes of the membrane 
with PBSdef + 0.1% Tween20. The secondary antibody was incubated for 1 h at 
RT followed by three 5 min washes with PBSdef + 0.1 % Tween20 and two washes 
with PBSdef. After addition of 1 mL of the SuperSignal™ West Femto Maximum 
Sensitivity Substrate per membrane, proteins were detected with the BioRad 
ChemiDoc system.  
Primary antibody Species Dilution 
α-VP40 (40-2-2) Mouse 1:500 
α-NP (59-9-10) Mouse 1:1.000 
α-GP (50-6-10) Mouse 1:10 
α-mCherry Mouse 1:1.000 
α-Tubulin Mouse 1:3.000 
α-Vinculin Mouse 1:5.000 
 
Secondary antibody Conjugate Species Dilution 
α-mouse HRP Mouse 1:30.000 
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2.2 Cell biological and virological methods 
 
2.2.1 Cultivation of mammalian cells 
 
The following cell lines were used in the present study: human Huh-7 cells, 
derived from a hepatoma and HEK293 derived from embryonic kidney cells; 
guinea pig cells derived from an adenocarcinoma (GPC16) and from fetal tissue 
(104C1) as well as cells from African green monkeys (VeroE6). The cells were 
grown in 75 cm² tissue culture flasks at 37°C and 5% CO2. DMEM+++ which 
contains 10% fetal calf serum (FCS), penicillin and streptomycin (P/S) and L-
Glutamine (Q) was used for cultivation of all cell lines, except 104C1 cells which 
were cultivated in RPMI+++ media. Passaging was performed under sterile 
conditions every 3-4 days once the cells reached confluency. Initially, media was 
removed from the cells and the cells were washed with pre-warmed PBSdef 
(37°C). This step removes Ca2+/Mg2+ allowing efficient cleavage of surface 
proteins by trypsin. PBSdef was removed and 2 mL of 0.05 % trypsin/EDTA was 
added and incubated until the cells detached from the surface. Trypsinization was 
stopped by adding 8 mL of pre-warmed DMEM+++ or RPMI+++. The desired 
number of cells was seeded into new tissue culture flasks or plates. 
 
2.2.2 Transient transfection of mammalian cells with TransIT© 
 
Plasmid DNA was delivered into eukaryotic cells by usage of cationic lipids which 
interact with the negative charged phosphates of the DNA backbone. In aqueous 
solutions these complexes form liposomes containing the plasmid DNA of 
interest. These liposomes interact and fuse with cellular membranes allowing 
recognition of the DNA in the cells and subsequent expression of the gene of 
interest. Transfection is performed on a 60-80% confluent monolayer of cells. The 
transfection mix of TransIT© and OptiMEM is prepared as recommended by the 
supplier (3 µL TransIT©/µg DNA). 
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For example for a transfection of a 12 well plate: 
 Mixture of Volume [µL] 
Mix 1 OptiMEM + DNA 50 
Mix 2 OptiMEM + TransIT 50 
 
Mix 1 and 2 are incubated separately for 5 min at RT, then thoroughly mixed and 
incubated at RT for additional 15 min. During that time period the cells are 
washed once with OptiMEM and then 900 µL of OptiMEM was added. After the 
incubation time the transfection mix was added carefully to the well and then 
incubated at 37°C and 5% CO2. 4-6 h post transfection the media was changed 
to 2 mL DMEM+++ or RPMI+++ depending on the transfected cell line. 
Depending on the assay the amount of DNA and TransIT© were adjusted 
accordingly. 
 
2.2.3  MARV specific minigenome reporter assay 
 
The MARV specific minigenome reporter assay was used to mimic and determine 
the transcription and replication capacity of the MARV nucleocapsid complex in 
cell lines from different species. Detailed information for the minigenome assay 
is available in chapter 1.8.1. The minigenome was essentially performed as 
described by (Koehler et al., 2016; Koehler et al., 2015; Mühlberger et al., 1998; 
Mühlberger et al., 1999) briefly, HEK293 cells or 104C1 cells (60-80% confluent) 
were transfected with all plasmids necessary for formation of the MARV 
nucleocapsid complex (L, NP, VP30, and VP35, a MARV-specific minigenome 
carrying the Renilla luciferase reporter gene) and the T7-pol. A pGL4 construct 
encoding Firefly luciferase was added to normalize the transfection efficiency. To 
test the effect of mutations in viral proteins, the wildtype encoding plasmids were 
substituted by plasmids containing mutations at specific sites, e.g. plasmids 
containing mutations in the active site of the L protein. In addition, other plasmids 
encoding viral proteins, such as VP40, were transfected and their impact on 
replication and transcription was analyzed in cell lines of different species. The 
mixture for one reaction in a 12 well plate was as follows:  
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Plasmids Promotor Amount [ng] 
1 pCAGGS-LWT resp. -LMutants β-actin (chicken) 400 
2 pCAGGS-NP β-actin (chicken) 100 
3 pCAGGS-VP30 β-actin (chicken) 20 
4 pCAGGS-VP35 β-actin (chicken) 20 
5 pAndy-3M5M 
(Renilla luciferase minigenome) 
T7 200 
6 pCAGGS- T7-pol β-actin (chicken) 100 
7 pCAGGS-pGL4 SV40 40 
 
A master mix is prepared from plasmids 2-7, resulting in the negative control 
without the L protein. Afterwards plasmid 1 is added. In chapter 3.5 increasing 
amounts of wildtype or VP40 mutant encoding plasmids were added. The 
transfection mix was removed after an incubation period of 4-6 h and 2 mL of 
DMEM+++ or RPMI+++ was added for 24 h to 48 h p.t at 37°C and 5% CO2. The 
cells were washed with 1 mL PBSdef and then harvested by scraping in 1 mL 
PBSdef. The cells are pelleted by 5000 rpm for 5 min. The supernatant was 
aspirated and the pellet was resuspended with 100 µL lysis buffer (2x Dual Lysis 
Juice, PJK GmbH) and incubated for 20 min at RT. Cellular debris was removed 
by centrifugation for 10 min at 13.000 rpm. The Renilla and Firefly luciferase 
activity of 5 µL from the supernatant was measured in a luminometer. The values 
of Renilla luciferase activity reflect minigenome specific transcription and 
replication and Firefly luciferase reflects cellular transcription and transfection 
efficiency used for normalization. The minigenome assays were performed in 
triplicates in at least three independent experiments. 
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2.2.4 Marburg virus specific infectious virus like particle assay 
(iVLP assay) 
 
The infectious virus-like particle assay (iVLP assay) allows the production of 
virus-like particles resembling authentic virions with the difference that they 
contain a minigenome encoding Renilla luciferase instead of the viral genome. 
The iVLP assay was carried out as described in (Koehler et al., 2016; Koehler et 
al., 2015; Wenigenrath et al., 2010) briefly, either HEK293 or 104C1 cells (80% 
confluent) were transfected in 6 cm dishes as follows for one reaction:  
 
Plasmids Promotor Amount [ng] 
1 pCAGGS-NP β-actin (chicken) 1000 
2 pCAGGS-VP30 β-actin (chicken) 200 
3 pCAGGS-VP35 β-actin (chicken) 200 
4 pCAGGS-VP24 β-actin (chicken) 140 
5 pCAGGS-GP β-actin (chicken) 200 
6 pAndy-3M5M 
(Renilla luciferase minigenome) 
T7 2000 
7 pCAGGS- T7-pol β-actin (chicken) 1000 
8 pCAGGS-pGL4 SV40 1000 
9 pCAGGS-VP40 resp. VP40D184N β-actin (chicken) 500 
10 pCAGGS-LWT resp. -LMutants β-actin (chicken) 2000 
 
The transfected cells were named p0 cells. These p0 cells were used for the 
production of VLPs, the minigenome reporter gene activity in these cells reflected 
transcription and replication in the presence of all viral proteins. Plasmids 1-9, or 
1-8 and plasmid 10, were prepared as a master mix and the corresponding LMut 
or VP40Mut plasmid was added and substituted the wildtype protein encoding 
plasmid. The transfection mix was removed after an incubation period of 4-6 h 
and 6 mL of DMEM+++ or RPMI+++ was added to the cells for further incubation 
until 72 h post transfection (p.t.) at 37°C and 5% CO2.  
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Harvesting and analysis of iVLPs  
Supernatants were collected 72 h p.t. and cellular debris was removed by 
centrifugation at 3.000 rpm for 10 min. The supernatant was transferred into Ultra-
Clear™ ultra-centrifuge tubes for SW41 ultracentrifuge rotors and was under laid 
with 2 mL of 20% sucrose in TNE, which allows to purify membranous particles 
from cellular supernatants. The tubes were filled with sterile PBSdef, tared and 
centrifuged at 36.000 rpm for 2 h at 4°C. The supernatant was removed and the 
pellet resuspended in 220 µL of sterile PBSdef. 200 µL of the resuspended iVLPs 
were mixed with either 1 mL of DMEM++ (lacking FCS) or RPMI++ (lacking FCS) 
and used for subsequent infection of indicator (p1 cells). 20 µL of iVLPs and were 
added to 7 µL of 4x loading Buffer and used for SDS-PAGE and Western blot 
analysis.  
 
Minigenome RNA extraction from iVLPs  
72 h p.t. the iVLPs were harvested in 200 µL of PBSdef and the RNA from the 
minigenome containing iVLPs was isolated using the QIAamp Viral RNA Mini Kit 
(Qiagen) according to the manufacturer’s instructions. The eluted RNA was 
digested with RNase-free DNase using the RNeasy mini kit and eluted in 50 µL 
of RNase-free water. Equal amounts of purified RNA were used for QuantiTect® 
one-step RT-qPCR using primers against the minigenome.  
 
Measurement of MARV specific minigenome transcription and replication 
in p0 cells  
72 h p.t. the cells were washed once with PBSdef and then scraped in 1 mL of 
PBSdef. Cells were pelleted by centrifugation at 5.000 rpm for 5 min. The 
supernatant was aspirated and the pellet was resuspended with 200 µL lysis 
buffer (2x Dual Lysis Juice, PJK GmbH) and incubated for 20 min at RT. Cell 
debris was pelleted by centrifugation of the cell lysate at 13.000 rpm for 10 min. 
The Renilla- and Firefly luciferase activity was measured in 5 µL of cleared cell 
lysate. 
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Infection of indicator p1 cells with iVLPs  
From p0 cells purified iVLPs were used to infect either Huh-7 or 104C1 cells. Up 
to 400 µL of the iVLPs were resuspended in DMEM or RPMI used for infection of 
p1 cells per well in a 12 well plate. The amounts of iVLPs used for infection were 
normalized by the amount of VP40 measured by Western blot. The infection of 
p1 cells was performed for 2 h at 37°C and 5% CO2. After that time period 1.6 mL 
of DMEM+++ or RPMI+++ were added and incubation of cells was continued for 
48h p.i.. Indicator p1 cells were either pre-transfected with plasmids encoding L, 
NP,VP30, VP35 and pGL4, see table below (reflecting the ability of iVLPs to 
induce reporter gene activity, namely replication and transcription in target cells) 
or remained naïve (reflecting the capability of the iVLPs to induce primary 
transcription in target cells). Depending on the goal of the experiment LWT or one 
of the LMut was pre-transfected 24 h before infection with iVLPs. The pre-
transfection mix containing following plasmids was added to one well of a 12 well 
plate:  
 
Cell lysates from minigenome, VLPs, and iVLPs assay were used for 
measurement of minigenome reporter gene activity and analyzed by Western 
blotting. The cell lysates were harvested by washing the cells once with PBSdef 
and then scraped in 1 mL of PBSdef. The cells were pelleted by centrifugation at 
5000 rpm for 5 min. The supernatant was aspirated and the pellet was 
resuspended in 50 µL of lysis buffer (2x Dual Lysis Juice, PJK GmbH) and 
incubated for 20 min at RT. Cell debris was pelleted by centrifugation of the lysate 
at 13.000 rpm for 10 min The Renilla- and Firefly activity in 10 µL of the cleared 
cell lysate was measured.  
Plasmids Promotor Amount [ng] 
1 pCAGGS-LWT resp. LMutants β-actin (chicken) 400 
2 pCAGGS-NP β-actin (chicken) 200 
3 pCAGGS-VP30 β-actin (chicken) 40 
4 pCAGGS-VP35 β-actin (chicken) 40 
5 pCAGGS-pGL4 SV40 40 
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2.2.5 Interferon signaling assay 
 
The Mx1 reporter gene assay was performed as described previously (Hug et al., 
1988; Jorns et al., 2006; Koehler et al., 2015). Briefly, HEK 293 cells or GPC16 
cells were co-transfected with a reporter plasmid encoding a Firefly luciferase 
under the control of the Mx1 promoter, a pGL 4.73 encoding Renilla luciferase 
reporter construct, and either VP40 or VP40D184N. At 24 h p.t., cells were washed 
with PBS and incubated for additional 24 h in presence or absence of a 
recombinant interferon (IFN) hybrid (interferon-α/β B/D hybrid, 500 U/ml), shown 
to have a broad host-range activity in antiviral assays (Horisberger & de Staritzky, 
1987). After the IFN treatment, cells were harvested using Dual Passive lysis 
buffer (Promega, Madison, WI), and the Firefly and Renilla luciferase activities 
were measured.  
2.2.6 Flotation assay  
 
VP40 is a peripheral membrane protein synthesized as cytosolic protein and 
associates to membranes shortly after synthesis. Flotation analysis allows to 
characterize the capability of proteins to interact with cellular membranes. 
Flotation analysis was performed as described in (Kolesnikova et al., 2012). 
Briefly, Huh-7 or 104C1 cells were transfected with plasmids encoding either only 
one of the VP40 constructs, or NP, or combination of these plasmids. To maintain 
comparable DNA amounts for the single expression of NP or VP40 an empty 
vector construct was used to ensure equal DNA amounts upon transfection. 
Plasmids Amount [ng] 
1 pCAGGS-VP40 or -VP40D184N 500 
2 pCAGGS-NP 500 
3 pCAGGS (empty vector) 500 
 
At 24 h p.t. the cells were washed three times with lysis buffer for flotation assay 
for 10 min at 4°C. Cells were harvested in 300 µL of lysis buffer and mechanically 
destroyed by passing the lysate through a 26 gauge needle for ten times. 60% 
Nycodenz in TNE were added to the cell lysates to reach a final concentration of 
40% Nycodenz. The cell lysate in 40% Nycodenz was transferred into Ultra-
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Clear™ ultra-centrifuge tubes for SW60 ultracentrifuge rotors and then carefully 
overlaid with 3 mL 30% Nycodenz solution and 500 µL 5% Nycodenz solution. 
The samples were centrifuged overnight at 4°C with 36.000 rpm. After the 
centrifugation the membrane-associated proteins were visible as a small band 
between the 5% and 30% layers. For analysis 5 fractions of 900 µL each were 
taken from the sample, the last fraction was thoroughly resuspended. 50 µL of 
each fraction were mixed with 12.5 µL of 4x loading buffer. The samples were 
analyzed via SDS-PAGE and Western blot analysis.  
 
2.2.7 Budding assay 
 
Single ectopic expression of VP40 leads to the release of VLPs into the 
supernatant, these VLPs can be quantified by Western Blot analysis (Swenson 
et al., 2004). Either HEK293 or 104C1 cells were transfected with plasmids 
encoding VP40 or VP40D184N and 24 h p.t. the supernatants were harvested.   
Plasmids Amount [ng] 
1 pCAGGS-VP40 or -VP40D184N 500 
2 pCAGGS-NP 500 
 
Cellular debris was removed by centrifugation for 10 min at 3.000 rpm. To purify 
the VLPs the supernatant was transferred into Ultra-Clear™ ultra-centrifuge 
tubes for SW41 ultracentrifuge rotors and was under laid with 2 mL of 20% 
sucrose in TNE. The tubes were filled up with sterile PBSdef tared and centrifuged 
at 36.000 rpm for 2 h at 4°C. The supernatant was removed and the pellet was 
resuspended in 50 µL of 4x loading buffer, similar amounts of sample were used 
for SDS-PAGE and consecutive Western blot analysis.  
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2.2.8 Indirect immunofluorescence microscopy analysis (IFA) 
 
Immunofluorescence analysis allows to study the intracellular localization of 
proteins. Indirect immunofluorescence analysis is based on efficient binding of 
two antibodies, a primary antibody recognizing the target protein and a secondary 
antibody, conjugated with a fluorophore, and reacting with the primary antibody. 
The UV light excites the fluorophore which leads to emission of light followed by 
detection. Huh-7, VeroE6 or 104C1 cells were seeded on coverslips (12 mm 
diameter) and either transfected with plasmids encoding the desired proteins or 
infected in the BSL-4 laboratory with recombinant MARV. Transfected cells were 
fixed with 4% PFA in DMEM for 30 min at RT. Infected cells were fixed with 4% 
PFA in DMEM for at least 16 h, the fixed coverslips where then transferred into 
4% PFA in DMEM in a new 12 well plate and the samples were exported from 
the BSL-4 laboratory. For the immunofluorescence staining 4% PFA in DMEM 
was removed and the coverslips were washed three times for 3 min in PBSdef. To 
reduce the background and to quench free aldehyde groups from residual PFA, 
coverslips were incubated for 5 min in PBSdef + 100 mM glycine. Afterwards, cells 
were permeabilized using PBSdef + 0.1% Triton X-100 for 5 min. Then, unspecific 
antibody binding was blocked by incubation of the cells in blocking buffer for 
10 min. Coverslips were incubated with the primary antibodies diluted in blocking 
buffer for 1 h at RT in a wet chamber. After the incubation period the coverslips 
were washed three times for 3 min with PBSdef and then incubated for 1 h at RT 
with the secondary antibodies and DAPI, as staining for the nuclei, diluted in 
blocking buffer. Finally the cells were washed three times for 3 min with PBSdef; 
excess buffer was removed by placing the edge of the coverslip on a Kimtech 
wipe and then placed into mounting media (Fluoprep) on object slides. After 
drying of the mounting media the samples were analyzed on the Leica SP5 
confocal laser scanning microscope.  
Primary antibody Species Dilution 
α-VP40 (40-2-2) Mouse 1:50 
α-NP 2 Guinea pig 1:200 
α-MARV Goat 1:100 
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Secondary antibody Conjugate Species Dilution 
α-mouse  Alexa 488 Goat 1:300 
α-guinea pig Alexa 594 Goat 1:300 
DAPI (4’,6-Diamidin-2-phenylindol)  Goat 1:100 
Phalloidin FITC  1:10 
Phalloidin TRITC  1:10 
Filipin III   50 μg/ml 
 
2.2.9 Cloning and rescue of recombinant viruses 
 
Cloning and rescue of recombinant MARV (rMARV) was based on an approach 
developed in the group of Stephan Becker and performed as previously described 
in (Dolnik et al., 2014; Koehler et al., 2015; Krähling et al., 2010). Briefly, three 
individual pBlueScript plasmids containing different parts of the MARV genomic 
sequence have been digested on unique restriction sites. Fragment 1 contains 
the sequences of (T7- leader-NP-VP35-VP40-GP), fragment 2 (GP-VP30-VP24-
L) and fragment 3 contains the (L-Trailer-Ribozyme). The ligation of the three 
fragments results in the full genomic sequence of MARV Musoke (GenBank 
accession number: NC_001608) (Mühlberger et al., 1998). Recombinant viruses 
can be distinguished from wildtype isolates, since they carry two silent nucleotide 
substitutions at positions 6498 (CT) and 7524 (AG). This nucleotide 
exchanges result in the substitution of a KpnI restriction site with a SacII 
restriction site.  
The D184N mutation was inserted in fragment 1 via multisite-directed 
mutagenesis by Ulla Welzel as part of her Master studies in 2011, through 
substitutions of the nucleotides GAC to AAT at the positions 8104 to 8106.  
The rescue of the rMARVWT and rMARVVP40(D184N) was performed by Dr. Gordian 
Schudt in 2012. In detail, Huh-7 cells and VeroE6 cells were equally mixed and 
seeded into wells of a 6-well plate. Once the cells reached 50% confluency 
transfection with the helper plasmids, NP, VP30, VP35, L and the T7-pol, and the 
full-length plasmid was performed as described in (Dolnik et al., 2014; Krähling 
et al., 2010). The sequence integrity of the rescued rMARVWT and 
rMARVVP40(D184N) was verified by sequencing.  
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2.2.10 Infection of Huh-7- and 104C1-cells with rMARVs 
(BSL-4) 
 
HuH-7, 104C1 or VeroE6 were infected with either rMARVWT or rMARVVP40(D184N). 
For an infection of a 12 well plate the media on the cells was removed and 1 mL 
of virus containing media (FCS deficient) was added. Virus was incubated on the 
cells for 1 h at 37°C, allowing binding and internalization of virions. Virus 
containing media was removed and cells were washed with PBSdef and 2 mL of 
fresh media DMEM+++ (with 2% FCS) or RPMI+++ (with 2% FCS) were added 
to every well. The used multiplicity of infection (MOI) for the different experiments 
is specified for each experiment.  
 
2.2.11 Propagation and concentration of virus stocks  
(BSL-4) 
 
To produce sufficient amounts of infectious virus, a pre-culture of VeroE6 cells 
(T25 cm2 flask, 1x106 cells) were infected with virus an MOI of 0.1. The pre culture 
cells were incubated 7 days at 37°C, 5% CO2. The supernatant of the pre-culture 
was collected into 15 mL falcon tubes and centrifuged at 4°C for 10 min at 
2.500 rpm. The supernatant was diluted 1:10 and 10 mL were added to fresh 
VeroE6 cells (T175 cm2 flask, 7x106 cells). The virus was propagated for 4-7 days 
until a clear cytopathic effect (CPE) was apparent. The virus containing 
supernatant was centrifuged at 4°C for 10 min at 2.500 rpm. For non-
concentrated virus stocks 1 mL was aliquoted into 2 mL cryo tubes. For 
preparation of concentrated virus stocks 25 mL of the supernatant were added 
into SW32 ultra centrifuge tubes under laid with 5 mL 20% sucrose and filled up 
with the rest of the supernatant. Virus was pelleted by centrifugation for 2 h at 
4°C at 28.000 rpm. The supernatant was discarded and the pellet was 
resuspended in 1.2 mL PBSdef, 35 µL of virus were aliquoted into 1 mL cryo tubes. 
Non- and concentrated virus stocks were titrated by tissue culture infectious dose 
50 (TCID50).  
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2.2.12 Virus quantification by tissue culture infectious dose 
50 (TCID50) 
 
The TCID50 (tissue culture infectious dose 50) is a method to determine the titer 
of virus from supernatants. This method determines the virus dilution which is 
able to infect 50% of the cells. VeroE6 cell were seeded to a confluency of ~50% 
into 96 well plates. The media was removed and 100 µL of DMEM+++ (5% FCS) 
were added prior to infection in the BSL-4 laboratory. A dilution series of the virus 
was prepared (10-2 to 10-7). 100 µL of the virus dilution were added to the wells 
via a multi pipette, every dilution is tested in octuple. The cells were incubated for 
10-14 days at 37°C and 5% CO2 until the CPE remained constant. The 
calculations of the TCID50/mL were carried out according to the Spearman and 
Kärber method (Spearman & Karber, 1974).  
 
2.2.13 Infectivity assay (BSL-4) 
 
The infectivity of viruses in different cell species can be determined using a single 
step growth curve, allowing detection of infected cells before newly made virus is 
released from cells and infects neighboring cells, reflecting only initially infected 
cells. For the infection equal amounts of TCID50 units/mL were added to either 
VeroE6, as internal control for titration and infection, Huh-7 or 104C1 cells in the 
BSL-4 laboratory. The cell numbers were quantified prior to infection and the cells 
seeded on glass coverslips were infected at an MOI of 1. After a one hour 
infection the virus containing media was removed and cells were washed with 
1 mL PBSdef followed by addition of 2 mL fresh DMEM+++ (with 2 % FCS). or 
RPMI+++ (with 2 % FCS). 19 h p.i. the cells were fixed with 4% PFA in DMEM 
for at least 16 h, fixed coverslips where then transferred into fresh 4% PFA in 
DMEM into a new 12 well plate and the samples were exported from the BSL-4 
laboratory to the BSL-2 laboratory. Coverslips were stained with antibodies 
against NP and VP40 as well as DAPI and the percentage of infected cells was 
quantified.   
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2.2.14 Preparation of rMARV for electron microscopy (EM) 
by negative staining 
 
Electron microscopy allows to determine the morphology of virus particles. For 
preparation of virus for EM, an 1.5 mL microcentrifuge polyallomer tube was filled 
with 650 µL of virus containing suspension, then 200 µL of 20% sucrose were 
added to the bottom of the tube and additional 650µL were added to the top of 
the tube. The samples were centrifuged at 45.000 rpm for 2 h at 4°C. The 
supernatant was removed and the pellet was fixed in 4% PFA in DMEM for at 
least 16 h. The 4% PFA in DMEM was removed and the tube was completely 
filled with fresh 4% PFA in DMEM and exported from the BSL-4 laboratory. The 
4% PFA in DMEM was removed and the pellet was resuspended in 100 µL of 4% 
PFA in DMEM. The following steps including preparation of the samples and the 
EM analysis was performed by Dr. Larissa Kolesnikova. To improve adherence 
of viral particles Formvar-coated 400-mesh grids were pretreated with 1% alcian 
blue, an adherence time of virus samples was constant, 10 min. The grids were 
negatively stained with 2% phosphotungstic acid. Viral particles were analyzed 
by using a JEM1400 transmission electron microscope. Indirect immunostaining 
of GP was performed as described previously (Koehler et al., 2015; Mittler et al., 
2007), by using a goat serum anti-GP and a donkey anti-goat IgG coupled with 
colloidal gold beads, 12 nm in diameter. 
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2.2.15 Preparation of rMARV infected cells for thin 
sectioning 
 
The EM analysis of cellular ultrathin sections allows an insight into the 
ultrastructural changes of cells infected with different viruses. Huh-7 or 104C1 
cells were infected with rMARVs and fixed for 30 min at RT by adding an equal 
volume of double-concentrated fixative solution [120 mM piperazine-N,N′-bis(2-
ethanesulfonic acid), 50 mM HEPES, 4 mM MgCl2, 20 mM EGTA, 8% 
paraformaldehyde, 0.2% glutaraldehyde, pH 6.9] to the culture media in the  
BSL-4 laboratory. After the fixation the cells were scraped and pelleted at 4°C for 
10 min at 13.000 rpm. The pellet was overlaid with 4% PFA in DMEM for at least 
16 h. The PFA was exchanged and the tubes completely filled with fresh 4% PFA 
in DMEM and then removed from the BSL-4 laboratory. The following steps 
including embedding and the preparation of the samples for thin sectioning and 
the subsequent EM analysis were performed by Dr. Larissa Kolesnikova. The 
tubes were processed for embedding in Epon and Araldite as described in 
(Bharat et al., 2011; Koehler et al., 2015; Welsch et al., 2010). Samples were 
polymerized at 60°C for 24 h. Ultrathin sections (60 to 90 nm) of virus- and mock-
infected cells were prepared using an ultramicrotome (Leica EM UC6) and 
stained with uranyl acetate and lead citrate. Ultrathin sections were analyzed 
using a JEM 1400 transmission electron microscope.  
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3 Results 
 
3.1 Analysis of the impact of the D184N mutation in VP40 on 
its functions in guinea pig and human cells 
 
Even though the D184N was frequently observed in rodent-adapted MARV 
strains, the importance and function of this mutation for the increased virulence 
of rodent-adapted MARV is still unknown (Lofts et al., 2007; Lofts et al., 2011; 
Marzi et al., 2016; Warfield et al., 2009). The aim of this chapter is to elucidate 
whether the D184N mutation in VP40 affects any of the known functions of VP40 
in a species-specific manner. To determine species-specific effects of the D184N 
mutation in VP40, all experiments will be performed in human and guinea pig 
cells comparing wildtype VP40 to VP40D184N.  
 
3.1.1 Characterization of the interferon antagonistic function of 
VP40 and VP40D184N 
 
MARV VP40 is a potent suppressor of the innate immune response via inhibition 
of the Jak-STAT signaling (Valmas et al., 2010). To determine the impact of the 
D184N mutation on the interferon (IFN) antagonistic function of VP40 the 
suppression of the IFN signaling pathway by either wildtype VP40 or VP40D184N 
was analyzed in human (HEK293) and guinea pig cells (GPC16). Generally, 
transfection of 104C1 cells (guinea pig) resulted in higher transfection efficiencies 
and better production of iVLPs and VLPs than in GPC16 cells. However, for the 
interferon reporter assays GPC16 cells were used instead of 104C1 cells, since 
104C1 showed only a weak induction of the interferon response upon induction 
with the interferon hybrid. The cells were transfected with a reporter plasmid 
encoding Firefly luciferase under the control of the Mx1 promoter, a pGL 4.73 
encoding Renilla luciferase reporter construct under the control of a SV40 
promoter, and either VP40 or VP40D184N. The cells transfected with an empty 
pCAGGS vector instead of VP40 encoding plasmids, served as negative and 
positive controls and displayed the reporter gene activity with or without induction 
with interferon.  
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The IFN response was induced by incubation of the cell with 500 U/mL of an  
IFN-α/β B/D hybrid which had a broad species reactivity (Horisberger & de 
Staritzky, 1987).   
Treatment with IFN-α/β B/D hybrid in human cells increased the reporter gene 
activity by 28.3-fold. Expression of VP40 and VP40D184N significantly suppressed 
the IFN response, the reporter gene activity was only 2.1- and 1.7-fold over the 
reporter gene activity in untreated cells (Fig. 9, left graph). 
Guinea pig cells were less responsive to the treatment with IFN-α/β B/D and 
resulted in a 5.4-fold induction of the reporter gene activity. Presence of VP40 or 
VP40D184N suppressed the IFN response (Fig. 9, right graph). To sum this up, the 
D184N mutation does not alter VP40s IFN antagonistic function in human and 
guinea pig cells.  
‘ 
 
Figure 9: Characterization of the interferon antagonistic function of VP40D184N in human and 
guinea pig cells  
Human (HEK293) and guinea pig (GPC-16) cells were co-transfected with reporter plasmids expressing 
Firefly luciferase under the control of the Mx1 promoter, plasmids encoding VP40 or VP40D184N or an 
empty vector. Treatment of the cells with IFN hybrid (500 U/ml) was performed 24 h post transfection 
(p.t.) Cells were incubated with IFN-hybrid for 24 h. At 48 h p.t., cells were harvested and the Renilla; 
reflecting minigenome reporter activity and Firefly luciferase signal, to normalize for transfection 
efficiency, was measured. The relative reporter gene activity was determined by normalization of the 
Firefly luciferase (Mx1) to the Renilla luciferase signal (cellular transcription and transfection efficiency). 
The means and standard deviations displayed are from three independent experiments and shown 
above, statistical analysis was performed using Student’s t-test. ** P < 0.01. 
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3.1.2 Characterization of the intracellular distribution of 
VP40D184N 
 
VP40 is a peripheral membrane protein that starts to associate with membranes 
shortly after synthesis. Immunofluorescence analysis of VP40-expressing human 
cells showed that VP40 is distributed diffusely in the cytoplasm and sometimes 
in the nuclei. In addition, VP40 accumulates at the plasma membrane in form of 
very bright VP40-enriched clusters (Kolesnikova et al., 2004a; Kolesnikova et al., 
2002). To analyze whether the D184N mutation influenced the intracellular 
distribution of VP40, either human (Huh-7) or guinea pig (104C1) cells were 
transfected with plasmids encoding wildtype VP40 or VP40D184N. At 24 h p.t., cells 
were fixed and processed for IFA. Both proteins, VP40 and VP40D184N displayed 
a similar intracellular distribution in human and guinea pig cells. In addition to a 
diffuse distribution in the cytoplasm VP40 and VP40D184N were detectable in small 
amounts in the nuclei (arrowhead). The majority of the two proteins was located 
in the VP40-enriched clusters at the plasma membrane (arrows) (Fig. 10). These 
data suggest that the D184N mutation in VP40 does not influence the synthesis 
and transport of VP40D184N in human and guinea pig cells. 
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Figure 10: Cellular localization of VP40 and VP40D184N in human and guinea pig cells 
Human (Huh-7) or guinea pig (104C1) cells were transfected with plasmids encoding VP40 or VP40D184N 
and fixed 24 h p.t.. Cells were stained with a VP40-specific antibody (green) and DAPI (blue). 
Arrowheads show VP40 in the nuclei, arrows show VP40 in plasma membrane clusters. Bars represent 
20 µM. 
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3.1.3 Accumulation of VP40 in cholesterol enriched clusters 
 
Sites of filovirus budding have been shown to associate with cholesterol-enriched 
clusters (Bavari et al., 2002). Since VP40 is the driving force of virus budding, we 
wanted to test whether single ectopic expression of VP40 or VP40D184N is 
accompanied by recruitment of cholesterol into the VP40-enriched clusters in 
cells from different species. Human or guinea pig cells expressing either wildtype 
VP40 or VP40D184N were fixed and stained with a VP40-specific antibody and 
50 µg/ml of freshly prepared filipin III as marker for cholesterol (Fig. 11) (Börnig 
& Geyer, 1974; Du et al., 2011).  
 
Figure 11: Recruitment of cholesterol into VP40-enriched clusters  
Human (Huh-7) or guinea pig (104C1) cells were transfected with plasmids encoding VP40 or VP40D184N 
and fixed 24 h p.t.. Cells were stained with a VP40-specific antibody (red) and filipin III (green) to detect 
cholesterol. VP40 induced clusters are indicated by arrows. Bars represent 20 µM. 
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In both cell lines the VP40- and VP40D184N-enriched clusters displayed 
accumulation of cholesterol (arrows). The VP40-positive clusters were located 
predominantly at the dorsal site of guinea pig cells, while in human cells these 
clusters were at the cells’ periphery (Fig. 11, indicated by arrows). In spite of this 
slight difference, the intensity of the filipin staining in the wildtype VP40- and 
VP40D184N- enriched clusters were similar indicating that VP40D184N maintained 
the ability to recruit cholesterol with the same efficiency as wildtype VP40, and 
that this ability is conserved in human and guinea pig cells (Fig. 11). 
 
3.1.4 Membrane binding capability of VP40D184N 
 
As mentioned previously, VP40 is synthesized as a cytosolic protein and starts 
to associate with membranes quickly after synthesis (Kolesnikova et al., 2004b; 
Kolesnikova et al., 2002). It has been shown that binding of VP40 to membranes 
is dependent on the oligomeric state of VP40 (Oda et al., 2015). The D184N 
mutation in VP40 is located at the beginning of the C-terminal domain which has 
no influence on oligomerization of VP40, but is important for membrane binding 
(Bornholdt et al., 2013; Oda et al., 2015). To analyze the influence of the D184N 
mutation on the membrane binding capabilities of VP40, human and guinea pig 
cells expressing either VP40 or VP40D184N were subjected to flotation assays (Fig. 
12). The membrane-associated portion of wildtype VP40 was 47%, when it was 
expressed in human cells, and 46%, when it was expressed in guinea pig cells. 
This observation demonstrated that the intrinsic association of VP40 with 
membranes was not disrupted in guinea pig cells. The membrane-associated 
portion of VP40D184N was higher, in human cells it comprised 61% and reached 
62% in guinea pig cells. However, this effect was not statistically significant. 
Altogether, the D184N mutation in VP40 resulted in an increased membrane 
binding of VP40 in human and guinea pig cells. 
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Figure 12: Membrane association of VP40D184N in human and guinea pig cells  
The membrane binding capabilities of VP40 and VP40D184N were determined by flotation analysis in 
human (HEK293) and guinea pig (104C1) cells. The cells were transfected with either plasmids encoding 
VP40 or VP40D184N and cell lysates were harvested 24 h p.t.. Membrane-associated proteins and 
proteins from the cytosolic phase were separated by flotation assay analysis. Presence of VP40 was 
determined by SDS-PAGE and Western blot analysis via staining with a VP40-specific antibody (A). 
Fraction 1-2 (top) reflect membrane-associated VP40 and Fraction 5 (bottom) cytosolic VP40. (B) The 
percentage of membrane-associated VP40 (black) and VP40D184N (gray) in human and guinea pig cells 
is shown. The means and the standard deviations are shown from three independent experiments, 
statistical analysis was performed using the Student’s t-test. 
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3.1.5 Characterization of membrane-associated NP upon co-
expression with VP40D184N 
 
One of VP40’s assembly functions is the attraction of nucleocapsids to the 
plasma membrane (Dolnik et al., 2008). Although the mechanism of interaction 
between MARV VP40 and the nucleocapsid proteins remains obscure, it has 
been shown that the membrane binding capability of NP is increased upon co-
expression with VP40 (Dolnik et al., 2010).  
It was of interest to determine whether the D184N mutation in VP40 influences 
the recruitment of NP to membranes upon co-expression and thereby might 
modulate the assembly function. To address this question, flotation analysis was 
performed on human and guinea pig cells expressing NP only or co-expressing 
NP and either VP40 or VP40D184N. Single expression of NP resulted in 12-15% of 
membrane-associated NP in human and guinea pig cells (Fig. 13). The highest 
amount of membrane-associated NP, 34%, was detected when it was co-
expressed with VP40D184N in human cells, whereas co-expression with wildtype 
VP40 resulted in only 19% of membrane-associated NP (Fig. 13). In contrary to 
previously published data, instead of a 2-fold difference we observed only a 1.5-
fold increase of membrane associated NP upon presence of VP40 (Dolnik et al., 
2010). However, Dolnik et al. have used Huh-7 cells whereas in this experiment 
HEK293 cells have been used, might explaining the difference. In guinea pig cells 
a similar phenotype was observed, upon single expression 15% of NP was 
associated with membranes (Fig. 13). Co-expression of NP with VP40D184N 
resulted in 24% of membrane-associated NP compared to 18% in presence of 
VP40 (Fig. 13). These results indicate that the enhanced membrane binding 
properties of VP40D184N might recruit an enhanced amount of NP to the 
membranes in both human and guinea pig cells. Although this effect is not 
statistically significant it might result in a slight improvement in the attraction of 
nucleocapsid proteins to the site of budding in human and guinea pig cells.  
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Figure 13: Flotation analysis of VP40D184N co-expressed with NP in human and guinea pig cells. 
To determine the membrane binding capabilities of NP upon co-expression with either VP40 or 
VP40D184N we used flotation analysis for human (HEK293) and guinea pig (104C1) cells. Cells were 
transfected with plasmids encoding only NP or NP and either VP40 or VP40D184N, the cell lysates were 
harvested 24h p.t. and subjected to the flotation assay. The presence of NP was determined by SDS-
PAGE and Western blot analysis by staining with a NP-specific antibody (Fig. 13A). Fraction 1-2 (top) 
reflects membrane-associated NP and fraction 5 (bottom) cytosolic NP. (B) Shows the percentage of 
membrane-associated NP in human and guinea pig cells. The means and the standard deviations are 
shown from three independent experiments, statistical analysis was performed using the Student’s t-
test. 
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3.1.6 Analysis of the budding capacity of wildtype VP40 and 
VP40D184N 
 
Single expression of VP40 results in formation and budding of VP40-enriched 
VLPs (Kolesnikova et al., 2004b; Swenson et al., 2004). Released VP40-induced 
VLPs possess the filamentous form of authentic virions but do not contain 
nucleocapsids. The production of VP40-induced VLPs can be used as an 
indicator of the budding function of VP40 (Kolesnikova et al., 2004b; Swenson et 
al., 2004). To investigate whether the D184N mutation in VP40 has an influence 
on the budding capacity of VP40, we transfected human or guinea pig cells with 
either VP40 or VP40D184N. VLPs were purified from the supernatants of 
transfected cells 72 h p.t. by centrifugation through a sucrose cushion. Presence 
of VP40 in cell lysates and the amount of VP40 in VLPs were quantified by 
Western blot analysis (Fig. 14A). The relative VLP release was calculated as ratio 
of the intensity of VP40 signals in VLPs and cell lysates. The relative VLP release 
in cells expressing wildtype VP40 was set to 1. In human cells, the relative VLP 
release was not affected by the D184N mutation in VP40 (Fig. 14B, left graph). 
In contrast, the D184N mutation resulted in a 1.5-fold enhanced release of VLPs 
in guinea pig cells. These data demonstrated that the D184N mutation positively 
influenced the budding function of VP40 in a species-specific manner (Fig. 14B, 
right graph). 
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Figure 14: Analysis of the budding capacity of VP40D184N in human and guinea pig cells 
VLPs were purified from the supernatants of VP40 or VP40D184N expressing human (HEK293) and 
guinea pig (104C1) cells at 72 h p.t. through a sucrose cushion. SDS-PAGE and Western blot analysis 
was performed from equal amounts of cell lysates and VLPs (A). The mean intensity of the VP40-specific 
bands were measured with the Image Lab software and the relative VLP release was calculated (amount 
of VP40 in VLPs divided by the amount of VP40 in cell lysates). The graphics (B) represent the relative 
VLP release in either human or guinea pig cells expressing VP40 or VP40D184N from three independent 
experiments, statistical analysis was performed using the Student’s t-test. * P < 0.01. 
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3.1.7 Characterization of the VP40D184N-mediated suppression of 
replication and transcription 
 
It has been shown that VP40 of EBOV and MARV suppresses the transcription 
and replication activity in the minigenome system (Hoenen et al., 2010). To 
assess the influence of the D184N mutation on the VP40-mediated suppression 
of replication and transcription in human and guinea pig cells, we performed 
following experiments. Human and guinea pig cells were transfected with the 
plasmids necessary for the minigenome assay and with increasing amounts (100 
ng, 200 ng and 400 ng) of plasmids encoding either wildtype VP40 (pCAGGS-
VP40) or VP40D184N (pCAGGS-VP40 D184N). Cells were lysed at 24 h p.t. and the 
reporter gene activity was measured.  
Increasing amounts of wildtype VP40 resulted in a significant dose-dependent 
decrease of the reporter gene activity in both human and guinea pig cells. Both 
VP40 and VP40D184N decreased the reporter gene activity to comparable levels 
in human (Fig. 15). In guinea pig cells, the transfection of 100 ng DNA encoding 
wildtype VP40, reduced the reporter gene activity to 43%, whereas transfection 
of 100 ng pCAGGS-VP40D184N did not lead to any reduction of the reporter gene 
activity. In fact, the reporter gene activity in VP40D184N-transfected guinea pig 
cells was 2.5-fold higher than in pCAGGS-VP40 transfected cells (Fig. 15A, right 
panel). Nevertheless, VP40D184N preserved its inhibitory capabilities in guinea pig 
cells, which were observed at DNA concentrations of 200 ng and 400 ng. The 
reporter gene activity was reduced to 61% at 200 ng pCAGGS-VP40D184N and to 
27% at 200 ng pCAGGS-VP40 (Fig. 15). A distinct difference in wildtype VP40- 
and VP40D184N-induced suppression of minigenome transcription and replication 
activity was observed only in guinea pig cells (Fig. 15). These data demonstrates 
that the D184N mutation in VP40 relieved the effect of VP40 on viral replication 
and transcription in guinea pig, but not in human cells. 
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Figure 15: Characterization of the VP40D184N mediated suppression of minigenome replication 
and transcription in human and guinea pig cells  
(A) All plasmids required for the minigenome system including L (positive control, +L) or without L 
(negative control, -L) were transfected together with increasing amounts of either wildtype VP40 (black 
column) or VP40D184N (gray columns) coding plasmids (pC-VP40s) into human (HEK293) or guinea pig 
(104C1) cells. Cells were lysed 24 h p.t., and the reporter gene activity was measured. The normalized 
reporter gene activity was set to 100% (positive control). The means and standard deviations are shown 
from the results of triplicates of three independent experiments, statistical analysis was performed using 
the Student’s t-test. *, P < 0.05. (B) The protein levels of VP40 and tubulin in cell lysates of human 
(HEK293) and guinea pig (104C1) cells were determined by SDS-PAGE and Western blotting using 
alpha-tubulin (Tub)- and VP40-specific antibodies. Lane 1, 3 and 5 show VP40 and lanes 2, 4, and 6, 
VP40D184N. 
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3.1.8 The effect of the D184N mutation in VP40 on replication 
and transcription in an iVLP assay 
 
To verify the species-specific effect of the D184N mutation on the VP40-mediated 
regulation of transcription and replication in presence of not only VP40, but also 
VP24 and GP, we used the iVLP assay in human or guinea pig cells (chapter 
1.8.2). Producer (p0) cells were transfected with plasmids encoding all seven viral 
proteins, T7-pol and a Renilla luciferase-encoding minigenome. Expression of all 
viral proteins resulted in assembly of minigenome-containing nucleocapsid-like 
complexes which were transported to the cell surface, coated with a lipid 
enveloped enriched with VP40 and GP and released in form of iVLPs into the 
supernatant. The iVLPs were used for infection of indicator (p1) cells.  
 
The p1 cells were pre-transfected with plasmids encoding NP, VP30, VP35 this 
allowed to support the replication and transcription activity of incoming 
nucleocapsids (p1 tr cells). Alternatively, the p1 cells were not pre-transfected 
with plasmids encoding the nucleocapsid proteins (p1 naïve cells). In this case, 
the reporter gene activity reflected the ability of incoming nucleocapsids to 
mediate primary transcription.  
 
Expression of VP40D184N in human p0 cells (HEK293) resulted in a slight 
reduction of reporter gene activity compared to wildtype VP40 expressing cells 
(Fig. 16 A, left panel). In contrast, expression of VP40D184N in guinea pig p0 cells 
did not suppress the reporter gene as efficiently as wildtype VP40 (Fig. 16 B, left 
panel). These results confirm that the D184N mutation in VP40 allows higher 
levels of replication and transcription in the presence of all viral proteins in p0 
guinea pig cells.  
 
Supernatants of p0 cells were then used to purify iVLPs and equal amounts of 
iVLPs, quantified by Western blot analysis, were used to infect either p1 tr or p1 
naïve cells. In p1 tr cells, infection with iVLPs from VP40D184N-expressing human 
cells resulted in a lower reporter gene activity compared to infection with iVLPs 
produced upon expression of wildtype VP40 (Fig. 16 middle panel). In contrast, 
when guinea pig cells were infected with iVLPs from VP40D184N-expressing cells 
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the reporter gene activity was increased by 240% in p1 tr and by 150% in p1 
naïve cells (104C1) (Fig. 16, middle and right panel).  
 
 
 
Figure 16: Importance of the D184N mutation in VP40 on replication and transcription in the iVLP 
assay 
(A) Human cells (p0 = HEK293, p1 = Huh-7) were transfected with plasmids required for the iVLP assay. 
Either VP40 or VP40D184N were transfected. 72 h p.t. p0 cell lysates were harvested and the Renilla and 
Firefly activity was measured (left panel). The reporter gene activity was determined by normalizing the 
Renilla reporter signal to the measured Firefly activity. Equal amounts of iVLPs were used to infect either 
pre-transfected p1 (p1 tr, middle panel) or naïve p1 (p1 naïve, right panel). p1 tr were pre-transfected 
with the plasmids necessary to support replication and transcription of the minigenome, NP, VP30, VP35 
and L, transfection was done 24 h in advance to the infection with iVLPs. To monitor the ability of the 
iVLPs to induce reporter gene activity upon infection, both p1 tr and p1 naïve cells were lysed 24 h p.i. 
and the relative reporter gene activity was determined as indicated above. (B) Guinea pig (104C1) cells 
were treated as described in (A). Shown are the means and standard deviations from three independent 
experiments performed in triplicates, statistical analysis was performed using the Student’s t-test. 
* P< 0.05; **, P<0.01. 
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We suggest that the higher levels of the reporter gene activity in guinea pig p1 
naïve and p1 tr cells cannot be explained by the influence of the D184N mutation 
in VP40 on transcription and replication in indicator cells, because in these cells 
VP40 is provided only from incoming iVLPs and present in rather low amounts. 
We consider that the observed higher levels of transcription and replication in 
guinea pig cells was induced by the higher infectivity of iVLPs which were 
produced in guinea pig p0 cells and contained VP40D184N.  
 
3.1.9 Composition of the iVLPs in presence of VP40D184N 
 
To address the importance of the D184N mutation in VP40 on iVLP composition 
we quantified the amount of GP, NP and VP40 in iVLP preparations. The iVLPs 
were purified from the supernatant of human and guinea pig p0 cells at 72 h p.t. 
as described above and the amount of VP40, NP and GP was determined by 
Western blot. The ratio of NP or GP to VP40 was calculated (Fig. 17). In addition, 
we quantified the amounts of iVLP-associated minigenomes via RT-qPCR (Fig. 
17). The ratio of NP or GP to wildtype VP40 was set to 1. The GP to VP40D184N 
ratio in iVLPs produced by both human and guinea pig p0 cells was not altered. 
The ratio of NP to VP40D184N in iVLPs produced in human p0 cells was not 
affected as well (Fig. 17A). However, the ratio of NP to VP40D184N in iVLPs 
produced in guinea pig p0 cells showed a 1.3-fold increase (Fig. 17B). Although 
not statistically significant, the number of minigenomes in the VP40D184N-induced 
iVLPs was higher both for human and guinea pig p0 cells (Fig. 17A-B). These 
results suggest that the D184N mutation in VP40 enhances the incorporation of 
nucleocapsid-like structures into iVLPs in a species-specific manner. This result 
could explain the higher reporter gene activity VP40D184N-induced iVLPs 
produced in guinea pig p1 cells (Fig.16 A-B) 
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Figure 17: Impact of the D184N mutation on the particle composition of iVLPs produced in human 
and guinea pig cells  
iVLPs from either wildtype VP40- or VP40D184N-expressing human (A) or guinea pig (B) cells were 
analyzed by SDS-PAGE and Western blot analysis. The viral proteins VP40, NP and GP were detected 
by either VP40-, NP- or GP-specific antibodies (left panel). The signal intensity of VP40, NP and GP 
bands was measured by the Image Lab software and the relative ratio of either GP to VP40 or NP to 
VP40 was determined. The relative ratio of either GP (left middle panel) or NP (right middle panel) to 
wildtype VP40 was set to one. The amount of minigenomes incorporated into iVLP minigenomes was 
measured by qRT-PCR (right panel). Shown are the means and standard deviations from three 
independent experiments performed in triplicates, statistical analysis was performed using the Student’s 
t-test. **, P<0.01. 
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3.2 Analysis of the impact of the D184N mutation in VP40 on 
the viral fitness of recombinant MARV in guinea pig and 
human cells 
 
This chapter aims to determine the species-specific viral fitness of a recombinant 
wildtype MARV and a recombinant MARV containing only the D184N mutation in 
VP40 in human and guinea pig cells. 
3.2.1 Characterization of a recombinant Marburg virus (rMARV) 
containing a single point mutation D184N in VP40 
(rMARVVP40(D184N)) 
 
To evaluate the importance of the D184N mutation in the viral context, a 
recombinant virus containing only the D184N mutation in VP40 was used. As 
mentioned in the methods section, a full-length plasmid encoding the genomic 
sequence of a recombinant virus containing only the D184N single point mutation 
in VP40 was cloned by Ulla Welzel, and the rescue of this recombinant virus 
(rMARVVP40(D184N)) was performed by Gordian Schudt. A recombinant MARV 
Musoke with the wildtype genome (rMARVWT) was rescued by Olga Dolnik 
(Dolnik et al., 2014).  
  
To determine the virion morphology of rMARVWT and rMARVVP40(D184N), VeroE6 
cells were infected at an MOI of 1 and incubated for three days. Virus was purified 
from supernatants of infected cells by centrifugation through a sucrose cushion. 
EM analysis and immunogold staining with a goat polyclonal anti-GP antibody 
were performed by Larissa Kolesnikova. A comparative EM analysis determined 
that preparations of rMARVWT and rMARVVP40(D184N) were indistinguishable from 
each other (Fig. 18A). To compare the amount of the glycoprotein GP 
incorporated into viral particles of rMARVWT and rMARVVP40(D184N), the number of 
immunogold particles associated with virions were quantified in at least 13 
particles for each preparation. When the amount of GP present on rMARVWT was 
set to 100%, the amount of GP in rMARVVP40(D184N) particles comprised 99.2% 
(Fig. 18C).  
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To determine changes in the protein composition of rMARVWT and 
rMARVVP40(D184N), purified virus stocks were subjected to SDS-PAGE and silver 
stained. The protein composition of rMARVWT and rMARVVP40(D184N) was similar 
(Fig. 18B).  
  
 
Figure 18: Characterization of rMARVWT and rMARVVP40(D184N)  
(A) Electron microscopic analysis of rMARVWT and rMARVVP40(D184N). The virus preparations were fixed 
in 4% PFA in DMEM and immunogold labelled with anti-GP specific antibody, 12 nm gold particles. 
Negative staining was performed using 2% phosphotungstic acid. An overview of each preparation is 
shown in the upper panel. The black box indicates the single particle shown at a higher magnification in 
the lower panel, 12 nm gold particles are indicated by arrows. The bar indicates 500 nm in the upper 
panel and 100 nm in the lower panel. (B) SDS-PAGE and subsequent silver staining of rMARVWT and 
rMARVVP40(D184N) preparations. (C) Relative incorporation of GP into virus particles in rMARVWT and 
rMARVVP40(D184N) preparations. Shown are the means and standard deviations from at least thirteen 
particles, statistical analysis was performed using the Student’s t-test. 
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3.2.2 Comparison of viral growth of rMARVVP40(D184N) and 
rMARVWT in human and guinea pig cells 
To determine the effect of the D184N mutation on the viral production kinetics in 
human and guinea pig cells, growth curve analysis of rMARVWT and 
rMARVVP40(D184N) was performed by Astrid Herwig.  Either human (Huh-7) or 
guinea pig (104C1) cells were infected with rMARVWT or rMARVVP40(D184N) at an 
MOI of 0.01. Supernatants and cell lysates were harvested on day one to four 
and at day seven p.i. and used for Western blot analysis. Viral titers in the 
supernatants were quantified by TCID50.  
The titers of both recombinant viruses in human Huh-7 cells one day p.i. were 
 
Figure 19: Comparative growth curve analysis of rMARVVP40(D184N) and rMARVWT in human and 
guinea pig cells. 
(A-B) Growth kinetics of rMARVWT (black circles) and rMARVVP40(D184N) (gray circles) in (A) Huh-7 and 
(B) 104C1 cells infected with either virus at an MOI of 0.01. (C-F) Western blot analysis of viral protein 
levels, in culture supernatants (C-D) or cell lysates (E-F) of Huh-7 or 104C1 cells infected at different 
days after infection. Supernatants and cell lysates were collected at the indicated time points and 
analyzed by SDS-PAGE and Western blotting using NP- and VP40-specific antibodies. dpi, Days p.i. 
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two to three logarithmic magnitudes higher than those in guinea pig 104C1 cells, 
indicating a major difference in the intrinsic susceptibility of these cell lines to 
MARV infection. Comparison of growth kinetics of both recombinant viruses 
showed that in human cells, the titer of rMARVVP40(D184N) at day one p.i. (1x104) 
was one order of magnitude higher than the titer of rMARVWT (1x103) (Fig. 19A). 
After two days of infection the titers of rMARVWT and rMARVVP40(D184N) were 
comparable in human cells (Fig. 19A). A different picture emerged in guinea pig 
cells. At day two and three p.i, the titers of rMARVVP40(D184N) were more than one 
logarithmic magnitude higher compared to rMARVWT (Fig. 19B). A difference in 
titers was not detectable after day four p.i., possibly due to cell death. In general, 
rMARVVP40(D184N) showed improved growth compared to rMARVWT in guinea pig 
cells.   
Western blot analysis showed that infection with rMARVVP40(D184N) resulted in 
earlier detection of the viral proteins, VP40 and NP, compared to rMARVWT in 
both, human and guinea pig cells (Fig. 19 C-F). In the supernatant of 
rMARVVP40(D184N) infected cells,  viral proteins were detectable at day two 
(supernatant of human cells) or day three (supernatant of guinea pig cells). In the 
supernatant of rMARVWT infected cells, viral proteins were detectable at day three 
(human cells) and at day four (guinea pig cells) (Fig. 19C and 18D). The viral 
proteins of the rMARVVP40(D184N) were detectable at day one p.i. in cell lysates 
from human cells and at day two p.i. in guinea pig cells. In fact, viral proteins of 
rMARVVP40(D184N) were detectable in cell lysates one day earlier in human cells 
and two days earlier in guinea pig cells compared to rMARVWT-infected cells (Fig. 
19E and Fig. 19F). In summary, infection with rMARVVP40(D184N) resulted in earlier 
detection of viral proteins in the supernatant and cell lysates of human and guinea 
pig cells.  
The amount of NP in released virions was significantly higher in rMARVVP40(D184N) 
resulting in an increased ratio of NP over VP40. The increased ratio of NP to 
VP40 suggests an enhanced incorporation of nucleocapsid-like structures, which 
in turn would result in more infectious virions (Fig. 19C and Fig. 19D, day seven). 
Altogether, rMARVVP40(D184N) replicated better in guinea pig cells compared to 
rMARVWT. This is reflected by higher viral titers and earlier detection of viral 
proteins in the supernatant and cell lysates of rMARVVP40(D184N)-infected guinea 
pig cells. 
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3.2.3 Quantification of viral genomes in the supernatant and 
cells infected with rMARVVP40(D184N) or rMARVWT 
To determine the number of viral genomes in the supernatant of either rMARVWT- 
or rMARVVP40(D184N)-infected human or guinea pig cells RT-qPCR was performed. 
For this purpose either Huh-7 or 104C1 cells were infected with either rMARVWT- 
or rMARVVP40(D184N) at an MOI of 3. The used qPCR probe targets a highly 
conserved region of the viral polymerase. In order to quantify the genome copy 
numbers a standard curve of serially diluted MARV-specific in vitro transcripts 
was amplified in parallel to samples of viral RNA. Total cellular RNA and RNA 
 
Figure 20: Comparative quantification of viral genomes of either rMARVWT or rMARVVP40(D184N) 
infected human and guinea pig cells  
(A-B) Viral genomes copies present in the supernatants (A) or cells(B) infected with rMARVWT or 
rMARVVP40(D184N) at an MOI of 3 were determined by RT-qPCR. Cellular RNAs were harvested at 0, 1 
and 3 days p.i.. Supernatants were collected at day 1 and 3 p.i.. rMARVWT (black columns) and 
rMARVVP40(D184N) (gray columns). Shown are the means and standard deviations from two independent 
experiments performed in duplicates, statistical analysis was performed using the Student’s t-test. 
*,P<0.05; **,P<0.01, ***,P<0.001. 
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from cell culture supernatants was isolated at day one and three p.i. In addition, 
cellular RNA was isolated from cells harvested immediately after 1 h of incubation 
with virus (0 dpi). The amount of viral genome copies present in the supernatant 
of human cells infected with rMARVVP40(D184N) or rMARVWT did not differ (Fig. 
20A). However, infection with rMARVVP40(D184N) resulted in the detection of 
significant more viral genome copies in the supernatant of guinea pig cells 
compared to those infected with rMARVWT (Fig. 20A). Namely, the number of viral 
genomes in the supernatant of rMARVVP40(D184N) infected guinea pig cells was 
4.7-fold higher at day one p.i. and 7.8-fold higher at day three p.i. compared to 
rMARVWT (Fig. 20A).   
The amount of viral genomes detected in the total RNA of rMARVVP40(D184N)-
infected human cells showed an increase of 4.4-fold 1 h p.i. (0 dpi) compared to 
rMARVWT. At day one and three p.i. the number of viral genomes detected in the 
total RNA was similar between rMARVWT- and rMARVVP40(D184N)-infected human 
cells (Fig. 20B). The number of viral genomes in the total RNA of 
rMARVVP40(D184N)-infected guinea pig cells were increased compared to 
rMARVWT-infected cells at all tested time points, although these differences were 
not statistically significant. Briefly, the increase of viral genome copies in 
rMARVVP40(D184N)-infected guinea pig cells 1 h p.i., one day and three days after 
infection was 3-fold, 2.2-fold and 5.1-fold higher than those of rMARVWT-infected 
guinea pig cells (Fig. 20B). These findings underline that rMARVVP40(D184N) 
replicates more efficiently only in guinea pig cells but not in human Huh-7 cells. 
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3.2.4 Comparison of the infectivity of rMARVWT and 
rMARVVP40(D184N) 
 
Our data on growth kinetics of rMARVWT and rMARVVP40(D184N) in human and 
guinea pig cells suggested that rMARVVP40(D184N) might display higher infectivity 
compared to rMARVWT specifically in guinea pig cells. To determine the infectivity 
of MARVWT or rMARVVP40(D184N) in cells from different species, human (Huh-7), 
guinea pig (104C1) and monkey (VeroE6) cells were infected with either 
rMARVWT or rMARVVP40(D184N) at an MOI of 1. The cells were fixed after a single 
cycle growth curve, 19 h p.i.. Cells were stained with DAPI and antibodies against 
NP. The number of infected cells was quantified by immunofluorescence 
analysis. Cells displaying NP-positive inclusion bodies were considered as 
infected. The number of cells infected with rMARVWT was set to one and the 
relative fold change was calculated for rMARVVP40(D184N)-infected cells.   
VeroE6 cells were used as control for the inoculum, since preparation and titration 
of both viral stocks was carried out in this cell line. Infection of VeroE6 cells with 
equal TCID50 units of both recombinant viruses was expected to result in similar 
numbers of infected cells. Indeed, infection of VeroE6 cells displayed comparable 
infectivity of rMARVWT and rMARVVP40(D184N) (35.7% and 40.6% cells, Fig. 21A 
bottom panel and Fig. 21B, right graph). Infection of human Huh-7 cells with 
rMARVVP40(D184N) resulted in 2.2-fold higher number of infected cells (76.8%) 
compared to rMARVWT-infected cells (34.8%) (Fig. 21A, top panel and Fig. 21B, 
left graph). Guinea pig 104C1 cells were less susceptible to infection, the number 
of rMARVVP40(D184N)-infected cells comprised 13.1%, but this number was 5.5-fold 
higher than the number of guinea pig cells infected with rMARVWT (2.4%) (Fig. 
21A middle panel and Fig. 21B, middle graph). In summary, rMARVVP40(D184N) 
displayed a higher infectivity than rMARVWT both in human and guinea pig cells, 
but the effect was more pronounced in guinea pig cells. This data supported the 
results of the growth kinetics analysis shown in Fig. 19 A-B. 
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Figure 21: Analysis of the intrinsic infectivity of rMARVVP40(D184N) and rMARVWT in human and 
guinea pig cells  
(A) Huh-7, 104C1 and VeroE6 cells were grown on coverslips and infected at an MOI of 1. The cells 
were fixed with 4% PFA in DMEM at 19 h p.i. and stained with DAPI (nuclei) and a NP-specific antibody 
(shown in red). Bars indicate 20 µm. (B) Graphics show the relative amount of infected cells based on 
the percentage of infected cells, this number was set to 1 for cells infected with rMARVWT in all tested 
cell lines. Means values and standard deviations of the results from three independent experiments are 
shown. For each experiment infection was quantified for 10 random fields. The results reflect data from 
three independent experiments, statistical analysis was performed using the Student’s t-test. 
***,P< 0.001. 
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3.2.5 Characterization of the inclusion body formation in 
rMARVWT and rMARVVP40(D184N) infected cells 
 
Perinuclear inclusion bodies containing viral nucleocapsid proteins are a hallmark 
of filovirus-infected cells. The NP-positive inclusion bodies can be detected at  
10-12 h p.i., and are considered as site of viral replication and transcription 
(Dolnik et al., 2015). To assess the influence of the D184N mutation on inclusion 
body formation, human or guinea pig cells were infected with either rMARVWT or 
rMARVVP40(D184N) with at an MOI of 1. 
Inclusion bodies were detected in the perinuclear region of rMARVWT- and 
rMARVVP40(D184N)-infected cells, the shape of the inclusion bodies did not differ 
between human and guinea pig cells, however the size of inclusion bodies in 
rMARVVP40(D184N)-infected guinea pig cells was larger than those in rMARVWT-
infected guinea pig cells (Fig. 22). This observation was further analyzed by 
quantifying the cross-sectional area of the maximal size of a single inclusion 
body, the total area of inclusions per cell, and the average area of a single 
 
Figure 22: Inclusion body formation upon infection of human and guinea pig cells with rMARVWT 
and rMARVVP40(D184N)  
Huh-7 or 104C1 cells were infected with either rMARVWT or rMARVVP40(D184N) at an MOI of one. The cells 
were fixed at 19 h p.i. with 4% PFA in DMEM and stained with MARV NP- (red) and MARV VP40- specific 
(green) antibodies as well as the nuclei with DAPI (blue). Shown images are maximum intensity 
projections of infected cells. Yellow arrows indicate viral inclusions. Bars represent 20 µm. 
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inclusion body within an infected cell. No differences were found in all tested 
parameters in human cells infected with either rMARVWT or rMARVVP40(D184N). 
Thus, the single inclusion size in human cells infected with rMARVWT was 19.2 
µm2 compared to 17.7 µm2 in rMARVVP40(D184N)-infected cells. The total area of 
inclusion bodies in human cells comprised 46.1 µm2 in rMARVWT-infected cells 
compared to 47.2 µm2 in rMARVVP40(D184N)-infected cells. Finally, the maximal 
inclusion body size in human cells was 46.4 µm2 in rMARVWT-infected cells 
compared to 43.2 µm2 in cells infected with rMARVVP40(D184N). These findings 
demonstrated that both viruses rMARVWT and rMARVVP40(D184N) form inclusions 
of equal size in human cells (Fig. 23, upper panel).  
In contrast, infection of guinea pig cells with rMARVVP40(D184N) led to formation of 
significantly larger inclusions (Fig. 23, lower panel). The cross-sectional area of 
a single viral inclusion was 21.7µm2 in rMARVWT-infected guinea pig cells and 
reached 36.9 µM2 in cells infected with rMARVVP40(D184N), thus the difference was 
1.7-fold. The total area of inclusion in rMARVVP40(D184N) infected guinea pig cells 
was 84.9 µm2 and 54.9 µm2 in cells infected with rMARVWT infection resulting in 
a 1.5-fold difference. The maximum inclusion body size displayed the strongest 
change (by 2.0-fold) and comprised 93.5 µm2 in cells infected with 
rMARVVP40(D184N) and 47.5 µm2 in guinea pig cells infected with rMARVWT (Fig. 
23, lower panel).  
To assess whether the observed difference in the inclusion body size in guinea 
pig and human cells is associated with morphologic changes within the inclusion 
bodies, a comparative electron microscopic analysis of either rMARVWT or 
rMARVVP40(D184N) infected human or guinea pig cells was performed. In human 
cells, the morphology of viral inclusions, as well as the number of mature 
nucleocapsids, were similar in cells infected with either rMARVWT or 
rMARVVP40(D184N) (Fig. 24, left panel). In contrast, guinea pig cells infected with 
rMARVVP40(D184N) showed significant larger viral inclusions and a significantly 
increased amount of mature nucleocapsids (Fig. 24, right panel). Altogether, 
these data suggests that the insertion of the D184N mutation into MARV VP40 
provides MARV more efficient replication and improves the virus assembly, 
specifically in guinea pig cells.  
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Figure 23: Comparative quantification of viral inclusions in human and guinea pig cells   
The graphs indicate the size of the viral inclusion bodies in human (Huh-7) or guinea pig (104C1) cells 
infected with either rMARVWT (black) or rMARVVP40(D184N) (gray) at an MOI of 1. The pictures were 
acquired as described in Figure 21. The Leica Application Suite X software was used for analysis of the 
inclusion body size. The cross-sectional area of a single inclusion body (left panel), the total area of 
inclusions (middle panel) and the maximal size of a single inclusion body (right panel) were measured in 
at least ten cells. Shown are the means and standard deviations, statistical analysis was performed using 
the Student’s t-test. *, P<0.05; **,P<0.01. 
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Figure 24: Electron microscopic analysis of rMARVWT and rMARVVP40(D184N)-infected human and guinea 
pig cells   
Cells were infected with viruses at an MOI of 1 fixed with 4% PFA in DMEM 24 h p.i. and embedded in an epoxy 
resin. Ultrathin sections of infected cells were contrasted with uranyl acetate and lead citrate. Tubular-like 
structures with electron dense wall represent mature nucleocapsids and indicated by arrows. Bars indicate 
500 nm.  
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3.3 Influence of the mutations S741C, D758A, A759D in L on 
its functions in guinea pig and human cells 
 
This part aims to shed light on the species-specific importance of the S741C, 
D758A and A759D mutations on the L protein function in guinea pig and human 
cells. Due to the lack of detection tools, a plasmid encoding a mCherry-tagged L 
protein was created and characterized. This plasmid (pCAGGS-mCherry-L) 
containing the tagged L variant was used to generate L mutants containing the 
different combinations of the mutations observed in the guinea pig-lethal MARV. 
The mutations were characterized regarding their function and species-specific 
effects in human and guinea pig cells.  
 
3.3.1 Characterization of mCherry-tagged L 
 
The L protein of MARV is the largest MARV protein with a size of 220 kDA. It 
carries out several functions such as replication, transcription, capping and 
methylation of mRNAs. L has six conserved domains, CR I - VI (Fig. 25). 
Functional studies on the MARV L protein are complicated, due to the lack of 
tools for proper detection of the L protein. To assess the importance of the three 
mutations present in a guinea pig-lethal MARV we created a mCherry-tagged 
MARV L construct allowing to perform such studies.  
 
For tagging of the MARV L protein with mCherry we used an approach developed 
for the closely related EBOV L (Hoenen et al., 2012). The mCherry-tag was 
introduced to a variable hinge region between the amino acids 1704 and 1705 
(Fig. 25). The recently published crystal structure of the closely related VSV 
polymerase allowed to assume that the mCherry-tag places between the 
connector- and the methyltransferase domain of the polymerase (Liang et al., 
2015). MARV-L containing a mCherry-tag (L) preserved 60% of its reporter gene 
activity in a minigenome assay compared to wildtype L (LWT) (Fig. 25). A previous 
study on a flag-tagged MARV L showed that co-expression of the L protein with 
NP and VP35 resulted in localization of the L protein in NP-derived inclusion 
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bodies through interactions with VP35, while solely expressed L protein was 
diffusely distributed in the cytoplasm (Becker et al., 1998).  
  
 
Figure 25: Characterization of a mCherry-tagged L (L)  
(A) Schematic domain architecture of wildtype L (LWT) and mCherry-tagged L (L). Amino acid region from 
740 to 763 including the highly conserved GDN active site motif (bold) and the positions of the amino 
acid substitutions of the guinea pig-lethal MARV L (L1,2,3,) (upper scheme red, lower scheme asterisks) 
are shown. Below each scheme a schematic presentation of the non-segmented negative strand viruses 
conserved regions (CR I to CR VI). The location of the mCherry-tag is shown in red. RdRp: polymerase 
domain Cap: capping domain, CD: connector domain, MT: methyltransferase domain, and CTD: C-
terminal domain (B) Comparison of the polymerase activity of LWT and L in HEK293 cells. Cells were 
transfected required for to the minigenome assay and either LWT or L encoding plasmid was used. Cells 
were lysed 48 h post transfection and the reporter gene activity was determined. The LWT activity was 
set to 100%. Shown are the means and standard deviations from three independent experiments 
performed in triplicates in a logarithmic scale, statistical analysis was performed using the Student’s t-
test. * P < 0.05. 
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To analyze whether MARV L containing a mCherry-tag (L) preserved the 
capability to relocate into inclusion bodies, we performed IFA of cells transfected 
either with only pCAGGS-mCherry-L or together with the plasmids necessary for 
the minigenome assay (pCAGGS-NP, VP30, VP35, 3M5M, T7-pol). In agreement 
with previous observations, single expression of L led to diffuse expression in the 
cytoplasm (Fig. 26, i), whereas co-expression with the viral nucleocapsid complex 
and the minigenome resulted in localization of L into NP-induced inclusion bodies 
where a clear colocalization with VP35 and NP was observed (Fig. 26, ii-v)  
  
 
Figure 26: Cellular distribution of a mCherry-tagged L (L)  
(i) Localization of singly expressed mCherry-tagged L (L). (ii-v) Expression of L in the context of the 
minigenome assay. Huh-7 cells were transfected only with L gene or L was co-expressed with proteins 
required for the minigenome assay. Cells were fixed 48 h p.t. and stained with anti-VP35 (green) and 
anti-NP (blue) specific antibodies. The auto fluorescence of mCherry was detected (i, ii, black and white). 
Bars indicate 20 µm. 
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3.3.2 Intracellular localization of the mCherry-L mutants 
 
Efficient interactions of L with the nucleocapsid proteins are mandatory to fulfill 
efficient replication and transcription (Becker et al., 1998; Mühlberger et al., 
1998). It was unclear whether the three mutations of the guinea pig-lethal MARV 
L affect the interactions of the viral polymerase with other proteins of the viral 
polymerase complex. Efficient replication and transcription requires interaction of 
the L protein with the polymerase co-factor VP35 leading to recruitment of L into 
NP-derived inclusion bodies (Becker et al., 1998; Mühlberger et al., 1998). To 
analyze whether the mutations in L affect the interactions with nucleocapsid 
proteins, we constructed L mutants. Recombinant L proteins containing only a 
single amino acid substitution L1 (S741C), L2 (D758A), L3 (A759D), all possible 
double amino acid substitutions L1,2 (S741C, D758A), L1,3 (S741C, A759D), L2,3 
(D758A, A759D) and a mutant containing all three amino acid substitutions L1,2,3 
(S741C, D758A, A759D) were constructed (Fig. 27).   
To determine whether the L mutants are efficiently recruited into NP-induced 
inclusion bodies plasmids required for the minigenome assay and one of the 
plasmids encoding the mCherry-tagged L mutants were transfected into human 
and guinea pig cells. The cells were fixed 48 h post transfection and stained with 
Phalloidin-FITC (green). The cellular localization of the wildtype mCherry-L 
protein and of the mCherry-L protein mutants (red) was assessed by IFA. All 
tested mCherry-L proteins were located in perinuclear inclusion bodies, in both 
human and guinea pig cells (Fig. 27). None of the mutants displayed a diffuse 
cytoplasmic distribution, indicating that the mutations in the active site of viral 
polymerase did not alter the interactions with the nucleocapsid proteins. In 
addition, the size and shape of the inclusion bodies was not affected by the 
polymerase mutations and no significant changes were observed in the intensity 
of mCherry fluorescence between all mutants.  
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Figure 27: Localization of L mutant constructs in human and guinea pig cells   
Indicated in the table are the construct names and the corresponding amino acid substitutions. Human 
(Huh-7) or guinea pig (104C1) cells were transfected with plasmids required for the minigenome assay. 
Cells were fixed with 4% PFA in DMEM 48 h p.t. The localization of the L protein was determined by 
auto fluorescence of mCherry (black and white images). The smaller colored images in the lower right 
corner show cells at lower magnification. L auto fluorescence (red), actin filaments stained with FITC-
phalloidin (green) and nuclei (blue, DAPI staining). All images were acquired with Leica SP5 confocal 
laser scanning microscope. Bars indicate 20 µM.  
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3.3.3 Characterization of the impact of the mutations in L on the 
polymerase function 
 
All mutations in the guinea pig-lethal MARV L are located in the conserved 
region III, the active site domain. The appearance of the adaptive mutations in 
the active site domain suggests a direct effect on the replication and transcription 
capacities of the polymerase complex. Whether this is the case, the polymerase 
activity of the L mutants was analyzed by the minigenome assay. Human and 
guinea pig cells were transfected with plasmids required for the minigenome 
assay, a plasmid encoding either wildtype L or one of the L mutants were used 
(Nomenclature of the mutants is indicated in Fig. 27). Cell lysates were harvested 
48 h post transfection and the reporter gene activity was determined using the 
dual luciferase assay. The reporter gene activity of the L protein was set to 100%. 
Mutants displaying less than 5% of reporter gene activity were considered as 
non-functional.  
Western blot analysis verified proper expression of all constructs. The amino acid 
substitution S741C (L1) significantly increased the reporter gene activity by 2.6-
fold in human- and 4.6-fold in guinea pig cells (Fig. 28A-C). Surprisingly, the 
mutations D758A and A759D in L2, L3, L1,3, L2,3, and L1,2,3 abrogated the 
polymerase function (reporter gene activity was 1.4% or less) (Fig. 28A-C). The 
observed effect of these mutations was consistent in human and guinea pig cells. 
Polymerase activity of L1,2 was inhibited in human cells, the reporter gene activity 
was lower than 2.5%. However, in guinea pig cells expression of L1,2 resulted in 
12.1% reporter gene activity, indicating a possible species-specific effect of these 
mutations (Fig. 28A). Interestingly, even highly expressed L3, L2,3 or L1,2,3 proteins 
were not able to induce reporter gene activity (Fig. 28A). These data indicate, 
that the mutations D758A and A759D strongly inhibit the polymerase function 
without any effects on expression and localization.  
 
The body core temperature is one of the many physiological differences between 
humans and guinea pigs. Guinea pigs have a higher body temperature than 
humans, whereas the body temperature of guinea pigs is 39.5°C, the body 
temperature of humans is at 37°C (Terril, 1998). It was of interest to determine 
whether the change in temperature could restore the polymerase activity of the L 
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mutants. To address this question human and guinea pig cells were transfected 
as described above (Fig.27A) and then incubated at 39.5°C (Fig. 28B). During 
incubation of cells at 39.5°C, expression of L1 resulted in a 3.5- / 5.2-fold increase 
in reporter gene activity in human /guinea pig cells. Expression of L1,2 resulted in 
reporter gene activity levels of 2.1% in human and 6.8% in guinea pig cells. The 
mutations D758A and A759D in the L2, L3, L1,3, L2,3, and L1,2,3 mutants abrogated 
the replication and transcription activity in both human and guinea pig cells, the 
reporter gene activity level was 0.8% or less. Altogether these data indicate that 
the impairment of the polymerase function of the L2, L3, L1,3, L2,3, and L1,2,3 
mutants is temperature-independent (Fig. 28B).   
To exclude an effect of the mCherry-tag on the active site of the polymerase, we 
constructed the polymerase mutants without mCherry-tag. Removal of the 
mCherry-tag did not alter the activity of the polymerase constructs (Fig. 28C). The 
S741C mutation in L1 enhanced the minigenome based replication and 
transcription activity by 2.5-fold in human- and 3.1-fold in guinea pig cells. 
Expression of L1,2 without mCherry-tag resulted in a slight increase in polymerase 
activity: 17,7% activity in human cells and 29.8% activity in guinea pig cells. 
Despite the slight increase in activity of the L1,2 mutant, the polymerase activity 
of the mutants L2, L3, L1,3, L2,3, and L1,2,3 was not rescued in constructs without 
the mCherry-tag (Fig. 28C). These results indicate that the mCherry-tag is not 
involved in the strong inhibitory effect of the D758A and A759D mutations on the 
transcription and replication activities of the L protein. 
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Figure 28: Characterization of the polymerase mutants in human and guinea pig cells 
Human (HEK293, shown in black) and guinea pig (104C1, shown in gray) cells were transfected with the 
plasmids required for the minigenome assay and plasmids encoding either wildtype L or one of the L 
mutants (the name of the mutants is indicated in Fig. 26). 48h p.t. cells were lysed and the reporter gene 
activity was determined. (A) Incubation of the cells at 37°C. The lower panel shows the Western blot data 
on the expression of the L protein constructs and vinculin. Detection of the proteins was performed by 
SDS-PAGE and Western blot analysis using mCherry- and vinculin-specific primary antibodies. (B) Cells 
were transfected and processed as described above and incubated at 39.5°C. (C) Cells were transfected 
and processed as described in above, but the polymerase constructs without mCherry-tag were used 
instead of the mCherry-tagged constructs. L expression was set to 100%. The negative control was 
without expression of L (-L) and displayed the background of the assay. Shown are the means and 
standard deviations of three independent experiments in a logarithmic scale, statistical analysis was 
performed using the Student’s t-test. **P<0.01, ***P<0.001. 
  
Results 
87 
 
3.3.4 Characterization of the polymerase mutants in an iVLP 
assay 
 
To exclude that unknown interactions of the polymerase with other viral proteins 
such as VP24, VP40 or GP contribute to the reconstruction of the polymerase 
function, the polymerase activities of L1, L1,2 and L1,2,3 were analyzed using the 
iVLP assay. In addition, it was of interest to determine the capacity of the different 
polymerase constructs to induce primary transcription, using infection of naïve 
cells with iVLPs.  
 
The reporter gene activity of the L1 mutant increased by 3.6-fold in human p0 
cells and by 2.7-fold in guinea pig p0 cells (Fig. 29A-B). As expected, the reporter 
gene activity of the L1,2,3 mutant was strongly inhibited in human and guinea pig 
cells (less than 5% reporter gene activity). This finding indicates that the 
expression of the other viral proteins does not recover the polymerase function 
of the L construct carrying all three mutations (Fig. 29A-B). The polymerase 
activity of L1,2 was reduced to 26.3% in guinea pig cells and almost undetectable 
in human cells (Fig. 29A-B).  
The reporter gene activity in pre-transfected (p1 tr) indicator cells infected with 
iVLPs reflects the capacities of the incoming nucleocapsid complex to transcribe 
and replicate the minigenome with the support of the ectopically expressed 
nucleocapsid proteins. To compare the reporter gene activity of different L 
mutants, the p1 tr human and guinea pig cells were infected with iVLPs, 
containing different L mutants. The reporter gene activity in p1 tr cells infected 
with L1,2,3-containing iVLPs was extremely low (less than 5% of reporter gene 
activity) in human and guinea pig cells (Fig. 29A-B). The reporter gene activity in 
p1 tr cells infected with L1-containing iVLPs was strongly enhanced upon 
infection, by 7.4-fold in human and 13.5-fold in guinea pig cells (Fig. 29A-B). 
Interestingly, while L1,2-containing iVLPs did not induce reporter gene activity in 
human p1 tr indicator cells, these iVLPs induced 28% of reporter gene activity of 
L-containing iVLPs in p1 tr guinea pig cells. The different reporter gene activity of 
L1,2 in human and guinea pig cells supports the conclusion that this combination 
of mutations might provide a species-specific advantage.  
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However, it must be noted that L1,2 is significantly impaired in its function 
compared to L.  
Infection of naïve indicator cells with iVLPs reflects the incoming nucleocapsid 
complex to perform primary transcription of the minigenome in the absence of 
de novo viral protein synthesis. Infection of p1 naïve cells with L1 containing iVLPs 
enhanced primary transcription by 4.1-fold in human- and 3.4-fold in guinea pig 
cells. Reporter gene activity was below 5% in human and guinea pig cells infected 
with iVLPs containing L1,2,3, reflecting only background activity (Fig. 29A-B). In 
agreement with data obtained with p1 tr cells, the reporter gene activity in human 
p1 naïve cells infected with iVLPs containing L1,2 was extremely low, but retained 
 
Figure 29: Characterization of the polymerase mutations in the iVLP assay 
(A) Human (p0, HEK293, p1, Huh-7) or (B) guinea pig (p0, 104C1, p1, 104C1) cells were transfected 
with plasmids required for the iVLP assay. Cells were harvested 72h p.t. and the reporter gene activity 
was measured (left panel). Either human or guinea pig p1 tr (middle panel) or p1 naïve (right panel) cells 
were infected with iVLPs containing different L variants. Cells were lysed 24h p.t. and the reporter gene 
activity was determined. The reporter gene activity of L was set to 100%. Results are shown in a 
logarithmic scale as well as the means and standard deviations from triplicates from three independent 
experiments, statistical analysis was performed using the Student’s t-test., ***P<0.001. 
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29% of activity in guinea pig cells (Fig. 29A-B). Altogether, these data confirm 
that the S741C substitution led to a gain of function of the polymerase complex, 
whereas the substitutions on position 758 and 759 abrogate the polymerase 
function. 
 
3.4 Characterization of the synergistic effect of the D184N 
mutation in VP40 and the S741C mutation in L on 
replication and transcription 
 
In the present study we have found that the D184N mutation in VP40 relieves the 
suppressive effect of VP40 on replication and transcription of the minigenome 
specifically in guinea pig cells (Fig. 15). All three analyzed mutations in the 
polymerase L influenced the polymerase activity. While the S741C mutation 
induced higher polymerase activity, the D758A and A759D mutations 
dramatically inhibited the polymerase function both in human and guinea pig 
cells. In the following experiment we wanted to analyze whether the D184N 
mutation in VP40 and the S741C mutation in L have species-specific synergistic 
effects on replication and transcription.  
 
To address this question, human or guinea pig cells were transfected with all 
plasmids required for the minigenome assay. Plasmids encoding wildtype L or L1 
were used as indicated. In addition, plasmids encoding either wildtype VP40 or 
VP40D184N were transfected. Cells were lysed 24 h post transfection and the 
reporter gene activity was measured. The reporter gene activity of L wildtype 
without co-expression of VP40 and VP40D184N was set to 100% in human and 
guinea pig cells.  
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As expected, expression of VP40 significantly reduced the reporter gene activity 
in human and guinea pig cells, independent of the tested L variant (Fig. 30A-B). 
In human cells, the replication activity of L was inhibited by 6.3-fold upon co-
expression of VP40D184N and by 4.8-fold in presence of wildtype VP40 (Fig. 30A). 
In guinea pig cells, the replication activity of L was inhibited by 2.1-fold upon co-
expression of VP40D184N, and to 3.2-fold in presence of wildtype VP40.  
 
In human cells, the polymerase activity of L1 was decreased upon co-expression 
of VP40D184N by 10.2-fold, whereas in presence of wildtype VP40 the polymerase 
activity was suppressed by 4-fold. In guinea pig cells, the polymerase activity of 
L1 was decreased upon co-expression of VP40D184N by 2.8-fold, whereas in 
presence of wildtype VP40 the polymerase activity was suppressed by 6.1-fold. 
Thus, in guinea pig cells, the inhibitory effect of VP40D184N on reporter gene 
activity of both L and L1 was consistently lower than the inhibitory effect of 
wildtype VP40 on the polymerase activity of L and L1 (Fig. 30B). Remarkably, the 
polymerase activity of L1 remained high in the presence of both wildtype VP40 
and VP40D184N and comprised 125% and 280%, correspondingly (Fig. 30B). 
Expression controls showed that all transfected constructs were expressed (Fig. 
30C-D). It is important to note that the polymerase activity of L1 in presence of 
VP40D184N in human cells comprised 35%, while in guinea pig cells the 
polymerase activity of L1 in presence of VP40D184N reached 280%, showing an 
8.0-fold species-specific increase in reporter gene activity. These data suggests 
a synergistic effect of L1 and VP40D184N on replication and transcription in guinea 
pig cells. 
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Figure 30: Characterization of synergistic effects between VP40D184N and L1  
(A, C) Human (HEK293) or (B, D) guinea pig (104C1) cells were transfected according to the 
minigenome assay and either VP40 or VP40D184N encoding plasmids were added. Either L (white 
columns) or L1 (gray columns) was transfected. 24 h p.t. cells were lysed and the reporter gene activity 
was determined. The means and standard deviations of three independent experiments are shown, 
statistical analysis was performed using the Student’s t-test. *P<0.05, **P<0.01. (C-D) Expression control 
of the samples from A, B. Western blot analysis of proteins was carried out using vinculin-, VP40- and 
mCherry-specific antibodies. Lane 1 shows the negative control lacking L. Lanes 2, 5 are the positive 
controls expressing either L (Lane 2) or L1 (Lane 5) Lanes 3 and 6 show VP40 expression and lanes 4, 
7 VP40D184N expression. 
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4 Discussion 
 
The rodent model for filoviruses provides a unique possibility for the analysis of 
the molecular mechanisms modulating filoviral pathogenicity. The uniqueness of 
rodent animal models for filoviruses is that variations in the filoviral pathogenicity 
are only observed in rodents, while for NHPs filoviral infections are always highly 
pathogenic (Banadyga et al., 2016). The increase in filoviral pathogenicity in 
rodents is accompanied by mutations in the viral genome leading to the 
hypothesis that the mutations are responsible for the enhanced pathogenicity. 
The analysis of how these mutations affect the functions of the viral proteins and 
the ability of the virus to grow within cells of a new host can help to understand 
the molecular mechanisms of filovirus virulence.  
 
Our study was based on the analysis of four mutations detected in a guinea pig-
lethal MARV, three amino acids substitutions, S741C, D758A, A759D, were 
located in the active site of the L protein, and a D184N mutation in the C-terminal 
domain of VP40. (Lofts et al., 2007). The goal of our study was to analyze how 
these individual mutations changed the function of the MARV proteins L and 
VP40 in guinea pig cells compared to human cells.  
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4.1 The guinea pig-adaptive mutation D184N in VP40 
 
Using a reverse genetics approach we have shown that the D184N mutation in 
VP40 provided a recombinant MARV (rMARVVP40(D184N)) with a replicative 
advantage in guinea pig cells. Our studies indicated that this replicative 
advantage of rMARVVP40(D184N) was based on the improved assembly and 
budding functions of VP40D184N, as well as an relieve of its inhibitory effect on 
transcription and replication in guinea pig cells. The ability of VP40D184N to 
suppress the IFN signaling in guinea pig cells was not affected. 
Mutations in viral matrix proteins, upon adaptation to a new host, have been rarely 
been observed in lenti- and paramyxoviruses. For example, a E89K mutation in 
the matrix protein of a cotton rat-adapted measles virus (MeV) has been 
suggested to have an influence on the viral fitness in a new host (Dong et al., 
2009). A single amino acid substitution in the matrix protein of simian 
immunodeficiency virus (SIV) obtained in course of passages in human lymphoid 
tissue resulted in increased viral replication in new host cells, however the 
mechanism explaining the impact of this mutation on the increased viral fitness 
remained unclear (Bibollet-Ruche et al., 2012). 
MARV VP40 is known as an important interferon antagonist (Valmas et al., 2010). 
It was therefore tempting to presume that the single amino acid mutation D184N 
in VP40 influenced the interferon antagonistic function of VP40 in guinea pig cells. 
However, previous studies on MARV adaptive mutations in VP40 demonstrated 
that the D184N mutation did not alter the interferon antagonism in mouse cells 
while three other mutations in VP40 of MA-MARV were responsible for the 
inhibition of the innate immune response (Feagins & Basler, 2014; 2015; Valmas 
& Basler, 2011). Supporting this data, our results suggested that the D184N 
mutation alters another than the IFN-antagonistic function of VP40 (Fig. 8-9). A 
similar observation was made for other filoviral proteins with IFN antagonistic 
function. Three mutations in VP24 of MA-EBOV, did not alter the interferon 
antagonistic function of EBOV VP24 in guinea pig cells, however, these mutations 
were sufficient to induce a lethal disease in guinea pigs (Mateo et al., 2011; Reid 
et al., 2006).  
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Figure 31: Effects of D184N on the viral life cycle in an rMARVVP40(D184N) infected guinea pig cell  
Schematic representation of the viral life cycle upon MARV infection in either rMARVWT (left, indicated 
by yellow) and rMARVVP40(D184N) (right, indicated by purple) in a guinea pig cell. Attachment and binding 
of MARV particles to the cell surface via one or more receptors, such as TIM-1 or DC-SIGN (Step 1). 
Followed by fusion via the endosomal receptor NPC1 and release of the nucleocapsid, containing the 
viral genome, into the cytoplasm (Step 2). Afterwards primary transcription is initiated, a process which 
can be inhibited by VP40 from incoming virions (orange/purple spheres, Step 3). The cellular machinery 
translates the viral mRNAs into the according viral proteins (Step 4). Translation of the viral proteins is 
followed by replication and secondary transcription within inclusion bodies, replication is inhibited by 
presence of VP40 (orange/purple spheres, Step 5). Nucleocapsids are transported to the plasma 
membrane and interact with membrane-associated VP40 leading to the assembly and release of virions 
(Step 6). Finally, budding of mature virions from the infected cells is facilitated by VP40 (Step 7) 
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Mutations in the viral matrix proteins may result in changes in the transmission 
efficiency mediated by morphological changes of virus particles, as it was recently 
shown for the swine influenza A virus containing a single mutation in the matrix 
protein (Campbell et al., 2014; Ward, 1995). However, our comparative EM 
analysis of rMARVWT and rMARVVP40(D184N) showed that the morphology of the 
viral particles was indistinguishable. These data demonstrated that the virus 
particle morphology was not altered by the D184N substitution in VP40.  
 
Mutations in viral matrix proteins can modulate the viral infectivity, by increasing 
or decreasing the incorporation of the viral glycoprotein into viral particles, as it 
has been shown for mutations in the matrix protein (MA) of SIV (Manrique et al., 
2003). We observed an increase in the infectivity of rMARVVP40(D184N) in human 
and guinea pig cells, and wanted to analyze whether this increase depends on 
the incorporation of GP. We followed three different approaches which 
consistently showed that the D184N mutation in VP40 did not alter the 
incorporation of GP into virus particles. First, equal amounts of GP were detected 
in iVLP preparations produced either upon expression of VP40 or VP40D184N. 
Second, equal amounts of GP were detected by a silver stained gel of rMARVWT 
or rMARVVP40(D184N) virus particles. And, third, comparable amounts of 
immunogold-labeled GP spikes were detected in rMARVWT or rMARVVP40(D184N) 
particles. Thus our data indicated that the D184N mutation in VP40 did not affect 
the infectivity of rMARVVP40(D184N) by altering the incorporation of GP into viral 
particles.  
 
Another factor that might have influenced the infectivity of rMARVVP40(D184N) was 
the efficiency of incorporation of nucleocapsid complexes into viral particles. 
MARV VP40 has been shown to be important for the attraction of nucleocapsid 
proteins into infectious virus-like particles (Dolnik et al., 2008; Urata et al., 2007). 
Although the mechanism of the interactions between VP40 and NP remains 
unknown, it could not be excluded that the D184N mutation in VP40 altered the 
assembly function of VP40. The comparison of the composition of rMARVWT or 
rMARVVP40(D184N) particles assembled in guinea pig cells indeed showed an 
increase in the ratio of NP to VP40 in rMARVVP40(D184N) virions. An increased ratio 
of NP to VP40 was also detected in VP40D184N-induced iVLPs formed in guinea 
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pig cells (Fig. 31, step 6). Hence the D184N mutation in VP40 improved the 
attraction of NP (or nucleocapsids) into iVLPs and virions in a species-specific 
manner.  
 
MARV VP40 is the driving force of virus budding, evidenced by the ability of VP40 
to form VLPs upon single ectopic expression (Kolesnikova et al., 2004b; Swenson 
et al., 2004). It has been suggested that the endosomal sorting complex required 
for transport (ESCRT) machinery is involved in mediating budding of MARV 
VP40-induced VLPs (Urata et al., 2007). The interactions of MARV VP40 with the 
ESCRT machinery are mediated by a PPPY motif at the amino acid residues 16 
to 19 (Urata et al., 2007). Since the D184N mutation is rather far away from the 
PPPY motif, it seems unlikely that the D184N substitution affects the interaction 
of VP40 with the ESCRT machinery. The observed 1.5-fold increase in the 
relative amount of released VLPs specifically in guinea pig cells might be the 
result of an altered interaction of VP40D184N with so far unknown guinea pig host 
factors (Fig. 31, step 7). Among others, tetherin might be a host-specific 
candidate factor interacting with VP40. It has been shown that VP40 of a MA-
Marburg virus Ravn (RAVV) interacts with murine tetherin, but not with human 
tetherin. However, analysis of mutations in VP40 of MA-RAVV showed that the 
improved VLP budding in mouse cells was mediated via interactions of tetherin 
with VP40 containing adaptive mutations at residues 57 and 165 but not via the 
D184N mutation (Feagins & Basler, 2014).  
 
Filoviral budding does not depend entirely on the ESCRT machinery and was 
previously shown to be negatively affected by overexpression of dominant 
negative Sar1, a marker for COPII vesicles (Kolesnikova et al., 2009; Urata et al., 
2006; Yamayoshi et al., 2008). Thus, Sar1 might be another host factor possibly 
interacting with VP40D184N in guinea pig cells, which was responsible for the 
enhanced release of VLPs.  
 
The matrix proteins of NNS viruses, for example, the matrix proteins of the Lassa 
virus, rabies virus and VSV are known to play a regulatory role in viral replication 
and transcription (Carroll & Wagner, 1979; Finke et al., 2003; Hass et al., 2004). 
The same phenomenon was observed for VP40 of MARV and EBOV (Hoenen et 
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al., 2010; Watanabe et al., 1996). However, it was unknown whether mutations 
in matrix proteins can specifically affect the regulation of transcription and 
replication. Our data showed that the D184N mutation in VP40 relieved the 
suppressive effect of the matrix protein on minigenome replication and 
transcription specifically in guinea pig cells. This effect likely contributes to the 
enhanced virus production of rMARVVP40(D184N) in guinea pig cells (Fig. 31, step 
3,5). The identification of host cell factors mediating the species-specific increase 
of replication and transcription in presence of VP40D184N requires further studies. 
 
4.2 The effect of the mutations S741C, D758A, A759D on the 
replication capacities of MARV L 
 
The functional analysis of L mutants showed that the polymerase function was 
strongly enhanced by an amino acid substitution at position 741 (S741C), and 
robustly inhibited by the other two amino substitutions (D758A and A759D) in a 
non-species-specific manner.  
  
To date there is no specific antibody recognizing MARV L, therefore it was 
necessary to construct tagged MARV L mutants to confirm proper expression. 
Our study demonstrated that addition of a fluorescence tag in a highly variable 
region of the MARV L polymerase neither destroyed the polymerase activity nor 
affected its interactions with other proteins of the polymerase complex. An 
insertion of mCherry into the closely related EBOV L resulted in a loss of activity 
of approx. 90% (Hoenen et al., 2012). The decrease in activity of MARV L with 
the mCherry-tag (L) was not as dramatic as in the case of EBOV L and showed 
only 38% reduction of reporter gene activity. This suggests that MARV L tolerates 
the insertion of mCherry better than EBOV L.  
  
Most of the mutations observed in viral polymerases of NNS viruses during 
adaptation to a new host were detected in CR V or CR VI (Ackermann et al., 
2007; Brown et al., 2011; Dortmans et al., 2011; Ebihara et al., 2006; Fujii et al., 
2002; Heiden et al., 2014; Kim et al., 2014b). The CR V of the viral polymerase 
mediates capping of viral mRNAs, and CR IV represents the methyltransferase 
function (Liang et al., 2015). CR V and CR VI of NNS virus polymerases are not 
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highly conserved and considered as domains interacting with unique host cell 
transacting transcriptional cofactors (Dortmans et al., 2011; Poch et al., 1990; 
Sidhu et al., 1993).  
  
The position of the mutations, S741C, D758A and A759D, detected in the guinea 
pig-lethal MARV L is uncommon for adaptive mutations in L proteins, because 
they locate into the CR III close to the highly conserved GDN motif (residues 744-
746). The CR III represents the active site of the viral polymerase function, and 
mutations located in or close to the GDN motif in the polymerase of NNS has 
been shown to destroy the processivity of viral RdRps (Carroll et al., 2015; Dietzel 
et al., 2016; Malur et al., 2002; Schnell & Conzelmann, 1995; Sleat & Banerjee, 
1993; Smallwood et al., 2002). Adaptive mutations were only rarely observed in 
CR III, for example, a T820A substitution has been detected in a guinea pig-
adapted EBOV polymerase L (Mateo et al., 2011). However, it is hard to estimate 
the influence of the T820A mutation in EBOV L on the polymerase activity in a 
new host, because the recombinant EBOV containing the T820A mutation in L 
and an additional mutation in NP (F648L) did not induce a lethal disease in the 
infected guinea pigs, and the polymerase activity of the L mutant was not 
analyzed by the minigenome assay in guinea pig cells (Mateo et al., 2011). 
Another example, and the only positive effect on replication due to an amino acid 
substitution in the active site was observed when a D759G amino acid 
substitution in EBOV L appeared during the 2014-2016 EBOV outbreak and 
resulted in an increased polymerase activity in minigenome-based reporter 
assays (Dietzel et al., 2016).  
 
We have found that the mutation S741C in the active site of MARV L improved 
the polymerase function. The increased polymerase activity of the L1 mutant both 
in human and guinea pig cells suggested that the S741C mutation enhanced the 
polymerase activity in a species-independent manner (Fig. 27-30). The negative 
effects of the D758A and A759D mutations on the function of L were astonishing 
since it was expected that all the selected mutations should contribute to the 
enhanced replication of the guinea pig-lethal MARV in the new host (Lofts et al., 
2007).  
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It seems reasonable that the amino acid exchange, in the active site of MARV L, 
at position 741 from serine to cysteine might be beneficial for the polymerase 
activity. In fact, serines are found regularly in active centers of proteins and can 
be exchanged with an cysteine fulfilling similar roles in the active center (Betts & 
Russel, 2007). The lack of polymerase activity in presence of the D758A and 
A759D substitutions in MARV L is still unclear and needs further investigation. It 
is possible that the two abrogating mutations represent a minority of the viral 
quasi-species which had been selected during plaque purification of guinea pig-
lethal MARV (Beaucourt et al., 2011). It can only be speculated that these 
mutations in the active site of the polymerase, destroy either the structure or 
charge of the active site resulting in a loss of activity. Aspartate is frequently 
observed in active sites of enzymes to facilitate interactions with positively 
charged non-protein interactors (Betts & Russel, 2007). Aspartate played a role 
in both abrogating mutations D758A and A759D. We assume that the exchange 
of the negatively charged aspartate to the nonpolar alanine might disrupt tightly 
regulated complex interactions with non-protein interactors such as metal ions 
necessary for efficient enzymatic activity (Ng et al., 2008).  
 
4.3 The synergistic effect of the S741C mutation in L and the 
D184N mutation in VP40 on the replication activity in 
guinea pig cells 
 
The polymerase activity of L carrying the S741C substitution in presence of 
VP40D184N was eightfold higher in guinea pig than in human cells, suggesting an 
additive effect of these two mutations on the replication activity in the new host.  
 
Whether only one mutation or a combination of the mutations present in the 
guinea pig-lethal MARV VP40 and the L protein are necessary to increase the 
pathogenicity of MARV in guinea pigs remains to be determined by a reverse 
genetics approach. Based on the finding that the D184N mutation in VP40 
appeared at early passages of MARV in mice, but did not result in a lethal 
disease, it seems reasonable to suggest that additional mutations were 
necessary to increase MARV virulence in mice (Lofts et al., 2011).   
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Our study demonstrated that the S741C mutation in the L protein and the D184N 
mutation in VP40 might have an additive effect on replication and transcription. 
Rescue of recombinant viruses containing either the D184N mutation in VP40, or 
the S741C mutation in L or both mutations in combination with challenge studies 
in guinea pigs will shed light on the role of these mutations as molecular 
determinants of MARV pathogenicity in guinea pigs.  
 
4.4 Future plans  
 
The several species-specific effects of the D184N mutation in VP40 on many 
functions of the viral protein in guinea pig cells suggest that the D184N mutation 
mediates the interaction of VP40 with guinea pig-specific cellular factors. It is of 
special interest to determine these host factors by co-immunoprecipitation 
studies. We expect that the detection of guinea pig factors specifically interacting 
with VP40D184N using conventional co-immunoprecipitation strategies is 
problematic, due to the potentially transient character of the interaction. 
Therefore, we plan to use a so called proximity biotin ligation assay which could 
identify even weak or transiently interacting proteins (Kim et al., 2014a; Kim et 
al., 2016).  
The additive effects of the D184N mutation in VP40 and the S741C mutation in L 
on the polymerase activity specifically in guinea pig cells suggests that both 
mutations are important for the replicative fitness of MARV in guinea pig cells. 
Therefore, full-length cloning and rescue of recombinant viruses containing 
different combinations of these mutations are necessary for further studies to 
elucidate the molecular determinants of MARV pathogenicity in guinea pigs. The 
recombinant viruses will be used to investigate the effects of the mutation in 
primary guinea pig cells, and finally in the guinea pig model. 
 
Summary (english) 
101 
 
5 Summary 
 
5.1 Summary (english) 
Marburg virus (MARV) is a highly pathogenic virus that causes severe, often lethal 
diseases specifically in humans and non-human primates. In rodents MARV is non-
pathogenic. However, sequential passaging of MARV in rodents results in selection of 
a rodent-lethal virus. Lofts et al. established a guinea pig-lethal MARV containing only 
four non-silent amino acid changes in viral genome (Lofts et al., 2007). One amino acid 
substitution (D184N) was detected in the viral matrix protein VP40 and three amino 
acid substitutions were detected in the RNA-dependent RNA polymerase L (S741C, 
D758A and A759D). We analyzed the effects of the guinea pig-adaptive mutations on 
the functions of VP40 and L in a comparative study including human and guinea pig 
cells. Functional analyses were performed with ectopically expressed VP40D184N and 
L mutants by using different assays. The influence of the D184N mutation in VP40 on 
the replicative capacities of MARV in guinea pig cells was analyzed by infection of cells 
with recombinant MARV containing the D184N mutation in VP40.  
The first part of the study demonstrated that a recombinant rMARV containing only the 
 
Figure 32: Schematic presentation of the results  
Mutations present in viral proteins of the guinea pig-lethal MARV (Lofts et al. 2007) are indicated by arrows 
above the schematic viral genome. The boxes show the effect of the mutations on the viral protein function of 
either VP40 (yellow), L (green) and synergistic effect of mutations in both proteins (pink). The bold arrows 
indicate whether the mutation increased, arrow up, or decreased, arrow down, the specific function. Red bold 
arrows represent species-specific effects observed only in guinea pig cells, black arrows represent non-species-
specific effects. The red and black striped arrow indicates that the effect was present in both human and guinea 
pig cells but more pronounced in guinea pig cells.  
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D184N amino acid substitution in VP40 displayed a higher level of viral fitness 
specifically in guinea pig, but not in human cells. The mutant virus showed higher 
replicative capacities, enlarged inclusion bodies and enhanced infectivity only in 
guinea pig cells. Detailed comparative analysis of VP40 functions, in human and 
guinea pig cells, indicated that the membrane binding capabilities and the interferon 
antagonistic function were not altered by the D184N amino acid substitution. However, 
presence of the D184N mutation in VP40 enhanced the production of VP40-induced 
virus-like particles (VLPs) specifically in guinea pig cells. In addition, the amount of NP 
in infectious virus-like particles (iVLPs) and virus preparations was enhanced in 
presence of the D184N mutation in VP40 specifically in guinea pig cells. These data 
might partially explain the higher infectivity of VP40D184N containing iVLPs compared 
to wildtype VP40 containing iVLPs. Most importantly, the inhibitory capacity of VP40 
on replication and transcription was species-specifically lowered by the D184N 
mutation in VP40, allowing significantly higher levels of replication and transcription in 
guinea pig cells.  
The second part of the study focused on the importance of the mutations in the L 
protein observed in the guinea pig-lethal MARV. Interestingly, only the S714C 
substitution increased replication in both species while the other mutations, D758A and 
A759D severely impaired the polymerase function. All L mutant proteins displayed 
proper expression and were able to localize into inclusion bodies which represent the 
sites of viral transcription/replication.  
Finally, co-expression of plasmids encoding L with the S741C amino acid substitution 
and VP40D184N in guinea pig cells resulted in eight fold higher levels of replication and 
transcription in comparison to human cells. This suggested that the D184N mutation 
in VP40 and the S741C mutation in L together significantly improve replication of 
MARV in guinea pig cells. Altogether these data suggests that the D184N substitution 
in VP40 and the S714C substitution in L can contribute to the increased pathogenicity 
of guinea pig-lethal MARV.  
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5.2 Zusammenfassung (deutsch) 
Das Marburg Virus (MARV) ist hochpathogen und verursacht häufig schwere oft 
tödlich verlaufende Infektionen in Primaten. In Nagetieren hingegen verursacht das 
MARV jedoch keine Erkrankung. Sequentielles Passagieren des MARV in 
Nagetieren führt jedoch zur Selektion von Virusvarianten die eine tödliche 
Erkrankung in Nagetieren hervorrufen. Lofts et al. konnten durch sequentielles 
Passagieren ein Meerschweinchen adaptiertes MARV etablieren, das sich vom 
wildtypischen MARV lediglich durch vier ausgetauschte Aminosäuren unterschied, 
für die Tiere aber tödlich war (Lofts et al., 2007). Eine, Mutation, D184N, befindet sich 
in VP40 dem viralen Matrix Protein und drei weitere Mutationen, S741C, D758A, 
A759D, befinden sich in der viralen RNA-abhängigen RNA Polymerase, dem L 
Protein. Die molekularen Mechanismen, die durch diese Mutation beeinflusst wurden 
blieben unklar. Ziel dieser Arbeit war es zu analysieren ob diese adaptiven 
Mutationen im Meerschweinchen-letalen MARV die Funktionen der Proteine VP40 
und L in Meerschweinchenzellen im Vergleich zu menschlichen Zellen beeinflussen. 
Dazu untersuchten wir durch verschiedene Assays mit Hilfe von ektopischer 
 
Figure 33: Schematische Darstellung der Ergebnisse  
Als Übersicht dargestellt die Effekte der D184N Mutation in VP40 und der S741C, D758A und A759D 
Mutationen in L des Meerschweinchen-letalen MARV (Lofts et al. 2007). Die Mutationen werden dargestellt 
durch die Pfeile oberhalb des schematischen viralen Genoms. Die Boxen stellen die beobachteten Effekte der 
Mutationen auf die jeweiligen Proteinfunktionen für VP40 (gelbe Box) und L (grüne Box) und der Kombinationen 
beider dargestellten Mutationen in VP40 und L (pinke Box) dar. Die Pfeile innerhalb der Boxen zeigen in welcher 
Form die jeweilige Proteinfunktion beeinflusst worden ist (nach oben, Funktionssteigerung, nach unten, 
Funktionsverlust). Rote Pfeile zeigen nur in Meerschweinchenzellen auftretende spezies-spezifische 
Unterschiede an, die schwarzen nicht-spezies-abhängige Effekte. Der rot-schwarz gestreifte Pfeil zeigt 
Unterschiede welche in beiden Spezies beobachtet wurden, jedoch deutlich ausgeprägter in 
Meerschweinchenzellen waren. 
Zusammenfassung (deutsch) 
104 
 
Überexpression der rekombinanten Proteine VP40 mit der D184N Mutation und für 
verschiedene L Protein Varianten die jeweiligen Proteinfunktionen.  
Zusätzlich wurde der Einfluss der D184N Mutation in VP40 auf die replikative Fitness 
eines rekombinanten MARV bestimmt, welches lediglich die D184N Mutation in VP40 
trägt (rMARVVP40(D184N)).  
 
Im ersten Teil dieser Arbeit wurde gezeigt das rMARVVP40(D184N) spezifisch in 
Meerschweinchenzellen eine gesteigerte Fitness besitzt. Die viralen 
Transkription/Replikation war verstärkt, es fanden sich vergrößerten viralen 
Einschlusskörperchen in den infizierten Zellen und die Infektiösität von 
rMARVVP40(D184N) war spezifisch für Meerschweinchenzellen erhöht. VP40 ist ein 
multifunktionelles Protein, welches bei der Abwehr der Interferonantwort der Zelle 
sowie beim Zusammenbau und Abknospen der Viren und bei der Regulation von 
Transkription/Replikation beteiligt ist. Vergleiche der einzelnen VP40 Funktionen in 
humanen und Meerschweinchenzellen zeigten, dass die D184N Mutation den VP40-
mediierten Interferon Antagonismus sowie die Assoziation von VP40 mit 
Zellmembranen nicht beeinflussten. Jedoch führte die D184N Mutation in VP40 zu 
einer Zunahme der Abknospung von VP40-induzierten virus-ähnlichen Partikeln 
(VLPs) in Meerschweinchenzellen. Zudem führte die D184N Mutation in VP40 zu 
einer Erhöhung der Menge an Nukleoprotein (NP) in infektiösen virus-ähnlichen 
Partikeln (iVLPs) lediglich in Meerschweinchenzellen. Diese Daten zeigen, dass viele 
der Funktionen des VP40 durch die D184N Mutation exklusiv in 
Meerschweinchenzellen beeinflusst werden und erklären zumindest teilweise die 
gesteigerte Infektiösität von VP40D184N enthaltenden iVLPs in 
Meerschweinchenzellen. Der bedeutendste spezies-spezifische Unterschied durch 
die D184N Mutation in VP40 betraf jedoch die VP40-vermittelten Inhibition der viralen 
Replikation und Transkription. Diese führte zu einer signifikanten Steigerung der 
viralen Replikation und Transkription in Meerschweinchenzellen was die 
Geschwindigkeit des Viruswachstums deutlich beeinflusste.  
  
Der zweite Teil dieser Arbeit untersuchte die Bedeutung der deri Mutationen im L 
Protein des Meerschweinchen-letalen MARV. Interessanterweise führte die S741C 
Mutation im L Protein zu einer deutlichen, spezies-unabhängigen, Steigerung der 
viralen Replikation und Transkription. Die Mutationen D758A und A759D hingegen 
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hatten einen massiven Verlust der Polymerase Funktion des L Proteins zur Folge. 
 
Abschließend wurde durch Ko-expression der L Variante mit der S741C Mutation und 
VP40D184N gezeigt dass die Kombination dieser beiden Mutationen zu einer 
achtfachen Steigerung der viralen Replikation und Transkription in 
Meerschweinchenzellen gegenüber humanen Zellen führte. Die Daten dieser Arbeit, 
lassen vermuten, dass die D184N Mutation in VP40 und die S741C Mutation in L zu 
der hohen Letalität des Meerschweinchen-adaptierten MARV beitragen. 
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7 Materials 
 
7.1 Equipment 
 
Incubator HERAcell150 Thermo Fisher, Hudson (USA) 
Incubator Function line BB16 Thermo Fisher, Hudson (USA) 
DNA- Gel chambers bsb11, Schauenburg (GER) 
Ice machine  Ziegra, Isernhagen (GER) 
Eppendorf centrifuge 5415R Eppendorf, Hamburg (GER) 
Centrifuge Mikro 200R Hettich, Tuttlingen (GER) 
Eppendorf Research Plus® Pipetten Eppendorf, Hamburg (GER) 
Micro scale Sartorius, Göttingen (GER) 
Gel documentation system GelDoc 2000 Biorad, Hercules (USA) 
Light microscope Axiovert200M Zeiss, Jena (GER) 
Light microscope Wilovert® Will, Wetzlar (GER) 
Luminometer Centro LB 960  Berthold, Bad Wildbad (GER) 
Magnetic stirrer Heidolph, Kelheim (GER) 
Metal block Thermostat TCS neoLab®, Heidelberg (GER) 
Microwave Bosch, Stuttgart (GER) 
Table centrifuge Sprout Heathrow scientific, Illinois (USA) 
PCR Cycler Primus 25 Peqlab, Erlangen (GER) 
pH-Meter Φ32 Beckmann Coulter, Palo Alto (USA) 
Pipetting aid Pipetboy Integra Bioscience, Chur (CH) 
Power Supply PowerPacTM HC Biorad, Hercules (USA) 
Power Supply Standard Power Pack P25  Biometra, Göttingen (GER) 
Vortex neoLab®, Heidelberg (GER) 
Rotor Ultracentrifuge SW32, SW41, SW60  Beckmann Coulter, Palo Alto (USA) 
SDS-Gel chamber XCell Sure Lock Thermo Fisher, Carlsbad (USA) 
SDS-Gel chamber Mini-Protean  Biorad, Hercules (USA) 
SemiDry Blot chamberTrans-Blot SD  Biorad, Hercules (USA) 
NuAire Biological Safety Cabinets Class II NuAire, Plymouth (USA) 
Spectrophotometer NanoDrop Lite  Thermo Fisher, Waltham (USA) 
StepOne™ ABI, RealTime PCR Cycler Applied Biosystem, Carlsbad (USA) 
Thermomixer compact  Eppendorf, Hamburg (GER) 
Materials 
 
119 
 
Tabletop-ultracentrifuge Optima™ MAX-XP  Beckmann Coulter, Palo Alto (USA) 
Ultracentrifuge Optima™ L-100K/ -80XP  Beckmann Coulter, Palo Alto (USA) 
UV-Light table 302 nm Bachofer, Reutlingen (GER) 
Vacuumpump Mini-Vac E1 Axonlab, Reichenbach (GER) 
Weight scale excellence  Sartorius, Göttingen (GER) 
Water bath MT  Lauda, Lauda-Königshofen (GER) 
Leica SP5 confocal microscope Leica, Wetzlar (GER) 
 
7.2 Chemicals 
 
Agarose PeqGold universal Peqlab, Erlangen (GER) 
Ammonium persulfate (APS) Biorad, Hercules (USA) 
Ampicillin Serva, Heidelberg (GER) 
BactoTM-Agar Becto, Dickinson & Company, Sparks 
(USA) 
Bovine serum albumin (BSA) Sigma-Aldrich, München (GER) 
Bromphenol blue (BPB) Roth, Karlsruhe (GER) 
Calcium chloride (CaCl2 x 2 H2O) Merck, Darmstadt (GER) 
Casein hydrolysate Merck, Darmstadt (GER) 
Coomassie® Brilliant Blue R250  Serva, Heidelberg (GER) 
Chloroform Merck, Darmstadt (GER) 
D(+)- Glucose Merck, Darmstadt (GER) 
Dextran blue Sigma-Aldrich, München (GER) 
4’,6-Diamidino-2-phenylindol (DAPI) Sigma-Aldrich, München (GER) 
1,4 Diazabicyclo-[2.2.2]-octan (DABCO) Sigma-Aldrich, München (GER) 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt (GER) 
Sodium carbonate (Na2CO3) Merck, Darmstadt (GER) 
Sodium hydrogen phosphate (Na2HPO4) Merck, Darmstadt (GER) 
Ethylenediaminetetraacetic acid (EDTA) Roth, Karlsruhe (GER) 
Acetic acid (HAc) Merck, Darmstadt (GER) 
Ethanol abs. (EtOH) Sigma-Aldrich, München (GER) 
Ethanol vergällt (EtOH) Fischar, Saarbrücken (GER) 
Ethidium bromide Promega, Mannheim (GER) 
Filipin III Sigma-Aldrich, München (GER) 
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Fluorescein Phalloidin Thermo Fisher, Carlsbad (USA) 
Fluoprep BioMérieux, Nürtingen (GER) 
Formvar Sigma-Aldrich, München (GER) 
6x Gel Loading Dye New England Biolabs, Frankfurt (GER) 
Glutamine 200 mM Gibco® /InvitrogenTM, Karlsruhe 
(GER) 
Glutaraldehyde Sigma-Aldrich, München (GER) 
Glycerol Roth, Karlsruhe (GER) 
Glycine Roth, Karlsruhe (GER) 
Yeast extract Merck, Darmstadt (GER) 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Sigma-Aldrich, München (GER) 
Isopropanol Sigma-Aldrich, München (GER) 
Potassium chloride (KCl) Merck, Darmstadt (GER) 
Monopotassium phosphate (KH2PO4) Roth, Karlsruhe (GER) 
Milk powder Saliter, Obergünzburg (GER) 
Magnesium chloride (MgCl2 x 6H2O) Merck, Darmstadt (GER) 
Magnesium sulfate (MgSO4 x 7H2O) Merck, Darmstadt (GER) 
Manganese(II) chloride (MnCl2 x 4H2O) Merck, Darmstadt (GER) 
β-mercaptoethanol Sigma-Aldrich, München (GER) 
Methanol (MeOH) Sigma-Aldrich, München (GER) 
Roswell Park Memorial Institute 1640 
Media (RPMI) 
Gibco®/InvitrogenTM, Karlsruhe (GER) 
Sodium azide (NaN3) Merck, Darmstadt (GER) 
Sodium chloride (NaCl) Roth, Karlsruhe (GER) 
Sodium dodecyl sulfate (SDS) Merck, Darmstadt (GER) 
Sodium hydroxide (NaOH) Riedel-de-Haën, Seelze (GER) 
SuperSignal™ West Femto Thermo Fisher, Carlsbad (USA) 
N(onidet)P40 Merck, Darmstadt (GER) 
Nycodenz Axis-Shield, Oslo (NOR) 
Paraformaldehyde (PFA) Roth, Karlsruhe (GER) 
Penicillin/Streptomycin 5000 IU/ml Gibco® /InvitrogenTM, Karlsruhe 
(GER) 
Trypone Merck, Darmstadt (GER) 
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Phosphotungstic acid Serva, Heidelberg (GER) 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, München (GER) 
Polyacrylamide Rotiphorese Gel 30 Roth, Karlsruhe (GER) 
Hydrochloric acid (HCl) Merck, Darmstadt (GER) 
Nitrogen (99,996 %) Messer-Griesheim, Siegen (GER) 
Sucrose Serva, Heidelberg (GER) 
Tetramethylethylenediamine 
(TEMED) 
Biorad, Hercules (USA) 
TransIT® LT1 Transfection Reagent Mirus Bio, Madison (USA) 
Tris(hydroxymethyl)aminomethane (Tris) Acros Organics, Geel (B) 
TritonX- 100 Sigma-Aldrich, München (GER) 
Tween® 20 neoLab®, Heidelberg (GER) 
T-PER Tissue protein extraction reagent Thermo Fisher, Carlsbad (USA) 
Xylene cyanol FF Gibco®/InvitrogenTM, Karlsruhe (GER) 
Dulbecco’s Modified Eagle Medium 
(DMEM)  
Gibco®/InvitrogenTM, Karlsruhe (GER) 
Fetal calf serum (FCS)  Gibco®/InvitrogenTM, Karlsruhe (GER) 
OptiMEM®  Gibco®/InvitrogenTM, Karlsruhe (GER) 
Trypsin-EDTA (0,5 %) Gibco®/InvitrogenTM, Karlsruhe (GER) 
 
7.3 Consumables 
 
6, 24, 96 well cell culture dishes Greiner bio-one, Frickenhausen (GER) 
25 cm², 75 cm², 175 cm² Cell culture 
flasks 
Greiner bio-one, Frickenhausen (GER) 
96 well Plates LumiNunc™ Nunc, Roskilde (DK) 
2 ml Cryotubes Corning ®, Acton (USA) 
Blotting paper GB 002 (3 mm) Whatman, Maidstone (UK) 
Coverslips, Ø 12 mm Menzel, Braunschweig (GER) 
Indicator paper Merck, Darmstadt (GER) 
Reaction tubes (screw top) Sarstedt, Nürnbrecht (GER) 
Object slide 76 x 22 mm  Menzel, Braunschweig (GER) 
Parafilm Pechiney Plastic, Menasha (USA) 
PCR-Tubes, 0.2 ml Biozym, Hess. Oldendorf (GER) 
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Petri dishes  Sarstedt, Nürnbrecht (GER) 
Pipettes 1, 2, 5, 10, 25 ml Cellstar® Greiner bio-one, Frickenhausen (GER) 
Pipette tips 0.1-1 μL, 10-100 μL, 100-
1000 μL TipOne® (with and without filter) 
Starlab, Ahrensburg (GER) 
Polypropylene reaction tubes 15 ml/50 ml Greiner bio-one, Frickenhausen (GER) 
Immobilion®-P (PVDF-Membrane), Pore 
size 0,45 μm  
Millipore, Billerica (USA) 
Reaction tube 1,5 ml  Sarstedt, Nürnbrecht (GER) 
Reaction tube 2 ml  Eppendorf, Hamburg (GER) 
Scalpel no.22  Feather Feather, Osaka (J) 
Sterile filter Ø 0,2 μm  Schleicher & Schuell, Maidstone (UK) 
Cell scraper  Sarstedt, Nürnbrecht (GER) 
Centrifuge tubes, Ultra-Clear™ for SW41, 
SW60, SW32, TLA55 
Beckmann, Palo Alto (USA) 
NuPAGE Tris-Acetate Gels Thermo Fisher, Carlsbad (USA) 
 
7.4 Kits 
 
Gibson Assembly NEB, Ipswich (USA) 
E.Z.N.A. Plasmid DNA Mini I OMEGA bio-tek, Norcross (USA) 
E.Z.N.A. FastFilter Plasmid DNA Maxi OMEGA bio-tek, Norcross (USA) 
E.Z.N.A. DNA Probe Purification OMEGA bio-tek, Norcross (USA) 
E.Z.N.A. Gel Extraction  OMEGA bio-tek, Norcross (USA) 
QuikChange Multi Site-Directed 
Mutagenesis 
Agilent Technologies, Waldbronn 
(GER) 
QuikChange Site-Directed Mutagenesis  Agilent Technologies, Waldbronn 
(GER) 
QIAamp Viral RNA Mini Qiagen, Hilden (GER) 
Gel Extraction OMEGA bio-tek, Norcross (USA) 
Z-Competent™ E.coli Transformation Kit Zymo Research, Orange (USA) 
Renilla-Juice PJK GMBH, Kleinblittersdorf (GER) 
RNeasy Mini Kit Qiagen, Hilden (GER) 
Beetle-Juice PJK GMBH, Kleinblittersdorf (GER) 
peqGOLD Plasmid MiniprepI Peqlab, Erlangen (GER) 
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Pierce Silver Stain Thermo Fisher, Carlsbad (USA) 
QuantiTect® Probe RT-PCR Qiagen, Hilden (GER) 
QuantiTect® SYBR® Green RT-PCR Qiagen, Hilden (GER) 
 
7.5 Buffers and solutions 
 
Lysis buffer for flotation analysis 10 mM 
20 mM 
 mM 
200 µM 
1 mM 
1 x 
 
Tris Hcl, pH 7,5 
Sucrose 
EDTA 
Orthovanadat 
PMSF 
Complete 
in dH2O 
 
PBSdef, pH 7.5 0,2 g 
0,2 g 
1,15 g 
8 g 
ad 1 l 
KCl 
KH2PO4 
Na2HPO4 
NaCl 
dH2O 
 
Protein sample buffer (4x) 10 ml 
200 mg 
20 ml 
10 ml 
4 g 
ad 50 ml 
Mercaptoethanol 
Bromphenolblue 
Glycerine 
1 M Tris/HCl, pH 6,8 
SDS 
dH2O 
 
SDS running buffer (10X) 
for Tris-glycine gels 
144 g 
10 g 
30 g 
ad 1 l 
Glycine 
SDS 
Tris-Base 
dH2O 
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SDS running buffer (20X) 
for Tris-acetate gels 
89.5 g 
10 g 
60 g 
ad 0.5 l 
Tricine 
SDS 
Tris-Base 
dH2O 
 
SDS transfer buffer (1X) 100 ml 
144 mg 
300 mg 
ad 1 l 
Ethanol 
Glycin 
Tris 
dH2O 
 
Blocking buffer for western blot  10 %  
 
Milk powder 
in PBSdef 
 
Blocking buffer for IFA 2 % 
5 % 
0,05 % 
0,2 % 
 
Bovines Serum albumin 
Glycerin 
NaN3 
Tween® 20 
in PBSdef 
 
SDS-PAGE stacking gel buffer 0,4 % 
1,5 M 
 
SDS 
Tris/HCl, pH 8.8 
in dH2O 
 
SDS-PAGE separation gel buffer 0,4 % 
1,5 M 
 
SDS 
Tris/HCl, pH 8.8 
in dH2O 
 
TAE buffer, pH 8.0 (50x) 
 
100 ml 
1 M 
242 g 
ad 1 l 
0.5 M EDTA, pH 8.0 
Acetic acid 
Tris-Base 
dH2O 
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TNE-Puffer (1x) 1 mM 
150 mM 
10 mM 
in dH2O 
 
EDTA, pH 8.0 
NaCL 
Tris/HCl, pH 7.4 
Dilution buffer for antibodies 1 % 
0,1 % 
Milkpowder 
Tween® 20 
in PBSdef 
 
Washing buffer WB 0,1 % Tween® 20 
in PBSdef 
 
7.6 Solutions 
 
Ampicillin stock solution  100 mg 
ad 1 ml 
Ampicillin 
dH2O 
 
Coomassie®-Staining solution 300 ml 
100 ml 
0,05 % 
ad 1 l 
Ethanol 
Acetic acid 
Coomassie Brilliant Blue R250 
dH2O 
 
Nycodenz 60 % in TNE 60 g 
ad 1 l 
Nycodenz 
TNE-Buffer (1x) 
 
  
Materials 
 
126 
 
7.7 Growth media 
 
7.7.1 Growth media for bacteria 
 
LB-Agar (1,5 %)  3.75 g 
ad 250 ml 
Bacto™ Agar 
LB-Media 
 
LB-Media  10 g 
5 g 
10 g 
ad 1 l 
NaCl 
Yeast extract 
Tryptone 
dH2O 
 
SOB-Media 20 g 
5 g 
0.58 g 
0.19 g 
10 ml 
10 ml 
ad 1 l 
Tryptone 
Yeast extract 
NaCl 
KCl 
1 M MgCl2 
1 M MgSO4 
dH2O 
 
7.7.2 Growth media for mammalian cells 
 
DMEM 10 % FCS + Q + P/S 
(DMEM+++)  
500 ml  
50 ml  
5 ml  
5 ml 
DMEM 
FCS (fetal calf serum) 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
 
DMEM5 % FCS + Q + P/S  500 ml  
25 ml  
5 ml  
5 ml 
DMEM 
FCS (fetal calf serum) 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
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DMEM3 % FCS + Q + P/S  500 ml  
15 ml  
5 ml  
5 ml 
DMEM 
FCS (fetal calf serum) 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
 
DMEM+ Q + P/S  500 ml  
5 ml  
5 ml 
DMEM 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
 
RPMI 10 % FCS + Q + P/S 
(RPMI+++)  
500 ml  
50 ml  
5 ml  
5 ml 
DMEM 
FCS (fetal calf serum) 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
 
RPMI 5 % FCS + Q + P/S  500 ml  
25 ml  
5 ml  
5 ml 
DMEM 
FCS (fetal calf serum) 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
 
RPMI 3 % FCS + Q + P/S  500 ml  
15 ml  
5 ml  
5 ml 
DMEM 
FCS (fetal calf serum) 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
 
RPMI+ Q + P/S  500 ml  
5 ml  
5 ml 
DMEM 
L-Glutamine 200 mM (100x) 
Penicillin/Streptomycin 5.000 IU/ml 
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7.8 Nucleic acids and nucleotides 
 
O’Gene Ruler™ 1 kb 
Plus DNA Ladder 
75 bp-20 kb Fermentas, St. 
Leon-Rot (GER) 
dNTP-Mix 2’Desoxyadenosine 5’triphosphate 
2’Desoxyzytosine 5’triphosphate 
2’Desoxyguanosine 5’triphosphate 
2’Desoxythymidine 5’triphosphate 
each 10 mM 
Thermo Scientific, 
Waltham (USA) 
 
7.9 DNA-Oligonucleotides 
 
Primer # Name  Sequence (5’-3’) 
16 MBV GP 1112 F GAACATAAGTGATCCTCTCACT 
28 Klon 1-258 F GAG CTG TTT GGA ATA GCA GA 
184 L 12846 F TAT CAG CAT CTT TGG GAG TG 
201 L 15144 F AGAAGATAAGATCGGTTATC 
202 L 15530 F AGATATTGCATTGTCTCTTG 
280 Lv - 17601 GAC GCA GAG ACC ACC AAG GAT GAA 
ACA AGG 
1233 pCAGGS-forw CCTTCTTCTTTTTCCTACAG 
1234 pCAGGS-rev CCTTTATTAGCCAGAAGTCAG 
2124 11.MB AgeI 16274V GTCATCGCTACCGGTTTGG 
2283 MB16713SalIV CTAGTCGAAAATTGTCGACCATCAGAGGG
C 
2620 Luc (-) NB AGA ACC ATT ACC AGA TTT GCC TGA 
2621 Luc (+) NB GGC CTC TTC TTA TTT ATG GCG A 
2863 mCherry-fwd  CGAATTCGTCTCTTCCAATGGTGAGCAAGG
GCGAGG 
2864 mCherry-rev  GGAATTCGTCTCACTTGCTTGTACAGCTCG
TCCATGCC 
3125 MARV VP40 D184N GGCGCCCATCCAAGAATAAATTAATTGGG 
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3158 Sequenzierprimer 
MARV L 
GTCCAGCGTCATGGGTG 
3511 mcherry Bstb1S gggTTCGAAAATGGTGAGCAAGGGCGAGGA
GGA 
3512 mcherry Bstb1AS tacTTCGAATGCTTGTACAGCTCGTCCATGC
CGCCG 
3519 Sequenzierprimer 
Ende GFP 
GTATGCGAATCC 
3533 GA-mCherry-L_for TTCAGTCTCCTCTAATCAACAAGTGACCAA
TTCGAAAATGGTGAGCAAGGGCGAGGAGG
A 
3534 GA-mCherry-L_rev GTGATATTTTCTGGATAAACAATATACTTCG
AATGCTTGTACAGCTCGTCCATGCCGCCG 
3547 L-Mut_S741C-for AATTAAAATTGAAGTCCTGTGTCATGGGTG
ATAATCAATGTATAA 
3548 L-Mut_D758A-for ACTCTAAGTCTTTTTCCAATTGCGGCTCCC
AACGATTATCAAGAG 
3549 L-Mut_A759D-for ACTCTAAGTCTTTTTCCAATTGATGACCCC
AACGATTATCAAGAG 
3550 L-Mut_D758A, A759D-
for 
ACTCTAAGTCTTTTTCCAATTGCGGACCCC
AACGATTATCAAGAG 
3553 pC_beL_for CAGCCATTGCCTTTTATGGT 
3554 pC_wiL1_for TGATGAACTCCATGATCTCAATTT 
3555 pC_wiL2_for ATGGACTGGCAAAAGCATTC 
3556 pC_wiL3mC_for CAGAGATTATCAGACTTGTTATCACC 
3557 pC_wimCh_for GGAGCGCGTGATGAACTT 
3558 pC_wiL3_for ACCCAGGTTTTCGGAGTATGT 
3595 MARV L PartFrag_For GGGATCGATGTTATGGTGTGAAG 
3596 MARV L PartFrag_Rev GGGTCGCGAACTGTTTGTCTAAGGAACG 
3653 MARV_L_rev_Nt3677 TCATATCGGAAGGCGAGGTT 
3654 MARV_L_rev_Nt3249 CAACACTCCTGGTTCACAGC 
3655 MARV_L_rev_Nt2904 ACGGGATGACCCCAATGCTT 
3656 MARV_L_rev_Nt2146 CACACTGTGACCTTGCAGAA 
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3750 MARV-L Nt 5142 AAGGCTAATTGGTGCCACAC 
3751 MARV-L Nt 8909 TCACGCCAAAGACAAGCAAT 
 
The primer numbers reflect the unique identification within the research group. 
Thick letters indicate mutational site.  
 
7.10  Plasmids 
7.10.1 Vectors 
 
Vector  Origin 
pCAGGS Institute for Virology, Marburg (GER) 
pTM1 NIH, Bethesda, (USA) 
pGL4 Promega, Mannheim (GER) 
pGL4.73 Institute for Virology, Freiburg (GER) 
pGL3 Institute for Virology, Freiburg (GER) 
 
7.10.2 Plasmids encoding recombinant proteins 
 
Vector 
Encoded 
protein 
Name Origin 
pCAGGS T7-polymerase pCAGGS-T7 
Y. Kawaoka, Wisconsin 
(USA) 
pAndy 
3M-5M 
Luciferase 
pAndy-3M-5M Institute for Virology, 
Marburg (GER) 
pCAGGS GP pCAGGS-GP Institute for Virology, 
Marburg (GER) 
pCAGGS VP24 pCAGGS-VP24 Institute for Virology, 
Marburg (GER) 
pCAGGS VP30 pCAGGS-VP30 Institute for Virology, 
Marburg (GER) 
pCAGGS VP35 pCAGGS-VP35 Institute for Virology, 
Marburg (GER) 
pCAGGS L pCAGGS-L Institute for Virology, 
Marburg (GER) 
pCAGGS NP pCAGGS-NP Institute for Virology, 
Marburg (GER) 
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pCAGGS VP40 pCAGGS-VP40 Institute for Virology, 
Marburg (GER) 
pCAGGS VP40D184N pCAGGS-VP40D184N Institute for Virology, 
Marburg (GER) 
pCAGGS VPS41mCherry pCAGGS-VP41mCh Institute for Virology, 
Marburg (GER) 
pGL 4.73 Renilla pGL.4.73 Institute for Virology, 
Marburg (GER) 
pGL3 Mx1 pGL3 Mx1 reporter Institute for Virology, 
Marburg (GER) 
pCAGGS LS741C pCAGGS-L1 Institute for Virology, 
Marburg (GER) 
pCAGGS LD758A pCAGGS-L2 Institute for Virology, 
Marburg (GER) 
pCAGGS LA759D pCAGGS-L3 Institute for Virology, 
Marburg (GER) 
pCAGGS LS741C, D758A pCAGGS-L1,2 Institute for Virology, 
Marburg (GER) 
pCAGGS LS741C, A759D pCAGGS-L1,3 Institute for Virology, 
Marburg (GER) 
pCAGGS LD758A, A759D pCAGGS-L2,3 Institute for Virology, 
Marburg (GER) 
pCAGGS 
LS741C, D758A, 
A759D 
pCAGGS-L1,2,3 Institute for Virology, 
Marburg (GER) 
pCAGGS mCherry-LS741C *pCAGGS-mChL1 Institute for Virology, 
Marburg (GER) 
pCAGGS mCherry-LD758A *pCAGGS-mChL2 Institute for Virology, 
Marburg (GER) 
pCAGGS mCherry-LA759D *pCAGGS-mChL3 Institute for Virology, 
Marburg (GER) 
pCAGGS 
mCherry-LS741C, 
D758A 
*pCAGGS-mChL1,2 Institute for Virology, 
Marburg (GER) 
pCAGGS 
mCherry-LS741C, 
A759D 
*pCAGGS-mChL1,3 Institute for Virology, 
Marburg (GER) 
pCAGGS 
mCherry-LD758A, 
A759D 
*pCAGGS-mChL2,3 Institute for Virology, 
Marburg (GER) 
pCAGGS 
mCherry-LS741C, 
D758A, A759D 
*pCAGGS-mChL1,2,3 Institute for Virology, 
Marburg (GER) 
* The names of the mCherry-L encoding plasmids and the according mutants are 
shown without the mCh prefix, however it is indicated when MARV L encoding 
plasmids were used not containing a mCherry-tag (chapter 3.3.3) 
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Cloned plasmid Template Primer/Klonierung 
pCAGGS L1 pCAGGS- mCherry-L1 SC with RD with BstBI  
pCAGGS L2 pCAGGS- mCherry-L2 SC with RD with BstBI  
pCAGGS L3 pCAGGS- mCherry-L3 SC with RD with BstBI  
pCAGGS L1,2 pCAGGS- mCherry-L1,2 SC with RD with BstBI  
pCAGGS L1,3 pCAGGS- mCherry-L1,3 SC with RD with BstBI  
pCAGGS L2,3 pCAGGS- mCherry-L2,3 SC with RD with BstBI  
pCAGGS L1,2,3 
pCAGGS- mCherry-
L1,2,3 
SC with RD with BstBI  
pCAGGS mCherry-L 
pCAGGS-L + 
pCAGGS-
VPS41mCherry 
PCR of mCherry with 3533, 
3544. BstBI digested 
pCAGGS-L + mCherry for 
Gibson assembly with 3533, 
3544 
pCAGGS mCherry-L1 pTM1-L1 SC via RD with ClaI and NruI 
pCAGGS mCherry-L2 pTM1-L2 SC via RD with ClaI and NruI 
pCAGGS mCherry-L3 pTM1-L3 SC via RD with ClaI and NruI 
pCAGGS mCherry-L1,2 pTM1-L1,2 SC via RD with ClaI and NruI 
pCAGGS mCherry-L1,3 pTM1-L1,3 SC via RD with ClaI and NruI 
pCAGGS mCherry-L2,3 pTM1-L2,3 SC via RD with ClaI and NruI 
pCAGGS 
mCherry-
L1,2,3 
pTM1-L1,2,3 SC via RD with ClaI and NruI 
pTM1 Frag-L pCAGGS-L SC via RD with ClaI 
pTM1 Frag-L1 pTM-L MG with 3547 
pTM1 Frag-L2 pTM-L MG with 3548 
pTM1 Frag-L3 pTM-L MG with 3549 
pTM1 Frag-L1,2 pTM-L MG with 3547, 3548 
pTM1 Frag-L1,3 pTM-L MG with 3547, 3549 
pTM1 Frag-L2,3 pTM-L MG with 3550 
pTM1 Frag-L1,2,3 pTM-L MG with 3547, 3550 
SC: Subcloning 
RD: Restriction digest 
The table contains only the unique assigned laboratory number, for more details see 
chapter 7.9 
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7.11 Proteins 
7.11.1 Recombinant purified proteins  
 
Recombinant interferon-α/β hybrid kindly provided by Dr. Stéphanie Devignot, Institute 
for virology, Justus-Liebig Universität Gießen  
7.11.2 Enzymes 
 
Calf intestine phosphatase (CIP) Roche Diagnostics, Mannheim (GER) 
Complete Protease Inhibitor Cocktail 
Tablets  
Roche Diagnostics, Mannheim (GER) 
T4 DNA ligase NEB, Ipswich (USA) 
Pwo polymerase Peqlab, Erlangen (GER) 
 
7.11.3 Restriction enzymes  
 
All restriction enzymes and the associated Buffers (10x concentrated) were 
purchased at New England Biolabs (Frankfurt,GER) and Fermentas (St.Leon-Rot, 
GER) 
 
7.11.4 Primary antibodies  
 
Name Species Company            Dilution 
     IFA             WB 
α-MARV VP40 
(40-2-2) 
Mouse 
Institute for virology, 
Marburg (GER) 
1:200 1:1000 
α-MARV NP 
(59-9-10) 
Mouse 
Institute for virology, 
Marburg (GER) 
----- 1:500 
α-MARV NP 
(2) 
Guinea pig 
Institute for virology, 
Marburg (GER) 
1:200 ----- 
α-MARV GP 
(50-6-10) 
Mouse 
Institute for virology, 
Marburg (GER) 
----- 1:100 
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α-MARV VP35 Guinea pig 
Institute for virology, 
Marburg (GER) 
1:500 ----- 
α-mCherry Mouse 
Abcam, Cambridge 
(UK) 
----- 1:1000 
α-Vinculin Mouse 
Sigma-Aldrich, 
München (GER) 
----- 1:2000 
α-Tubulin Mouse 
Sigma-Aldrich, 
München (GER) 
----- 1:5000 
 
7.11.5 Secondary antibodies for IFA  
 
Name Species Company Dilution 
α-mouse Alexa 488 Goat Invitrogen, Karlsruhe (GER) 1:300 
α-guinea pig Alexa 488 Goat Invitrogen, Karlsruhe (GER) 1:300 
α-mouse Alexa 488 Goat Invitrogen, Karlsruhe (GER) 1:300 
α-mouse Marina blue Goat Invitrogen, Karlsruhe (GER) 1:300 
 
7.11.6 Secondary antibodies for WB  
 
Name Species Company Dilution 
α-mouse HRP Goat Dako, Hamburg (D) 1:30.000 
 
7.11.7 DNA marker 
 
O’GeneRuler 1 kb Plus DNA Ladder, Thermo Scientific, Waltham (USA) 
 
7.11.8 Proteinmarker 
 
PageRuler™ Plus Prestained Protein Ladder 10-250 kDa, Fermentas, St. Leon-Rot 
(GER) 
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7.12 Cells and viruses 
7.12.1 Prokaryotic cells 
Bacteria Origin 
E. coli XL1 blue Stratagene, Heidelberg (GER) 
E.Coli XL10-Gold Agilent technologies, Ratingen (GER) 
 
7.12.2 Eukaryotic cells 
 
Cell line  Origin 
Huh-7 cells Institute for virology, Marburg (GER) 
HEK293 cells Institute for virology, Marburg (GER) 
104C1 cells Robert Koch Institute, Berlin (GER) 
GPC16 cells ATCC, Wesel (GER) 
VeroE6 cells Institute for virology, Marburg (GER) 
 
7.12.3 Viruses 
 
Virus 
Recombinant Marburg Virus Musoke, Wildtype 
rMARVWT 
Recombinant Marburg Virus Musoke, D184N mutation in VP40 
rMARVVP40(D184N) 
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7.12.4 Software 
 
Software Used for 
BioEdit 7.0.5.3. Sequence analysis 
Clone Manager 9 Planning of cloning projects 
DoubleDigest finder Planning of restriction digests 
EndNote Web Reference Management 
ImageJ 1.47v Immunofluorescence analysis 
Image Lab 5.2 Detection and quantification of Western 
blot membranes 
Leica Application Suite X software Inclusion body size measurements 
Microsoft Excel 2013 Statistical analysis, Figure preparation 
Microsoft Power Point 2013 Graphics and scheme preparation 
Microsoft Word 2013 Protocol-/ Thesis writing 
QuikChange Primer Design tool Design of mutagenesis primers 
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10 List of abbreviations 
 
104C1 Fibroblast cells, Guinea pig 
APS Ammonium persulfate 
Ax1 Defensin-like protein 
BDBV Bundibugyo virus 
bp Base pairs 
BSA Bovine serum albumin 
BSL-2 Biosafety level 2 
BSL-3 Biosafety level 3 
BSL-4 Biosafety level 4 
CDC Center for disease control 
CIP Calf intestine phosphatase 
CPE Cytopathic effect 
CR Constant region 
C-terminus Carboxyterminus 
d Day 
d (in dH2O) deionized 
DC-SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin 
DMEM Dulbecco's Modified Eagle Medium 
DNA Desoxyribonucleic acid 
dNTP Deoxynucleoside triphosphate 
E.coli Escherichia coli 
e.g. exempli gratia, (engl.) for example 
EBOV Ebola virus 
EM Electron microscopy 
ER Endoplasmatic reticulum 
ESCRT Endosomal sorting complexes required for transport 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
for Forward 
GP Glycoprotein 
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GPC16 Adenocarcinoma cells, Guinea pig 
h Hour 
HEK293 Kidney cells, Human 
HRP Horseradish peroxidase 
Huh-7 Hepatoma cells, Human 
IFA Immunofluorescence analysis 
IFN Interferon 
iVLP Infectious virus-like particle 
Jak1 Janus kinase 1 
kb Kilo bases 
kDa Kilo Dalton 
L Large Protein 
LB media Lysogeny broth 
LLOV Lloviu virus 
LSECtin Liver and lymph node sinusoidal endothelial cell C-type 
lectin 
MA-MARV Mouse adapted Marburg virus 
MA-RAVV Mouse adapted Marburg virus RAVV strain 
MARV Marburg virus 
MeV Measles virus 
min Minute 
MOI Multiplicity of infection 
mRNA Messenger RNA 
NHP Non human primate 
NNS Nonsegmented negative strand 
NP Nucleoprotein 
NPC1 Niemann Pick 1 
N-terminus Amino-terminus 
OD Optical density 
ORF Open reading frame 
p.i.  Post infection 
p.t. Post transfection 
P/S Penicillin/Streptomycin 
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PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PBSdef Phosphate-buffered saline deficient in magnesium and 
calcium 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
pH potentia hydrogenii 
pmol Pico mol 
RAVV Marburg virus Ravn 
RdRp RNA-dependent RNA polymerase 
REBOV Reston ebolavirus 
rev Reverse 
RIG-I Retinoic acid inducible gene I 
RL-MARV Rodent-lethal Marburg virus 
rMARV Recombinant Marburg virus 
RNA Ribonucleic acid 
rpm Revolutions per minute 
RPMI Roswell Park Memorial Institute 
RT Reverse transcription 
RT-PCR Reverse transcription polymerase chain reaction 
RT-qPCR Quantitative reverse transcription polymerase chain 
reaction 
SDS Sodium dodecyl sulfate 
sec Second 
siRNA Short interference ribonucleic acid 
SIV Simian immunodeficiency virus 
SUDV Sudan virus 
T7-pol T7 DNA-dependent RNA polymerase 
TAFV Taï Forest virus 
TCID50 Tissue culture infectious dose 50 
TIM-1 T-cell immunoglobulin and mucin domain 1 
tr Transcription 
TRITC Tetramethylrhodamine 
List of abbreviations 
 
142 
 
UV Ultraviolet light 
VeroE6 Kidney cells, African green monkey 
VLP Virus-like particles 
VP24 Viral protein 24 
VP30 Viral protein 30 
VP35 Viral protein 35 
VP40 Viral protein 40 
VSV Vesicular stomatitis virus 
WHO World health organization 
ZEBOV Zaire ebolavirus 
α Anti 
λ Lambda, Wavenlength 
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11 Amino acid one letter code 
 
Amino acid One letter code 
Alanine A 
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